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Abstract 
Background: Cystic fibrosis (CF) is a life-shortening, chronic respiratory disease 
caused by mutations in the CFTR gene. Novel therapeutic agents such as gene 
therapy aim to correct CFTR and to demonstrate evidence of molecular, 
functional and (ultimately) clinical efficacy. It was hypothesised that currently 
used methods to detect these changes may be optimised to enhance sensitivity 
and allow quantification, and facilitate an understanding of geographical effects 
within the airway.  
Methods: Outcome measures were investigated within two UK CF Gene Therapy 
Consortium studies; a longitudinal observational study (‘Run-In’), and a single 
dose gene therapy study (‘Pilot’) which investigated safety and functional 
efficacy. Measurement of airway function with spirometry and lung clearance 
index in the Run-In study allowed investigation of variability and change over 
time and comparison with other outcomes. Development of methodology and 
data analysis from measurements of potential difference (PD) in the nose and 
lung in the Pilot study allowed investigation of these as measures of functional 
efficacy.  
Results: In the Run-In study, the choice of external reference source was crucial 
for interpretation of spirometry outcomes. Airway physiology outcomes 
correlated with structural changes on chest CT however were limited in their 
ability to detect site of airway abnormality. There was some evidence that 
disease severity was associated with intra-subject variability and affected rate 
of change over time. In the Pilot study, airway PD was shown to change post 
gene therapy within individuals but the responses were not universal and 
depended on the definitions used. A novel method of nasal PD quantification did 
not improve an ability to quantify change. 
Conclusions: There is no single universal outcome measure in CF, but it is 
important to take account of the patient population in terms of disease severity. 
Whilst it would be inappropriate to relate PD outcomes with clinical outcomes in 
the Pilot study; this will be an important relationship to understand in the future 
in order to allow rational design of CF gene therapy clinical trials.   
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1 Defining the context 
1.1 Clinical evaluation of novel therapeutic agents 
There is a constant search for better ways to treat patients with disease, 
irrespective of the underlying causality. This is particularly true for life-limiting 
diseases associated with significant morbidity. The processes involved in the 
journey from identification of a potential novel product to licensing and 
introduction in clinical practice result in only a fraction succeeding the translation 
from bench to bedside. Knowledge of the natural history of the disease of interest 
is imperative to ensure that an appropriate evaluation takes place. Even within a 
body system (e.g. respiratory), there is no single outcome measure to assess 
efficacy. Those optimal for a novel drug against community acquired pneumonia 
will be different to those for asthma.  Consideration of severity of disease, and 
patient characteristics such as age, is also important (1;2).  
This thesis describes an evaluation of outcome measures, both existing and novel, 
for a non-viral gene therapy product for cystic fibrosis (CF) developed by the UK 
Cystic Fibrosis gene therapy Consortium (UKCFGTC). The UKCFGTC was founded in 
2001 as a collaborative approach in working towards gene therapy for CF with 
detectable clinical benefit.  It includes clinical, scientific and administrative 
personnel from three geographical locations in the UK: Edinburgh, Oxford and 
London. Patients enrolled in the clinical programme attend either the Royal 
Brompton Hospital in London, or one of two centres in Edinburgh (Royal Hospital 
for Sick Children or Edinburgh Royal Infirmary).  
The Consortium’s clinical programme, which involves both observational and 
interventional studies, provides the platform for the data analysis presented.   
1.2 Cystic fibrosis 
Cystic fibrosis (CF) is a life-shortening, autosomal recessive, chronic multi-system 
disease, caused by mutations in the cystic fibrosis transmembrane conductance 
regulator (CFTR) gene on chromosome 7. It is the commonest lethal inherited 
condition in Caucasian populations, affecting around 1:2500 births in the United 
  21 
Kingdom and with a UK prevalence > 7000. Over 1500 mutations have been 
detected in the CFTR gene to date although in the UK p.Phe508del accounts for 
around 70% of cases (3). The clinical phenotype is difficult to predict according to 
underlying genetic mutation; patients with identical mutations can have widely 
contrasting disease courses (4;5). 
1.2.1 CFTR 
In health, the CFTR gene is responsible for the production of CFTR protein. CFTR 
functions as a cyclic adenosine monophosphate (cAMP) dependent chloride channel 
in epithelial cells as well as acting in a regulatory role for the epithelial sodium 
channel (ENaC) and the outwardly rectifying chloride channel (6). There is also 
evidence for a role in water conductance via aquaporin channels (7) and potassium 
ion transport at the basolateral surface of the airway epithelium (8). CFTR 
expression is thought to be maximally expressed in the submucosal glands and in 
the surface epithelium of the distal small airways (9;10).   
In CF, defective CFTR function results in abnormal ion transport across epithelium 
with absent or impaired chloride (Cl-) secretion and exaggerated sodium absorption 
(Figure 1.1). 
 
Figure 1.1. Schematic diagram of ion transport in airway epithelial cells. In 
healthy cells, CFTR (represented by pale blue circle) functions as a chloride ion  
(Cl-) channel allowing chloride secretion and regulation of sodium ion (Na+) 
transport. In cystic fibrosis, absent or defective CFTR does not permit chloride 
secretion and dysregulation of the sodium ion channel ENaC (purple square) results 
in sodium hyper-absorption.  
The downstream consequences of the ion transport defects result in a reduced 
volume of airway surface liquid which impacts on the ability to achieve effective 
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mucociliary clearance (11;12). This disrupts the host’s innate defence systems and 
provides opportunity for bacteria to thrive. Airway inflammation and chronic 
infection of the airway ensues. The downstream consequences of CFTR dysfunction 
ultimately lead to mucus plugging and airway remodelling, with airway destruction 
and extensive bronchiectasis can be detectable on chest computed tomography 
(CT) scan and obstructive ventilatory defects in tests of airway physiology.  
1.2.2 Morbidity and current approach to management 
Although respiratory morbidity is the greatest burden in CF, the disease impacts on 
multiple body systems. The digestive system is commonly involved, with pancreatic 
exocrine insufficiency affecting >90% of patients (3). Co-morbidities such as cystic 
fibrosis related diabetes are seen with increasing prevalence as patients survive to 
older ages. Pulmonary exacerbations are associated with a decline in respiratory 
function and preservation of respiratory status is important to minimise morbidity. 
Historically, management of CF has been supportive. To mirror the disease burden 
there is an associated heavy treatment burden. This includes agents to improve 
airway clearance (e.g. regular daily physiotherapy and nebulised mucolytics), 
antibiotics, nutritional support and often many other concurrent medications to 
counteract the consequences of this multisystem disease.  
With appropriate supportive treatment, life expectancy has improved considerably 
over the past four decades such that infants born today are predicted to have a 
median survival > 50 years (13). Historically, management strategies have tackled 
the downstream consequences of the underlying molecular defect in CFTR. The 
potential for treatments that could instead cure or modify disease progression 
increased following identification of the CFTR gene over two decades ago (14;15). 
Such approaches include gene therapy and small molecule drugs, and are exciting 
in their theoretical potential to favourably alter progression of disease and reduce 
the considerable burden of treatment associated with CF care. 
1.3 Gene therapy for cystic fibrosis 
Gene therapy describes the approach whereby a gene is delivered to target cells 
and then transcribed in vivo into functional protein to modify the pathogenesis of 
disease or the consequences thereof. The disease of interest and associated 
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morbidity determine the organs and type of cells that are targeted by gene 
therapy. In CF, as the conducting airways are responsible for the greatest morbidity 
and mortality, the airway epithelial cells are the target (16). In the case of CF and 
the CFTR gene, insertion of a healthy copy into airway cells aims to result in 
subsequent transcription of CFTR protein (with insertion in the cell membrane) 
which is able to fulfil its multitude of functions including ion transport and air 
surface liquid homeostasis.   
The target cells for the gene therapy agent along with the mode of delivery 
(systemic or local) in part determine the potential longevity of effect. For 
example, if a cell can divide and differentiate, an integrating transgene has 
potential for lifelong expression. This contrasts with strategies which either target 
relatively short-lived, terminally differentiated cells (e.g. airway epithelial cells) 
or do not involve integration of the delivered gene into the host cell genome. In 
the latter, the lack of integration means that even if the gene were to be delivered 
to dividing cells, it would not be expressed in successive generations.  
Thus, the duration of gene expression will be determined both by the natural life 
cycle of the cells targeted and the characteristics of the gene therapy agent. As CF 
is a lifelong, chronic disease, sustained long-term gene expression will be required; 
this will only be achievable by correcting airway progenitor cells with an 
integrating vector or by using an agent able to be repeatedly administered.  
As a single gene disorder, CF has been considered an attractive target for gene 
therapy. The CFTR gene was discovered in 1989 (14;15) and gene therapy seemed 
an obvious next step. Both in vitro and in vivo (in mice) proof-of-principle for CF 
gene therapy were quick to follow the identification of CFTR (17;18). The first 
human in vivo clinical trials followed shortly later (19-21). However, it was soon 
clear that effective CF gene therapy in man would be more challenging than 
anticipated for the reasons described below. Therefore despite initial widespread 
enthusiasm, with multiple researchers committed to taking the field forward, focus 
has reduced significantly over recent years. Around the globe there are now only a 
few research groups committed to developing and investigating the potential for CF 
gene therapy as a realistic future therapeutic strategy.  
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1.3.1  Vectors 
For CF gene therapy to work, efficient delivery of normal CFTR to the airway cells 
is a crucial first step. To help with this process, the CFTR DNA is delivered into 
cells by different vehicles known as vectors. Those used commonly include 
genetically-modified viruses and non-viral agents such as liposomes. Whilst viruses 
are generally more efficient, the repeated delivery needed to achieve sustainable 
expression of CFTR has proved impossible to date due to the host immune response 
(22).  
1.3.1.1 Viral vectors 
From first principles, it is easy to see why viruses may be attractive vectors for 
gene therapy.  Viruses have evolved to employ sophisticated methods of 
penetrating the body’s defence and invading the target host cells. These features 
have been utilised to increase the efficiency with which the CFTR gene can be 
delivered to the airway. The success with which airway epithelium can be 
transfected with viral vectors has overall been less impressive than anticipated. 
However, in vitro studies have demonstrated that the proportion of cells that need 
to be transfected to normalise chloride Cl- ion transport is as low as 6%; the 
mechanism underlying the normalisation of measured Cl- ion transport with such a 
low percentage of cells transfected may relate to intercellular gap junctions (23). 
This contrasts with a requirement to transfect almost 100% cells in vitro to 
normalise sodium ion (Na+) transport (24). Which one of these functions (and/ or 
others) requires correcting, and to what extent, is therefore an important 
consideration when assessing the outcomes of CFTR gene therapy trials. A trial of a 
small molecule potentiator drug (Ivacaftor, VX-770) which demonstrated evidence 
of correction of chloride secretion and improvements in lung function despite 
variable or no change in sodium transport lends some support to the notion that 
correction of chloride secretion may be sufficient for clinical benefit (25).  
Viruses which have been investigated as candidate vectors for CF gene therapy 
include adenoviruses, adeno-associated viruses, Sendai virus and Lentiviruses (16). 
Adenoviruses and adeno-associated viruses have been assessed in early phase 
clinical trials. Sendai virus and lentiviral vectors remain in the pre-clinical setting 
at present. Adenoviral (Ad) vectors were the first viral vectors evaluated in man for 
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CF gene therapy (19;21). However, significant limitations were discovered with 
immune responses limiting efficacy after re-administration (26). Furthermore, the 
primary receptor for Ad, rather than being conveniently located on the apical cell 
surface, is on the basolateral surfaces and therefore relatively inaccessible from 
the airway lumen without an agent to break down the tight junctions (27).  
Adeno-associated viruses (AAV) have also been extensively investigated including in 
clinical trials (16). They differ from Ad viruses in size, in addition to favourable low 
host pathogenicity.  However, their receptors are serotype-specific and most are 
similarly scarce on the apical surface of the airway epithelium. As they are small 
viruses, large genes such as CFTR may be difficult to package; to overcome this, 
approaches have been designed including truncating or dividing the CFTR gene 
(28). Recent progress with viral vectors has included directed evolution of viruses 
(using selection based criteria) or molecular techniques to engineer desirable 
characteristics to improve their transfection efficiency. For example, an exciting 
recent approach has been to combine the most favourable characteristics of two 
different viruses, neither of which in isolation is ideally suited for CF. This is 
termed pseudotyping and is being investigated for Sendai virus (SeV) and 
lentiviruses (16). Sendai virus (SeV) is highly efficient at transfecting airway 
epithelial cells due to the presence of sialic acid and cholesterol receptors on their 
apical surface. Another advantage is its cytoplasmic expression, which removes the 
barrier of the nuclear membrane common to other approaches. High levels of gene 
expression have been reported but, in common with Ad and AAV viruses, it cannot 
be successfully re-administered. Lentiviruses are also highly efficient gene transfer 
agents. They have certain advantages over other gene therapy agents including the 
ability to transfect both dividing and non-dividing cells, and long-term stable 
expression; they also seem, almost uniquely amongst viruses to be repeatedly 
administrable (29;30). However, they naturally target haematopoetic cells and do 
not possess the surface proteins which recognise receptors on respiratory epithelia. 
Therefore neither lentiviruses nor SeV are ideal vectors in isolation, but combining 
characteristics of both may produce a more attractive viral vector. The UK CF Gene 
Therapy Consortium has recently generated a simian immunodeficiency virus (SIV) 
lentivirus pseudotyped with Sendai viral surface proteins. The SeV envelope 
packaging removes the usual limitations of the ability of SIV to bind to and enter 
airway epithelial cells. A single administration of this lentiviral vector has recently 
been shown to result in transgene expression for periods of up to 2 years in a 
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mouse and uniquely, in our experience, re-administration is possible and remains 
efficacious (30). Furthermore, in comparison to the non-viral gene therapy product 
that we are evaluating in the UKCFGTC clinical trial programme (described section 
1.5), markers of gene expression are several hundred times greater. Although this 
does not automatically translate into sustained efficacious expression in man, such 
long lasting expression is encouraging and may ultimately result in a clinical 
product with greater clinical efficacy requiring infrequent administration. This is 
important to the CF patient population who have a high treatment burden with 
usual care alone.   
Relatively few patients (none with CF) have received lentivirus-based gene 
therapy. As with any novel therapeutic agent, but particularly with any novel viral 
vector, safety is paramount. Caution is necessary, as lentiviruses integrate with the 
host cell genome. Integration into haematopoetic cells following gene therapy 
using retroviral vectors for severe inherited immunodeficiencies led to the 
development of leukaemias in some of the patients (31;32). Airway epithelial cells 
are very different from the rapidly dividing cells of the bone marrow, and 
lentiviruses are likely to be safer than retroviruses. However, the past experiences 
with integrating viral vectors will mean that progression to clinical trials should 
only be undertaken following extensive pre-clinical toxicology studies and 
consideration of appropriate CF patient groups for any ‘first-in-man’ testing.  
1.3.1.2 Non-viral vectors 
There are several non-viral approaches which aim to aid transfection and preserve 
functionality of the delivered gene to the airway cells, albeit with generally lower 
efficiency than achievable with viral counterparts. Non-viral approaches include 
cationic liposomes, compacted DNA nanoparticles and naked DNA (33). Cationic 
liposomes consist of cationic lipids that are usually mixed with cholesterol and 
dioleoylphosphatidyl-ethanol-amine. When combined with DNA they form particles 
sized 100-500 nm in diameter which can penetrate cell membranes and enter cells 
(34). The complex of DNA and liposomes is resistant to nuclease degradation, thus 
improving the success rates of gene delivery. The UKCFGTC is using the cationic 
lipid GL-67A (Genzyme Corporation) in its clinical trial programme. This was 
compared against other non-viral vectors and taken forward to clinical trial on the 
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basis of its preclinical efficiency. This lipid has also been used in a previous trial of 
CF gene therapy with a different CFTR plasmid (35).  
Other non-viral approaches which have been investigated include DNA 
nanoparticles, where plasmid DNA is compacted with a peptide substituted with 
polyethylene glycol, and the cationic polymer polyethyleneimine (PEI) (33).  
A major advantage of non-viral vectors would be the potential for repeat 
administration. In the nose there is some evidence that repeat dosing does not 
reduce molecular efficacy (36) although data are lacking with regard to the lower 
airway. 
1.3.1.3 Plasmids for non-viral gene therapy 
Just as the type of vector to deliver the gene to the cells of interest is important, 
the characteristics of the plasmid DNA used in non-viral gene therapy are also 
crucial to the potential for gene expression and ultimate success. In previous 
clinical trials of CF gene therapy using a liposomal vector with plasmid DNA, a post-
dosing inflammatory response has been observed which is considered likely due, at 
least in part, to the presence of Cytosine-phosphate-Guanine (CpG) dinucleotides 
present in the plasmid molecule (37). Unmethylated CpGs occur commonly in 
bacterial DNA (occurring with a much lower frequency (and mostly methylated) in 
mammalian DNA) (38), and can be detected by the innate immune system as 
foreign to the host via Toll-like receptor 9 signalling (38). This activates signalling 
pathways resulting in the release of pro-inflammatory cytokines. Due to its 
amplification in Escherichia coli, CpGs on the plasmid CFTR DNA were considered 
likely responsible for the post dosing flu-like illness associated with rise in 
inflammatory markers seen when previously administered to man (35;39). Partial 
reduction of CpG content in plasmids only partially reduced the inflammatory 
effects following delivery by DNA–liposome complexes to the mouse lung (40). 
However, complete reduction of CpGs led to an absence of an inflammatory 
response in mice (41). 
Modification of the plasmid DNA can also be undertaken to maximise its potential 
for gene expression. The plasmid used in the CF gene therapy clinical trial by Alton 
et al (35) described in detail in section 1.3.2 incorporated a viral (cytomegalovirus 
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(CMV)) promoter, which had a rapid onset of action but was limited by a short lived 
duration of expression. In contrast, the CFTR plasmid DNA being investigated by 
the UKCFGTC in its clinical trial programme (pGM169) has been identified on the 
basis of extensive pre-clinical testing. It includes plasmid DNA which has been 
stripped of all CpG dinucleotides, and includes a promoter which has been 
optimised (Human Elongation Factor 1α) to enhance duration of expression. In 
mice, with this product, sustained expression for over a month can be achieved 
with a single dose (41). 
1.3.2 Clinical Trials  
Since the early 1990s, there have been over 20 previous early phase clinical trials 
of CF gene therapy, which have involved dosing to the nose, lung or both (42). 
These trials have largely been designed to assess safety and molecular (e.g. CFTR 
mRNA) or functional (electrophysiological tests e.g. airway potential difference 
measurements) proof-of-principle for gene transfer and expression in the host. 
Variable outcomes for both safety and efficacy have been reported but the 
principle of CFTR gene transfer has been proved, both with viral and non-viral 
approaches (16).  
A placebo controlled trial by Alton et al (35) of a single dose of non-viral nebulised 
CF gene therapy is referred to frequently throughout this thesis. Published over a 
decade ago, it represented a benchmark study for the field of non-viral CF gene 
therapy and provided the stimulus for continued development of a clinically 
effective CF gene therapy product by the UKCFGTC. For ease of reference it is 
referred to as the Lancet study throughout this thesis and outcomes described here 
are for comparison with the single dose CF gene therapy clinical trial in the 
UKCFGTC clinical programme, (the ‘Pilot’ study; see section 1.5.2). The Lancet 
study was a double blind, placebo controlled study involving 16 adult male patients 
with CF, with FEV1 at recruitment >70% predicted. It aimed to investigate safety 
and functional evidence of efficacy. Eight patients received a single dose of the 
nebulised and nasal CF gene therapy product (CFTR plasmid including a CMV 
promoter, complexed with GL67/DOPE/DMPE-PEG5000 (the lipid component 
collectively referred to as GL67A)). The 8 patients randomised to placebo received 
the lipid component alone.  
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Outcome measures for the Lancet study included measures to assess safety and 
efficacy. Patients were seen for a single pre-dose visit which included 
bronchoscopy and then for serial visits post-dosing at time points determined by 
the study protocol. Lung and nasal doses were administered at separate visits with 
an interval of 6 days. Safety outcomes included clinical assessment, chest 
computed tomography, lung function, sputum analysis (including sputum induction) 
and histological analysis. Efficacy was assessed in the upper and lower airway with 
molecular tests (CFTR mRNA and DNA), functional measurements of CFTR (upper 
and lower airway PD measurements), and in chloride efflux and bacterial 
adherence assays. All post-dosing bronchoscopies were performed at day 2. 
Patients were followed up until day 29 post lung dose. Post administration of the 
lung dose, patients in the active group experienced a self-limiting influenza type 
illness which resolved within 2 days. The safety outcomes and key results are 
summarised in Table 1.1.  
Outcome measure Mean maximal change from 
baseline in active 
treatment cohort 
Detection of maximal 
change (time point) 
FEV1 -17% (placebo: -15%) Within 6 hours post dose 
FVC -17% (placebo: -15%) Within 6 hours post dose 
Gas transfer -7.5% in active group  Day 2. Normalised by 
time of next 
measurement at day 29 
C-reactive protein Rise from 8.5 to 42.5mg/L  48 hours. Returned to 
baseline by day 6 
Serum IL-6 Rise from 6 to 25 pg/mL  6 hours post dose  
Total white cell count Rise from 9.0 to 12.1 
x109/ml  
6 hours post dose 
Chest computed 
tomography (CT) scan 
No significant change at day 
2 or 29 
N/A 
 
Table 1.1. Summary of the safety outcomes from the previous placebo 
controlled gene therapy clinical trial in CF patients by Alton et al. The table 
summarises the results from airway physiology, systemic inflammatory and structural 
outcomes from the previous clinical trial of non-viral CF gene therapy by Alton et al (35) 
including magnitude and time point of maximal change. Time points are post lung dose 
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The CFTR molecular and functional efficacy data from the Lancet study is 
summarised in the table below (Table 1.2), which has again been summarised to 
allow comparison with the results from the Pilot study.  
 
Outcome measure Mean change (active) 
group 
Post dose tests 
Bronchial brushings No vector specific CFTR 
mRNA.  
Day 2 (single post dose 
measurement) 
Nasal brushings and nasal 
biopsy 
No vector specific CFTR 
mRNA 
Day 2 and 4 post dose 
Lower airway potential 
difference (PD) 
No significant change in 
basal PD or response to 
amiloride in either active 
or placebo group. 
Increase towards normal 
values of chloride 
secretion in 6/8 patients 
in active group. 
Significant increase in 
active but not placebo 
group (p<0.05).  
Day 2 (single time point 
post dose) 
Nasal PD No significant change in 
basal PD or response to 
amiloride in active or 
placebo group.   
Significant difference 
between active and 
placebo groups in 
intrinsic chloride 
secretion (p<0.05). 
No change in response to 
isoprenaline in either 
group 
Follow up (6 tests) post 
nasal dose to day 23  
 
Table 1.2. Summary of the efficacy outcomes from the previous placebo 
controlled gene therapy clinical trial in CF patients by Alton et al. As per safety 
outcomes, the table summarises outcomes including post dose time points for data 
collection from the previous clinical trial of non-viral CF gene therapy by Alton et al (35). 
Time points are post lung administration unless otherwise stated.  
 
In addition to confirming proof-of-principle for CFTR gene transfer with molecular 
or electrophysiological tests, general themes which have emerged from the Lancet 
study and other clinical trials to date include a reduction in gene expression after 
subsequent doses of viral gene transfer agents, and that both viral and non-viral 
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approaches may induce an inflammatory response. Few studies have investigated 
clinical end points, and when included have largely been those which were not 
powered sufficiently for such end points (having been designed to assess primarily 
safety). A reduction in sputum inflammatory markers has been reported in studies 
involving viral (AAV) and non-viral (cationic liposome) vectors (35;43).  Small but 
significant improvements in lung function were reported in a CF gene therapy trial 
involving an AAV vector but this was not confirmed in a subsequent, larger trial 
(43;44).   
1.3.3 Challenges  
The airway has proved a challenge for effective topical delivery of gene therapy. 
The ciliated epithelial cells lining the airway are generally considered the target 
for topical application via nebulisation yet these cells, which are key in the lung’s 
defence mechanisms, are specifically designed to keep foreign particles out. The 
requirement for CFTR expression in other cell types in the airway is at present 
unknown. This may be a particularly relevant issue for cells which may be harder to 
reach with nebulisation including those within submucosal glands (9), and also the 
putative airway stem cells (such as basal cells). There are also physical challenges 
with the accessibility of the distal airways which are considered fundamental to 
disease pathology in CF, and the presence of thick sticky secretions lining the 
airway walls. The technology of different commercially available nebulisers to 
deliver the gene therapy has been an important consideration in accessing these 
distal airways, including the stability of the product during nebulisation and 
resultant particle size. For example, aerosolisation of DNA alone has been found to 
result in loss of function in vitro (45). 
Sustained efficacy has been a key challenge to CF gene therapy. Gene therapy is 
attempting to overcome well-evolved lung defence mechanisms. A key obstacle is 
to negotiate the body’s own defences: plasmid DNA or engineered viruses may be 
seen as foreign by the host. Minimising any host immune response is therefore 
important to allow repeated delivery of the gene therapy. A further challenge is for 
the DNA to pass through the cell membrane, evade the cytoplasmic defence 
mechanisms and penetrate the nuclear membrane. Finally, the challenge of 
measurement and outcome should also not be overlooked. Quantifying the 
distribution and functional efficacy of CF gene therapy in vivo is challenging for 
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early clinical trials which do not aim to look for clinical benefit. If a CF gene 
therapy product is to ultimately become a viable clinical option, it must fulfil a 
number of requirements. The current challenge for CF gene therapy clinical trials is 
to demonstrate clinical efficacy. Important considerations for CF lung gene therapy 
include: 
 Clinical efficacy demonstrated with appropriate outcome measures 
 Sustained clinical efficacy with repeat administration 
 Acceptable side effect profile 
 
1.4 Why we need ‘better’ outcome measures for CF clinical 
trials 
Novel medicinal products are required to pass through preliminary clinical studies 
in man before progressing to later phase trials. Initial clinical studies require 
evaluation of safety (with or without an assessment of efficacy) in a limited 
number of patients. At this early stage of clinical evaluation, efficacy may be 
evaluated at a molecular or cellular level indicative of functional change (“does it 
work?”) rather than clinically detectable endpoints (“does it help the patient?”) 
such as forced expiratory volume in one second (FEV1). A multidose study involving 
considerably more subjects must show clinical efficacy. Therefore, the optimal 
outcome measure to evaluate in vivo ‘success’ evolves during the evaluation for 
any novel therapeutic agent (2). 
Early death is of most concern to CF patients, but the improved prognosis of CF 
means that this is not a practical clinical trial outcome. The primary end-point of 
CF clinical trials has most commonly been spirometry, and in particular FEV1. 
However, the slow annual decline (around 1% per year) in FEV1 means that 
adequately powered studies need large numbers of patients to detect a change in 
the rate of decline (46). Furthermore FEV1 lacks sensitivity to detect early 
structural CF lung disease (47-49). This means we need new surrogate end-points 
for clinical trials. These will vary with the severity of the disease and the stage of 
drug evaluation. Importantly, the sensitivity, prognostic ability and variability of 
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any novel surrogate must be known. One outcome measure gaining prominence is 
lung clearance index. This has recently been shown to be superior to FEV1 in 
detecting a treatment effect of a small molecule drug in patients with early stage 
CF lung disease (50). There is also interest in the use of patient reported outcomes 
as methods of detecting clinical efficacy, but there is a lack of consensus amongst 
the regulatory authorities regarding their role.  It is also important that any 
outcome measure used in clinical trial is recognised by the relevant regulatory 
authority. The US Food and Drug Administration (FDA) and European Medicines 
Agency require new therapies to be assessed using FEV1 as a primary endpoint. 
However, there is increasing recognition that this may not be suitable for all 
studies.  
There is a balance between opportunity for effective delivery of CF gene therapy 
and potential to detect a change in outcome. For example, a potential disease 
modifying treatment for young children may be easy to deliver by nebulised 
therapy but difficult to assess efficacy over the short to medium term due to 
sensitivity of existing assays in early disease.  Conversely adults with late stage 
disease may have airways plugged with thick mucus which hinders delivery, yet 
abnormal baseline outcome measures (e.g. in spirometry) in which a treatment 
effect could easily be detected. These considerations are summarised in Table 1.3. 
Ensuring that we use the best available tests and have confidence in interpreting 
the results is not only important in the context of clinical trials but also for 
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Infants and young children 
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measure short to 
medium term 
efficacy due to 
baseline abnormal 
respiratory status  
 Subjects can consent 
to participation in 





 Difficult to 















 Physical barriers to 




 Apparent negative 
results due to 
physical barriers and 
irreversible pathology 
may lead to rejection 
of novel therapy 
 
 
Table 1.3. Challenges of identifying appropriate patient population for CF gene 
therapy clinical trials. 
 
1.5 The UK CF Gene Therapy Consortium clinical 
programme 
The UKCFGTC aims to develop gene therapy for CF with clinically detectable 
benefit. It is evaluating a non-viral CF gene therapy product in its current clinical 
programme. Three clinical studies comprise what is commonly referred to as ‘Wave 
1’ of this programme; the Run-In study, the single dose ‘Pilot’ study and a double 
blind placebo controlled multi-dose clinical trial. The relationship between the 
Run-In, Pilot and multidose trial in the Consortium’s Wave 1 programme and the 
aim(s) of each study are summarised in Figure 1.2.  
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Figure 1.2. Relationship between clinical studies in the UK CF Gene Therapy 
Consortium’s clinical programme.  
A description of the Run-In study and Pilot study are given below. Recruitment to 
the multidose trial was in progress at the time of writing this PhD and therefore 
results from this study are not included within this thesis.  
1.5.1 The Run-In study 
The Run-In study was a longitudinal observational study involving patients with CF 
recruited in London and Edinburgh as part of the UKCFGTC clinical programme. The 
full title of the study is ‘Longitudinal assessment of clinical measurements in 
patients with cystic fibrosis in preparation for clinical trial of CFTR gene therapy’, 
referred to as the ‘Run-In’ study throughout this thesis. 
By collecting serial measurements from a wide range of tests during periods of 
clinical stability, it aimed to identify both the most appropriate outcome measures 
and the most appropriate patients to take forward to multidose trial. Although the 
Run-In study was purely observational, outcome measures reflected interest in the 
potential to effectively deliver and detect clinical efficacy of a nebulised gene 
therapy product in a future interventional trial. They included outcomes 
encompassing particle deposition, airway physiology, airway structure, systemic 
and airway inflammation, and patient reported outcome measures. A list of 
outcome measures investigated within the study can be found in Appendix 9.1.  
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1.5.2 The single dose ‘Pilot’ study 
A phase 1b clinical trial of non-viral CF gene therapy has been undertaken by the 
UKCFGTC within the time course of this PhD. The study is entitled ‘Evaluation of 
safety and gene expression with a single dose of pGM169/GL67A administered to 
the nose and lung of individuals with cystic fibrosis’. It enrolled patients with CF 
aged 16 years and over with a forced expiratory volume in one second (FEV1) > 60% 
predicted at recruitment. Patients were given a single nebulised and/ or nasal dose 
of CF gene therapy (pGM169/GL76A). For simplicity and consistency the study is 
referred to as the ‘Pilot’ study throughout this thesis.  
The primary aim of the Pilot study was to investigate safety and choose a dose to 
take forward into the multidose trial. It was also designed to take the opportunity 
to explore gene expression and CFTR function and the end points used in the trial 
reflected both of these aims.  
Outcome measures for the Pilot study reflected the trial design of assessing safety 
and evidence of molecular and functional efficacy (Table 1.4). The Pilot study was 
not designed to investigate clinical efficacy.  
Safety Efficacy 
Clinical examination and pulse 
oximetry 
CFTR mRNA 
Whole blood and serum markers Upper airway PD 
Spirometry Lower airway PD 
Gas transfer Sputum inflammatory markers 
Lung clearance index (LCI)  
Chest CT scan  
Bronchial biopsy  
Table 1.4. Outcome measures in the Pilot study categorised according to 
primary role in assessing safety or efficacy.  
 
A full list of trial outcome measures is given in Appendix 9.2. This includes many 
established outcome measures in CF clinical trials (e.g. spirometry), but also others 
with as yet uncertain clinical roles.  
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1.6 Outcome measures of interest 
The work of this PhD thesis is an evaluation of the outcome measures used in both  
longitudinal study (Run-In study) and an interventional clinical trial for CF (Pilot 
study), as well as an investigation into the development of novel outcome 
measures relevant to the field.  
There are two main themes in this thesis. The first involves physiological 
measurements in the lower airway (e.g. spirometry) and their relationship with 
other outcomes (e.g. structural outcomes as measured by computed tomography). 
The other involves a functional readout at the cellular level of ion transport across 
epithelial cells (airway Potential Difference (PD)). These themes apply to opposite 
ends of the clinical trial process, but illustrate issues relevant to any phase of 
development.  
1.6.1 Airway physiology outcomes  
Physiological measurements of respiratory status including spirometry and lung 
clearance index represented important outcome measures for both the Run-In and 
Pilot studies. Longitudinal measurement of airway function in the Run-In study has 
offered a unique opportunity to investigate variability over time during apparent 
clinical stability. Serial measurements within patients pre and post nebulised gene 
therapy in an interventional study allow investigation of how post-intervention 
measurements relate to usual variability over time, and in particular how change in 
one test parameter reflects change in another physiological test of respiratory 
function. 
In the Run-In study, airway physiology tests included spirometry and lung clearance 
index. In the Pilot study, they additionally included transfer factor of carbon 
monoxide (referred to as ‘gas transfer’ throughout this thesis). 
1.6.1.1 Spirometry 
Spirometry involves measurement of the flow and volume of inspired or expired air 
over time (51).  In a forced expiratory manoeuvre, patients inhale to their 
maximum capacity (total lung capacity) from an end tidal expiration before 
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performing a forced manoeuvre in which they exhale rapidly with sustained 
expiration until no further air can be expired (residual volume). Spirometry indices, 
in particular forced expiratory volume in one second (FEV1), are widely used in the 
clinical and research arenas for monitoring disease progression. They play an 
important role as both safety and efficacy measurements and are well established 
outcome measures in clinical trials (1;2). FEV1 is attractive because the respiratory 
manoeuvre is relatively quick to perform, the test is non-invasive, test equipment 
relatively inexpensive and data collection in large epidemiological or cross-
sectional studies enables comparison of disease populations against ‘normal’ 
values. However, as described previously it lacks sensitivity to detect early 
structural change in mild CF lung disease (47-49), and in clinical trials for CF the 
relatively small annual decline in % predicted values per year (around 1% per year) 
(46) necessitates large numbers of participants to achieve adequate power to 
detect any influence on this. Despite these limitations, it is currently the only CF 
efficacy outcome acceptable to regulatory authorities and as such, is the primary 
outcome in the vast majority of phase 3 clinical trials. 
In comparison to FEV1, the forced expiratory flow between 25-75% of FVC (MEF25-75) 
has been considered a measure of peripheral airways obstruction (52). Histological 
examination of tissue from patients with CF including organs from children 
undergoing lung transplantation has confirmed that there is extensive involvement 
of the small airways (53), and small airways disease is apparent on CT scans as 
areas of air trapping on expiratory images (54). Having outcomes which are able to 
detect changes according to geographical site (e.g. central large vs. small 
peripheral airways) is attractive. Although challenged by a known greater 
variability in measurement than FEV1, measurement of forced expiratory flow at 
75% of FVC has been used as a primary outcome measure in clinical trial. For 
example, in a study of dornase alpha (recombinant human deoxyribonuclease 
(RhDNase)) delivered with nebulisers targeting either the small or larger airways, 
significant differences between baseline vs. 4 weeks were detected with this 
measure and also MEF25-75 but not with FEV1 (55). MEF25-75 correlates with the ratio 
of FEV1/FVC however in mild disease (i.e. mild obstruction to air flow) the former 
is associated with a greater decline (56). In practice the geographical region of the 
airway represented by the different spirometry outcomes is not uniformly agreed, 
and there is some evidence in the adult literature that MEF25-75 correlates poorly 
with other measures thought to reflect air trapping including FVC and the 
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plethysmographic derived value of residual volume divided by total lung capacity 
(57).   
In studies involving only adult subjects with spirometry as an outcome measure, 
absolute change in expired volumes or flows can be compared pre and post 
intervention, but this is more complicated when children and young adults are 
involved, as lung volumes increase with height. To take account of the influence of 
height, age and gender in interpreting spirometry, there are a large and constantly 
expanding number of linear regression reference equations reported in the 
literature for comparing the raw expired volumes and flow rates to those expected 
(58-62). It is important that the reference source used is valid for the study 
population of interest.  In the UK, it is currently recommended by the British 
Thoracic Society that Rosenthal values (62) are used for converting absolute values 
into % predicted values in childhood. In adults the European Community for Steel 
and Coal (ECCS) equations by Quanjer et al (61) are commonly used. Both use 
linear regression equations to predict values with which measured values can be 
compared. 
However, these regression equations have limitations. For example, they do not 
recognise the non-linear relationship between lung volumes and height in 
adolescence (63). The original paper describing the Rosenthal reference equations 
does include factors for pubertal correction which may go some way to address 
this, but in usual clinical practice these are not taken into account.  Stanojevic et 
al (64) have  created a reference source that combines data from multiple studies 
spanning all ages in an effort to create greater accuracy and relate the relationship 
between observed and expected values with standard deviation score (z scores) in 
addition to % predicted values. This uses a method described by Cole (65) and now 
well established for growth charts where z scores are calculated according to 
values in ‘look up’ tables using a LMS approach (L=skewness; M= median; S= 
generalised coefficient of variation) which take account of distribution in the 
measurement and normalizes it. This is achieved by expressing the changing 
distribution with three curves representing the median, coefficient of variation and 
skewness allowing the calculation of z scores (66). The data on which the 
Stanojevic reference source is based are from four large studies of spirometric 
indices including the UK Rosenthal data and NHANES III data from the US (58;62). 
The implications of external reference sources have been investigated by the 
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author and are described within this thesis, including the differences in outcome 
according to whether discontinuous (separate adult and child) or continuous (‘all 
ages’) sources are used.  
1.6.1.2 Lung clearance index 
Lung clearance index (LCI) is a measure of ventilation inhomogeneity obtained 
using a multiple breath washout (MBW) technique. This is achieved either by 
‘washing out’ nitrogen resident in the airways with 100% oxygen, or by measuring 
the progressive elimination of a non-absorbable, inhaled test gas over serial 
breaths from a starting equilibrium in the inspired and expired test gas 
concentration. From this equilibrium, the volume of expired gas taken to result in a 
concentration of the test gas 1/40th of the starting concentration is measured (an 
arbitrary cut off based on the limits of nitrogen detection in the original mass 
spectrometry equipment used to develop the MBW technique). The LCI can be 
calculated from this cumulative expired volume. Early studies with LCI used 
measurements collected with a mass spectrometer, which is still considered the 
gold standard for testing (47;49;67). There has been increasing interest in LCI as an 
outcome measure in CF over the past decade. Abnormalities in LCI in young 
children with CF in comparison to controls in the presence of often normal 
spirometry demonstrated its use as a more sensitive indicator of early lung disease 
(47;49). 
In some centres, all measurements continue to be performed using mass 
spectrometry although, increasingly, other methodologies are employed. The 
UKCFGTC uses the technique described by Horsley et al (68), with a modified 
Innocor device (Innovision, Odense, Denmark). LCI is being increasing used as an 
outcome measure in longitudinal studies in early childhood and is becoming 
established as an outcome measure in studies involving CF patients with mild 
disease (69;70). Use as an outcome measure in CF clinical trials for older children 
and adults with pre-existing abnormalities in spirometric parameters including 
variability over time is at present unknown.  
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1.6.2 Airway potential difference (PD) 
Abnormal or absent CFTR protein expression in the airway is associated with an ion 
transport defect that can be detected in vivo. This creates an opportunity to 
measure in vivo the function (rather than the presence) of CFTR protein, albeit 
indirectly. De novo CFTR protein (as could occur following gene therapy) or 
endogenous protein which has been potentiated or corrected can be detected by 
changes in the electrical characteristics of the tissue under test. Therefore it is not 
surprising that airway potential difference (PD), and particularly nasal PD, has an 
established role as an outcome measure in early phase clinical trials of novel 
agents for CF directed at tackling the underlying molecular defect. Nasal PD tests 
are only performed at a limited number of UK centres, a reflection on the 
equipment and technical expertise required for testing and a relatively recent 
evolving role in ‘difficult’ diagnosis. However the attractiveness of nasal PD as an 
outcome measure for clinical trials and as an aid in patients in whom the diagnosis 
of CF is difficult to confirm has led to its adoption by multiple centres on a 
worldwide basis. 
1.6.2.1 CFTR and its role in ion transport 
As described in section 1.2.1, CFTR is a cyclic adenosine monophosphate (cAMP)-
dependent chloride channel which also regulates sodium ion transport via the 
epithelial sodium channel (ENaC)(71;72) and in CF the ion transport defects 
involving chloride and sodium flux result in an altered potential difference (PD) 
across the respiratory epithelium, measurable in millivolts. When compared to 
healthy cells expressing CFTR, in CF the absent chloride secretion and sodium 
hyperabsorption result in an apical cell surface which is electrically more negative 
under basal or resting (non-stimulated) conditions (73). Amiloride, as a sodium 
channel blocker, results in a greater reduction (depolarisation) in nasal PD for CF 
than non-CF subjects (74;75) and subsequent ionic and pharmacological challenges 
to stimulate chloride secretion (via chemical gradients) are ineffective in CF but 
lead to pronounced hyperpolarisation in the presence of functional CFTR. There is 
recent evidence from a porcine model that abnormal transport of chloride ions 
(rather than abnormal transport of sodium ions) may be able to explain all of the 
abnormal airway PD measurements which are found in CF (76). Evidence in support 
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of this has since also been demonstrated in an in vitro model of cultured lower 
airway epithelial cells (77).  
In vivo measurements of PD across the respiratory epithelium are made either in 
the upper (nose) or lower (bronchial) airway. Nasal PD detects changes in electrical 
potential at the airway surface, measured using a millivolt meter in real time 
whilst a series of solutions are perfused onto the airway surface. The perfused 
solutions allow an evaluation of the cells within any fluid contact for their 
response(s) dependent (as least in part) on CFTR function. Measurement of nasal 
PD in vivo was first described in healthy adult subjects by Knowles et al in the early 
1980s (74;78). By measuring PD at the inferior surface of the inferior turbinate, he 
found no overlap between CF and non-CF subjects in basal PD measurements (74). 
Modification of the technique was performed by Alton et al, with measurement 
instead along the floor of the nasal cavity using an adapted Foley catheter 
containing diluted electrode gel and a solid silver/silver chloride (Ag/AgCl) 
electrode (79;80). The same group (Middleton et al) then described a protocol for 
measuring nasal PD with a series of perfusion steps including those permitting 
measurement of baseline, response to amiloride, and chloride secretion (75). The 
principles of this method were those employed in the UK CF Gene Therapy 
Consortium Pilot study.  
Several groups have attempted to define normal ranges for nasal PD, although 
differences in experimental set up contribute to variable results. In an early report 
of measurements undertaken on the nasal floor, Alton et al measured basal PD in a 
CF and control population (80). In healthy controls, mean PD was -19 (95% CI -7.6 
to -30.4). In CF, mean basal PD was -46.1mV (95% CI -27.7 to -64.5). Airway PD in 
vivo has been used to discriminate between CF and non-CF subjects (74;75), and 
correlates with the number and severity of CFTR mutations (81). In CF, the 
response to solution perfusion assessing response to sodium blocking agents or to 
encourage chloride secretion relates to clinical status (82). Nasal PD is included in 
the diagnostic algorithm for CF by the European Diagnostic Working Group for cases 
where diagnostic results are borderline or inconclusive (i.e. sweat chloride and 
CFTR genotyping) (83).  
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Additionally, airway PD measurements have been used as an outcome measure in 
clinical trials (35;36;84;85). Usually this involves nasal PD, but lower airway PD 
measurements have also been used in a small minority (35).  
1.6.2.2 Airway PD as an outcome measure in CF gene therapy clinical trials 
As a functional read-out of CFTR, nasal potential PD measurement has become an 
established end point for early phase clinical trials involving gene therapy.  
Although the lung is the primary target, the nose has gained an important role in 
assessing molecular and functional evidence of gene transfer in early stage clinical 
trials of therapies targeting the underlying molecular defect largely with nasal PD. 
Measurements pre- and post gene therapy can detect any normalisation of values as 
a result of de novo CFTR expression and can provide information on the duration of 
expression. Due to the technical challenges and the lack of repeatability, lower 
airway PD measurements have been used less often. However, a restoration of 25% 
towards normality of electrical values in the basic underlying (chloride) ion 
transport defect in the lung was demonstrated in the Lancet study (35). The 
correlation between degree of electrical normalisation and clinical outcome is 
unknown.  
In trials involving nasal dosing, nasal PD has been used as a main outcome for 
efficacy (20;35;36;42;86-91). However, nasal PD results have been variable, and 
correlation of any change in nasal PD with molecular evidence of CFTR has often 
been lacking (20;35;89). Looking at the PD results on a per patient basis (i.e. in 
isolation of group results), several suggest change towards non-CF values 
(20;35;36;87;89-93) however the responses have not been universal and the reasons 
for this are unclear. Many studies have suffered from limited numbers of pre-
intervention tests. Within-subject variability in nasal PD has been reported within 
the literature and is high (94). Therefore it can be difficult to confidently interpret 
post treatment values if only a single pre-treatment nasal PD has been conducted. 
This has been the case in much of the published literature. Where changes in PD 
have been reported following gene therapy, these have generally been restricted 
to sections of the test which represent improved chloride transport rather than 
correcting sodium hyperabsorption. This is likely to reflect the higher proportion of 
cells required to be corrected before changes in sodium hyperabsorption can be 
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corrected (>90% vs. <10% for restoration of chloride transport) (23;24;95) and is a 
reason why improved methods of quantification are required. A PD measurement 
set up which had the capacity to quantify the success of CFTR correction would 
allow comparison with clinical efficacy or evaluation of response to therapy over 
time, and be advantageous in comparison to conventional methodology. 
Use of nasal PD as an outcome measure is not limited to gene therapy evaluation, 
and recent studies have included trials of small molecule drugs (96-98). Not only 
does inclusion of nasal PD in such studies provide evidence of proof of principle, it 
could also allow retrospective analysis of how changes detected at the level of ion 
transport relate to the clinical picture and downstream consequences of disease.  
It is not yet known how any change between pre- and post treatment results (in 
mV) relates to clinical outcome. In a phase II clinical trial (97), the small molecule 
potentiator drug Ivacaftor, led to a modest 3.5mV change in chloride secretion on 
nasal PD (chloride response); in contrast, sweat chloride in response to this orally-
administered agent, fell dramatically by a mean of > 50 mmol/l and in some 
subjects into the normal range. The subsequent phase III clinical trial (in which 
nasal PD was not performed) reported a large change in absolute % predicted FEV1 
from baseline of 10.6% in comparison to the placebo group and a significant 
reduction in pulmonary exacerbation rate (99). Clearly therefore, small apparent 
changes in nasal PD can co-exist with much larger changes in clinically relevant, 
pulmonary end-points. 
Present methods for PD measurement cannot determine the quantitative success of 
gene therapy in vivo because correction of a higher proportion of cells within 
epithelial sheets does not result in further ‘super correction’ of Cl- ion transport 
(23), related to the arrangement of epithelial cells as if in a parallel electrical 
circuit. The clinical relevance of correcting a certain proportion of cells is 
unknown. The ability to quantify correction would allow comparison with clinical 
efficacy and could be used as a tool to assess the success of delivery over time 
(e.g. following repeated doses within the same patient to determine whether 
transfection occurs in the same or different cells). This would be potentially useful 
also for other novel CF treatments aimed at tackling the underlying molecular 
defect (and for which early phase clinical trials already use ‘standard’ nasal PD 
measurements as an outcome measure of functional efficacy).  
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1.7 Hypotheses, aims and objectives 
1.7.1 Hypotheses  
1. Non-viral CFTR gene transfer will lead to:  
a. Expression of functional CFTR protein 
b. Detectable improvements in airway health 
2. Currently used methods to detect these changes may be optimised to: 
a. Enhance sensitivity and allow quantification 
b. Facilitate an understanding of geographical effects 
3. Understanding the relationship between CFTR electrophysiological effects 
and the downstream consequences on airway physiology will allow the more 
rational design of future trials.  
1.7.2 Aims  
1. To optimise proximal and distal electrophysiological measures of CFTR 
function. 
a. To obtain proximal (nasal) and distal (lower airway) potential 
difference measurements using conventional techniques modified to 
be compliant with current regulatory requirements 
b. To design a novel electrophysiological method to allow quantification 
of corrected cells in the upper airway. 
2. To refine both the methodology and analysis of measures of airway 
physiology, both conventional (spirometry) and more novel (lung clearance 
index). 
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3. To explore correlations between electrophysiological and physiological 
outcomes in a trial of CFTR gene therapy. 
1.7.3 Objectives 
The objectives are divided according to the two main themes of this thesis; namely 
airway physiology and airway potential difference (PD) measurement. 
1. Airway physiology 
a. Analyse serial spirometric measurements focussing on the influences 
of variability and the impact of reference equations 
b. Compare the more novel measure, Lung Clearance Index, with 
conventional spirometry to assess its potential superior sensitivity and 
whether the two techniques are providing information from different 
geographical regions of the airway 
c. Explore relationships between both these and structural (CT), 
inflammatory outcome measures and electrophysiological measures. 
2. Airway PD measurements: 
a. Develop the skills required to measure nasal PD 
b. Assist in the design and implementation of an improved protocol for 
measuring bronchial PD which is compliant with current regulations 
c. Obtain repeated measures of both nasal and bronchial PD in patients 
receiving a single dose of non-viral CFTR gene therapy 
d. Design a novel nasal PD technique to allow quantification of 
transfected cells.  
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2   Methodology 
2.1 The Run-In study 
The Run-In study was a longitudinal observational study involving patients with CF 
recruited in London and Edinburgh as part of the UKCFGTC clinical programme. As 
outlined in Chapter 1, section 1.5.1, it aimed to identify both the most appropriate 
outcome measures and the appropriate patients to take forward to a subsequent 
multidose trial of CF gene therapy.  
2.1.1 Study personnel 
The clinical team at each site included clinicians and research nurses at the 
University of Edinburgh, and clinicians, nurses and physiologists at the London site. 
Scientists and administrative staff were based at all three Consortium sites (the 
Oxford site is non-clinical). Recruitment was complete prior to the author joining 
the clinical programme; however the study has been in progress throughout the 
time course of this PhD. Over this period, the author’s role has been predominantly 
in overseeing and refining the methodology of airway physiology tests, quality 
control and data analysis. 
2.1.2 Study recruitment and consent 
The Run-In study involved both adult and paediatric participants in Edinburgh 
(Western General Hospital and Royal Hospital for Sick Children) and London (Royal 
Brompton Hospital). Patients were recruited and enrolled in the study by the 
respective clinical teams at each site. Potential participants were enrolled if they 
gave informed consent (or assent with parental consent) and met inclusion criteria. 
2.1.2.1 Inclusion Criteria 
1. Cystic fibrosis confirmed by a combination of clinical symptoms/ signs and 
sweat test, genetic analysis or nasal potential difference measurements  
2. Forced expiratory volume in the 1st second (FEV1) > 40% predicted values*  
3. Clinical stability at entry defined by: 
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a. Not on any extra antibiotics (excluding routine, long-term treatments) 
for the previous 2 weeks 
b. No increase in symptoms such as change in sputum production/ 
colour, increased wheeze or breathlessness over the previous 2 weeks 
c. No change in regular respiratory treatments over the previous 4 weeks 
4. Aged 10 years and above 
5. Written informed consent from patient (aged 16 years and above) or parent 
if younger child; assent from child where appropriate 
6. Permission to inform GP of participation in study 
 
*Inclusion criteria for the Run-In study were based on spirometry reference 
equations as defined by Quanjer (61) (adults) or Rosenthal (62) (children).  
  
2.1.2.2 Exclusion Criteria 
1. Current participation in any other interventional clinical trial 
2. Infection with Burkholderia cepacia complex organisms or MRSA unless local 
infection control guidelines could be adhered to 
3. Awaiting/ referred for or post-lung transplant 
4. Chronic day-time oxygen requirement 
5. Previous spontaneous pneumothorax unless patient had had a subsequent 
pleurodesis  
6. Recurrent severe haemoptysis 
7. Current smoker  
8. Significant co-morbidity including: 
a. Moderate/ severe CF liver disease (varices or significant, sustained 
elevation of transaminases: (ALT/ AST>100 IU/l) 
b. Significant renal impairment (serum creatinine > 150 mol/l) 
c. Significant coagulopathy  
9. Receiving 2nd line immunosuppressant drugs such as methotrexate, 
cyclosporine, intravenous immunoglobulin preparations  
10. Pregnant  
 
There was no upper limit of FEV1% predicted at recruitment. Patients were made 
aware at time of enrolment that the Run-In study was a precursor to a future 
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multidose trial of CF gene therapy but that the study itself was observational and 
participation in the Run-In study did not guarantee an opportunity for enrolment in 
the future multidose trial.  
2.1.3 Study visits and clinical stability 
Study visits were performed during periods of clinical stability at intervals initially 
aimed to be around 3-5 months. Clinical stability was confirmed by telephone call 
prior to the study visit date. Importantly, visits were rescheduled if the patient 
reported a change in usual symptoms or recent change in medications (over past 4 
weeks), which resulted in many visit intervals being extended.  
At the study visit, patients were first asked to complete a short questionnaire 
which included a series of questions designed to assess clinical stability (see 
Appendix 9.3). Questions related to change in symptoms of cough, tiredness, 
breathlessness and sputum (volume and character). For each question, response 
was on a 5 point scale from -2 to +2 with negative numbers representing 
deterioration in symptoms. Potential scores were between -14 and +14. Patients 
were required to have a symptom score above -4 to continue with the visit.  
Tests were carried out at study visits as per trial protocol. Study visits took 
between two and three hours to complete per patient.  
2.1.4 Study protocol 
The Run-In study protocol was devised by the UKCFCTC Strategy Group. The Chief 
Investigator was Prof Eric Alton. A favourable ethical opinion was obtained in June 
2007 (REC reference 07/Q0703/78). Patient enrolment commenced in January 
2008. This thesis includes data from the first four study visits. It was at this time 
point that decisions were made regarding which outcome measures would be used 
and which participants would be eligible for the multidose trial. Following this 
decision, eligible patients were seen for visits 5 and 6 to ensure on-going 
longitudinal data collection prior to the start of the multidose trial. Those 
considered ineligible on the basis of disease severity (too severe or too mild) for 
inclusion in the multidose trial were offered the opportunity to attend a study 
‘exit’ visit.   
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The Run-In study outcome measures investigated in this thesis are summarised in 
Table 2.1. A full list of outcome measures investigated in the Run-In study can be 
found in Appendix 9.1.  
Test Outcome measure(s) 
Blood markers of infection and 
inflammation 
Neutrophil count, CRP 
Spirometry FEV1, FVC, FEV1/FVC, MEF25-75 
Multiple breath washout LCI 
Chest CT scan 
Extent and severity of bronchiectasis, 
airway wall thickness, air trapping 
Quality of life questionnaire (CFQ-R) Respiratory domain 
Table 2.1. Run-In study outcome measures described within this thesis 
 
  
2.1.5 Data analysis 
Data analysis described in this thesis is limited to the first 4 study visits. As 
described, this reflected the data on which decisions were made regarding 
appropriate assays and patients to take forward to the multidose trial. All data 
analysed from the Run-In study has been obtained from the official study database 
produced by the Royal Brompton Hospital Clinical Trials and Evaluation Unit 
(CTEU).  The CTEU database was created in Microsoft Access. This database 
included a series of individual data tables summarising patient characteristics and 
outcomes.  
Export of these Access data tables to Microsoft Excel was performed by the author. 
Patients were identified by their study number (RU001 to RU216) in each table. In 
order that serial measurements from individual patients could be aligned across 
study visits (to permit comparison between visits), additional ‘blank’ rows 
containing no data were inserted for any RU ‘number’ not actually representing an 
enrolled patient at visit 1. For visits 2-4, additional ‘blank’ rows were inserted as 
per visit 1, and also for any patients with no data for a particular visit due to prior 
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withdrawal from the study. These alignment processes resulted in the same patient 
being represented in the same row of data for each data table at each visit. 
Visit interval independent results are summarised as box and whisker plots (range, 
25th, 50th and 75th centile) for each outcome measure as a data summary of results 
from all patients with results from all 4 study visits. The coefficient of variation (%) 
between visits for an outcome at the 4 study visits was calculated by dividing the 
standard deviation of the result by its mean. This was performed for all patients 
with results for the outcome of interest at each visit unless stated otherwise in the 
text.  
 
Cross-sectional correlations between computed tomography (CT) scores and other 
outcome measures were performed only on measurements made at the same Run-
In visit (i.e. for a patient that had their CT scan at visit 2, comparison was made 
with the LCI measured at visit 2).  
 
Relationships between continuous and rank ordered variables were explored with 
correlation coefficients (Pearson and Spearman rank). As this was an exploratory 
data set, the author undertook multiple comparisons between outcome measures; 
to compensate for this, the author has assigned statistical significance only to 
analyses with a p value of <0.0001.  
Linear regression was used to investigate directional change over time. Using age in 
years as the x-axis variable, decimal age at each visit was plotted against different 
y-axis variables (e.g. lung clearance index) to calculate a ‘best fit’ regression 
equation for each patient. In the equation y=mx+c, where x was age in years, ‘m’ 
represented the change in variable per year. Comparison of the slope of change 
over time for an outcome of interest (‘m’ in the above equation) according to 
disease severity was performed with t-tests or Mann Whitney tests depending on 
normality of distribution. A p value <0.05 was considered significant.  
Statistical analysis was performed using SPSS or GraphPad Prism software (version 
4.03 GraphPad Software, Inc). Prism was used for graphical display of results. 
Statistical advice to the UKCFGTC has been provided by Dr Gordon Murray (GM), 
University of Edinburgh although formal statistical analysis of this dataset has not 
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yet been undertaken by his department. The analysis and results presentation 
described have been performed by the author with guidance from GM. 
2.2 The single dose Pilot study 
The Pilot study was a phase 1b clinical trial. It involved the administration of a 
single nasal and/or lung dose of non-viral CF gene therapy with outcome measures 
reflecting the study aims of investigating safety and functional efficacy. 
2.2.1 CFTR gene therapy product pGM169/GL67A 
2.2.1.1 Clinical plasmid 
The CFTR plasmid DNA administered in the Pilot study was pGM169. Its 
nomenclature represents the number of plasmids investigated by the UKCFGTC in 
pre-clinical testing. Prior to the Pilot study, this plasmid had not been 
administered to man. However, it has been subject to an extensive process of pre-
clinical testing within the UKCFGTC, leading to its selection for evaluation in 
clinical trial. To improve duration of CFTR expression, a humanised promoter 
rather than a viral (CMV) promoter (used in the Lancet study (35)) was inserted. In 
mouse studies, the human elongation factor 1 alpha promoter resulted in a 
sustained duration of expression in comparison to the CMV promoter (100).  
The other major modification to the CFTR plasmid DNA was to remove all CpG 
dinucleotides from the plasmid DNA (100). Removal of these CpGs resulted in 
significant modulation of the post dosing inflammatory profile observed in mice 
(100). Plasmid pGM169 was superior in duration of expression and in the reduced 
likelihood of a post-dosing inflammatory response when compared with other 
plasmids hence it was selected to take forward for clinical evaluation. 
The plasmid DNA used in the clinical programme was manufactured externally (VGX 
Immune Therapeutics, Texas, US). On site storage was maintained at -80 degrees C 
in pharmacy approved conditions until required for patient administration. 
Monitoring during storage on site included a locked temperature mapped freezer, 
within a controlled entry room.  
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2.2.1.2 Clinical liposomal vector 
The UKCFGTC Pilot study used a non-viral gene transfer agent (vector) to increase 
the potential delivery of CFTR to the airway cells. This vector was a cationic 
liposome, GL67A (OctoPlus, Leiden, NL), identical to that administered during the 
Lancet study (35). It was found to be superior to other non-viral gene transfer 
agents (25KDa-branched polyethyleneimine (PEI), the cationic liposome GL67A and 
compacted DNA nanoparticles) in pre-clinical evaluation (101). GL67A is produced 
with three components: GL67, DOPE and DMPE-PEG5000. On site storage was 
undertaken as per clinical plasmid conditions, at -80 degrees C until required for 
patient administration. Despite the lipid agent itself being identical, the method of 
administration was different in the Pilot study reflecting knowledge gained from 
animal models and nebuliser droplet distribution. Pre-clinical optimisation of 
nebulisation including droplet size to increase the likelihood of the product 
reaching the small airways (thought to be the site of initiation of disease pathology 
in CF) has been undertaken by researchers within the Consortium prior to the Pilot 
study (102).  
2.2.2 Trial protocol 
The study design and protocol were devised by the Strategy Group of the UKCFGTC, 
which comprises senior clinicians and scientists from the three UK sites involved in 
the Consortium. The funding for the Pilot study was from the UK CF Trust and the 
trial Sponsor was Imperial College, London.  
2.2.2.1 Study personnel  
The clinical team at the London site was led by Dr Jane Davies (Reader, Honorary 
Consultant at the Royal Brompton Hospital, London and primary supervisor for this 
PhD). Other members include nurses, physiologists, trial co-ordinator and clinical 
research fellows (including the author of this thesis). The scientists at the London 
site were led Dr Uta Griesenbach, and the Chief Investigator was Professor Eric 
Alton. Sample processing (sputum and serum) was performed by laboratory 
technicians within the Department of Gene Therapy, Imperial College and at the 
Edinburgh Consortium site. Routine clinical laboratory tests (blood and sputum) 
were processed by the Royal Brompton Hospital laboratory services.  Molecular 
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assays of CFTR were performed at the Oxford site of the Consortium, by the team 
of scientists led by Dr Steve Hyde.   
The Pilot study took place throughout the first 2 ½ years of the author’s PhD. The 
author had pivotal roles in the conduct of the trial: consenting patients, providing 
medical care for patients on bronchoscopy and dosing days, and performing airway 
potential difference (PD) measurements. During the study, the author also 
prepared summary progress reports for the UKCFGTC Strategy Group, Data Safety 
Monitoring Board (DSMB) and regulatory authorities. Post trial, the author’s focus 
has been on data analysis. This has included all upper and lower airway PD 
measurements, as well as the safety and physiological outcomes. 
2.2.3 Study enrolment 
Participants were all registered patients at the Royal Brompton Hospital, London. 
Potentially suitable patients were identified according to baseline lung function. 
This was done by all members of the clinical team, but predominantly nursing and 
physiologists, often by introducing the study to patients at routine outpatient 
appointments where a Patient Information Sheet was given to interested persons. 
These patients were then followed up by telephone to determine if they were keen 
to participate and a study visit (‘Initial visit’) was arranged. Eligible patients were 
enrolled in the study if informed consent was obtained. Informed consent was 
taken by a member of medical staff (JD, author or TB). Compensation for loss of 
earnings and travel expenses for study visits were reimbursed. 
At enrolment, patients were required to be clinically stable, and meet the trial 
inclusion and exclusion criteria as listed in the trial protocol as defined below.  
The trial was open-label and was specifically designed to be iterative, amendments 
to protocol being made on the basis of responses seen in an earlier dosing group. 
Recruitment was opportunistic, based on subject availability. There were no 
specific attempts made to ‘match’ patients on the basis of clinical characteristics 
within dosing cohorts.  
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2.2.3.1 Inclusion criteria 
1. Cystic fibrosis confirmed by sweat testing or genetic analysis  
2. Males and females aged 16 years and above  
3. Forced expiratory volume in the 1st second (FEV1) > 60% predicted* value (or > 
40% predicted* for patients receiving the nasal-only dose under Part B of the 
study) 
4. Clinical stability at entry defined by: 
a. Not on any additional antibiotics (excluding routine, long-term treatments) 
for the previous 2 weeks  
b. No increase in symptoms such as change in sputum production/colour, 
increased wheeze or breathlessness over the previous 2 weeks 
c. No change in regular respiratory treatments over the previous 4 weeks  
5. Prepared to take effective contraceptive precautions for the duration of their 
participation in the study and for 3 months thereafter 
6. If taking regular RhDNase were willing, and considered able by independent 
medical carers, to withhold treatment for 24 hours before and 24 hours after 
the gene therapy dose (nebulised doses only) 
7. Written informed consent obtained 
8. Permission to inform GP of participation in study 
 
 
*Percent predicted values for lung function at recruitment were based on Quanjer  
(61) and Rosenthal (62) reference values for adults (≥18 years) and children (<18 
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2.2.3.2 Exclusion criteria 
1. Infection with Burkholderia cepacia complex organisms or MRSA  (due to cross 
infection reasons) 
2. Significant nasal pathology including polyps, clinically-significant rhinosinusitis, 
or recurrent severe epistaxis   
3. Acute upper respiratory tract infection within the previous 2 weeks  
4. Previous spontaneous pneumothorax without pleurodesis  
5. Recurrent severe haemoptysis (Part A only) 
6. Sensitivity, allergy or inability to take non-steroidal anti-inflammatory agents 
(Part B of study/ Ibuprofen arm only)  
7. Current smoker (assessed by measuring cotinine level prior to study entry) 
8. Significant co-morbidity including: 
a. Moderate/severe CF liver disease (varices or significant, sustained elevation 
of transaminases: ALT/ AST>100 IU/l) 
b. Significant renal impairment (serum creatinine > 150 umol/l) 
c. Significant coagulopathy  
9. Receiving 2nd line immunosuppressant drugs such as methotrexate, cyclosporine, 
intravenous immunoglobulin preparations  




2.2.4 Ethics, MHRA and study protocol amendments 
The Pilot study was approved by GTAC (reference 140) and the MHRA and 
registered on the Clinical Trials database (EudraCT reference number 2007-004050-
85). MHRA and GTAC approval for the protocol version (version 4) used at the start 
of the trial were granted in December 2008 and January 2009 respectively. 
Favourable approval from the Royal Brompton Hospital Research and Development 
department was obtained prior to enrolling the first patient. 
The trial protocol was modified on several occasions during the course of the study. 
These modifications were designed to maximise the potential for obtaining 
appropriate information on product safety and dose response. Each protocol 
amendment was approved by the appropriate regulatory bodies. All patients 
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proceeding to the dosing study visit received a single dose of CF gene therapy (lung 
and/or nasal). No patients received placebo.  
The Pilot study was conducted in two main sections, referred to as Pilot A and Pilot 
B. 
2.2.4.1 Original trial design and protocol amendments (Pilot A) 
Based on the previous Lancet trial (35), the proposed nebulised dose of gene 
therapy for this trial was 20 ml. The original protocol included an initial three 
patients receiving half this dose (10ml) nebulised to the lung and a 1ml nasal dose 
(a ‘non-invasive cohort’). Following this, 12 patients would receive a 20ml lung 
dose and 2ml nasal dose with paired pre- and post- dose bronchoscopies. Post dose 
bronchoscopies were planned to occur on day 2 or day 14 post dosing.  
However, the post dosing side effect profile seen in the 10ml lung dose patients led 
to the submission of a protocol amendment to a) include a ‘non-invasive’ cohort of 
patients (n=3) receiving 20ml to allow the natural history of any adverse effects to 
be documented without a bronchoscopy potentially complicating this and b) to 
move the day 2 bronchoscopy as at this time point, a flu-like response was still 
apparent; these procedures were therefore designed to be conducted on day 6 or 
14 post dosing. Completion of the bronchoscopic cohort in late 2009 concluded this 
section of the Pilot study, referred to as ‘part A’. 
2.2.4.2 Amended trial design and protocol amendments (Pilot B) 
Part B of the Pilot study (2010 – 2011) was initiated once it was clear that the 
standard delivery of 20 ml would not be sufficiently safe to proceed to multiple 
dosing. The two strategies employed broadly focused on a) trying to deliver the 20 
ml dose more safely (slower nebulisation or with adjuvant anti-inflammatory 
therapies) and b) exploring the effects of lower doses. We also continued to 
investigate evidence of functional efficacy from nasal PD measurements and 
molecular assays. However, review of data by the independent Scientific Advisory 
Committee led to the recommendation that the focus of part B should be on safety 
outcomes and that the invasive bronchoscopic measures should be discontinued. 
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Patients in part B had lung and/ or nasal dosing. Protocol amendments were 
approved with removal of the bronchoscopic measures as above, and additionally 
chest CT scan and sputum cytokine assays were also taken out. CT was removed as 
there were no significant concerns raised following review of serial chest CT scans 
from patients in part A, and in an effort to reduce the time commitment required 
for study visits, sputum cytokine assays (and therefore sputum induction) were 
removed from the trial protocol. 
 
2.2.5 Study visits 
The number of study visits and tests carried out at each visit depended on the 
patient’s dosing cohort. A summary of study visits according to dosing cohorts for 
both part A and B, including assays carried out at visits is provided in Appendix 9.2.  
Post nebulised and/or nasal dosing, follow up was at pre-defined intervals until day 
28. Within the constraints of the trial protocol, additional study visits were 
undertaken on the basis of adverse clinical status coinciding with the end of follow 
up or on-going evidence suggestive of functional efficacy (nasal PD changes) at day 
28.  
2.2.5.1 Pre-dose visits 
Pre-gene therapy study visits were carried out during periods of clinical stability, as 
defined in the trial inclusion criteria. Pre dosing visits included the initial visit and 
a baseline visit (within 7 days of gene therapy dose), and additionally patients in 
the invasive cohort in Pilot A had a pre-dose bronchoscopy visit. All bronchoscopies 
were performed under general anaesthetic. Clinical stability on dosing day was 
confirmed by telephone call carried out by one of the research nurses prior to 
attendance and confirmed on the day of dosing according to symptom report.  
Patients were advised to continue taking all regular medications throughout the 
study period, with the exception of RhDNase which was omitted for a period of 24 
hours pre- to post gene therapy dose (due to a theoretical risk of degradation of 
the gene therapy product by the RhDNase).  
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2.2.5.2 Dosing visit 
Clinical history and examination pre administration of lung dose was performed by 
a member of the medical team (author/JD/TB). Any patient not considered 
clinically stable on the basis of clinical history had their gene therapy postponed. A 
detailed description of procedures followed on dosing day, including administration 
of the gene therapy product, is given below.  
2.2.5.3 Post dose visits 
Post-dose visits were carried out at intervals determined by trial protocol, and 
according to patient dose cohort. The tests carried out at post dose visits depended 
on the dosing cohort and whether they were enrolled during Pilot part A or part B. 
Patients in the invasive (bronchoscopic) cohort had a single post dose bronchoscopy 
carried out.   
2.2.6 Dosing: Preparation 
Reconstitution and preparation of pGM169/GL67A was undertaken by the 
designated clinical trial pharmacists in a room within the Department of Gene 
Therapy, Imperial College suitable for purpose. Each vial of GL67A was hydrated 
with 5.25ml sterile water for injection and vortexed at 2500 rpm for 40 minutes 
(VWR-VX2500 vortexer (VWR International, PA, US)). After this period, the vial was 
checked to ensure the lipid was completely resolved and if not vortexing was 
repeated in 10 minute cycles (if still incomplete at 100 minutes the vial was 
discarded). In comparison for the plasmid (pGM169), once thawed, no 
reconstitution was required. To prepare the pGM169/GL67A complexes, a 
pneumatic mixing device was used (LMD2 pneumatic mixer, as described by Davies 
et al (103)).This device utilises a pneumatic piston, which in conjunction with a 
dual lumen syringe (Plas Pak, CT, US) and static mixer, achieves reproducible 
mixing of the pGM169 and GL67A components to produce the product ready for 
patient administration (5ml of the reconstituted lipid is added to one lumen, and 
5ml of pGM169 to the other of the double lumen syringe). The gene therapy 
product (as a 10ml volume) was collected from the mixing device in a 20ml Sterilin 
container (Sterilin Ltd, UK).  
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Following preparation of the gene therapy product, it was delivered to the dosing 
cubicles in the Royal Brompton Hospital (RBH) in sterile universal containers in 
10ml aliquots. Transportation was undertaken in accordance with a risk assessment 
carried out by Dr U Griesenbach: the product was transported within designated 
containers (shatter proof metal containers) containing absorbent material, with the 
person responsible for transporting the product carrying a ‘spill kit’ in case of 
accidental product release. It was an approximately 10 minute walk between the 
room used for product formulation and the area in the Royal Brompton Hospital 
used for dose administration. The reconstituted product had an expiry of 4 hours 
following preparation by the trial pharmacists.  
On receipt of the product by study nursing or medical personnel within the RBH 
area designated for dose administration, a 10ml syringe was used to draw up the 
gene therapy into the nebuliser chamber or nasal spray bottle. This was done by 
study nursing or medical personnel.   
2.2.6.1 Lung dose 
For lung dosing, 5ml aliquots were inserted into a nebuliser chamber (AeroEclipse II 
Breath Actuated Nebuliser (BAN), Monaghan, NY, US). Further aliquots up to the 
total prescribed dose (in ml) were subsequently prepared.   
2.2.6.2 Nasal dose 
The nasal dose was administered using nasal spray bottles (GSK parts No. AR5989 
30mL bottle/AR9488 30mL actuator). On receipt of the gene therapy product, the 
10ml aliquot was transferred in its entirety to the nasal spray bottle, which was 
primed prior to use to ensure that the product would be delivered when required. 
This was done by inserting the spray bottle nozzle into an adapted 50ml Falcon 
tube (BD Biosciences, UK) which ensured that no product would enter the 
atmosphere following actuation. The Falcon tubes were part-filled with absorbent 
material so priming could occur into the tube within a contained space. 
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2.2.6.3 Weighing of nebuliser and nasal product 
The AeroEclipse II nebuliser chamber and nasal spray bottle were weighed 
separately pre- and post filling, post-priming of the nasal spray, and post patient 
administration. For each 5ml nebuliser aliquot, this was undertaken when the 
chamber looked visibly empty and no ‘mist’ could be seen with patient use. For 
nasal dosing, post dose weighing was carried out when the designated number of 
nasal sprays had been administered. Weights were recorded to the nearest 0.1g on 
a worksheet, and a simple calculation was undertaken to determine the actual 
amount (assumption 1ml gene therapy product = 1g) delivered to the nose and with 
each 5ml nebulised aliquot. No ‘top up’ doses were given if the weight suggested 
under-dosing, either for nasal or lung delivery. 
2.2.6.4 Risk assessment 
All handling of the gene therapy product was made in accordance with the trial risk 
assessment, which included the use of personal protective equipment (FFP2 mask, 
apron and gloves) worn by staff entering the gene therapy delivery dosing cubicle, 
and also by patients if they needed to come out of the cubicle prior to the end of 
dosing and including a 30 minute period following the end of delivery. Following 
this period, no additional precautions regarding protective clothing or equipment 
were required either by patients or staff, other than existing hospital policy and 
procedure for segregation of patients with cystic fibrosis and infection control.  
2.2.7 Dosing: Gene therapy administration 
The nebulised dose was driven by pressurised air at 8 litres per minute using a 
breath activated nebuliser. An AeroEclipse II BAN kit with PARI filter set 
(041G0500, PARI Medical Ltd, Surrey UK) attached was used for each 5ml aliquot of 
gene therapy, with the mouthpiece from the PARI set used for dosing (Figure 2.1).  
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Figure 2.1. Lung dose nebuliser set up. The photograph shows an AeroEclipse II BAN 
nebuliser with PARI filter and mouthpiece, as used for lung dosing administration.  
 
All dosing was carried out with the patients seated in small, individual cubicles. A 
glass window allowed continuous observation. Patients were instructed to breathe 
normally during nebulisation. Nebulisation was undertaken either at ‘standard 
delivery rate’ (3 minutes on the nebuliser and 2 minutes off to deliver each 5ml 
aliquot over approximately 25 minutes) or ‘slow delivery’ (1 minute on nebuliser 
and 4 minutes off, each 5ml aliquot delivered over a period of 75 – 150 minutes). 
Nebulisation was undertaken using the 5ml aliquots of gene therapy product, with 
the total number of aliquots administered dependent on intended dose as 
described above. All patients in Pilot part A received their nebulised gene therapy 
delivered at standard rate. Patients in Pilot B had either standard or slow rate 
delivery. 
The nasal dose was administered by instructing the patient to deliver a single spray 
to each nostril once every five minutes during the nebuliser ‘off period’ in patients 
who were also being lung dosed; nursing staff recorded the number of sprays 
delivered. The number of sprays equal to 1ml or 2ml of gene therapy product had 
been previously determined prior to clinical trial by Consortium members at the 
Oxford site (1ml = 12 sprays, 2ml = 24 sprays). Nasal spray bottles were re-weighed 
post delivery of the appropriate number of sprays to determine actual dose 
delivered. Nasal dosing was administered according to the number of sprays rather 
than change in weight of nasal spray container.  
The first three 10ml patients were dosed individually, 1 week apart. This was 
undertaken in view of this being a ‘first in man’ study to allow appropriate safety 
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monitoring. The first three patients in the 20ml nebulised (non-invasive) cohort 
were also dosed a week apart and admitted electively overnight for post-dosing 
monitoring. For subsequent dosing, the maximum number of patients treated on 
any day was 2, with considerations for patient safety and appropriate monitoring 
and staffing constraints paramount.   
All patients in Pilot part A were recruited to receive nasal and lung dosing. Nasal 
and lung doses were administered simultaneously. Patients in Pilot B were 
recruited to lung, lung and nasal or a nasal only cohort. This was done according to 
patient preference, and also according to results of nasal PD testing (evidence of 
chloride secretion on pre-dosing tests excluded some patients from nasal dosing, 
see Chapter 5).  
2.2.8 Clinical monitoring 
On dosing day, and following confirmation of clinical stability, spirometry and 
baseline clinical observations were undertaken prior to dosing.  
During dosing, patients could be directly observed through glass windows of the 
cubicles used for dose administration. They were asked to report any symptoms 
experienced during dosing to the nursing team. Oxygen saturation and heart rate 
were monitored every 30 minutes from the start of dosing.  
Patients were observed for a minimum of 30 minutes in the dosing cubicles 
following completion of nasal and nebulised dose. A period of not less than 6 hours 
observation was then undertaken either in the Clinical Studies Unit/Biomedical 
Research Unit or as an inpatient at RBH. Spirometry, oxygen saturation, blood 
pressure, heart rate, respiratory rate and temperature were measured hourly post 
dosing for a period of 6 hours.  
2.2.9 Adjunctive therapy 
2.2.9.1 Planned 
As per protocol, all patients (Pilot A and B) received a single 200 microgram dose of 
Salbutamol delivered via metered dose inhaler and large volume spacer 20 minutes 
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prior to dosing. This was administered because of an expected possible 
bronchoconstrictive effect of the hypotonic gene therapy product.  
In selected lung dosing cohorts (Pilot part B only), planned adjuvant treatment was 
co-prescribed with the gene therapy. The aim of any adjuvant therapy was to 
assess its impact on the post dosing adverse event profile. Adjuvants investigated 
in the Pilot study included the oral drugs ibuprofen, prednisolone and paracetamol. 
The dosing strategies for these adjuvants is summarised in Table 2.2.  
Planned 
adjuvant 
All or selected 
patients only? 
Dose and regime 
Salbutamol All 200 mcg (inhaled) via MDI and large 
volume spacer 20 minutes pre- nebulised 
dose 
Ibuprofen Selected only 400mg (oral) between 3 and 1 hour pre-
dose with re-administration post dosing at 
intervals no less than 6 hours and no more 
than 3 doses in 24 hours  
Prednisolone Selected only 30mg (oral) daily from 24 hours pre- to 24 
hours post nebulised dose (3 day total 
course) 
Paracetamol Selected only 1g (oral) at 2, 6, 12 and 18 hours post 
start of nebulised dose 
Table 2.2. Adjuvant medication administered with lung gene therapy dose 
 
Doses for planned adjuvant treatment with either ibuprofen or paracetamol were 
according to standard anti-inflammatory doses appropriate for adult patients. The 
dose selected for adjuvant prednisolone therapy was undertaken following 
consultation with a senior researcher with expertise in corticosteroids and 
relationship with inflammatory processes in chronic lung disease external to the 
trial employed within our institution (Professor P Barnes, National Heart and Lung 
Institute, Imperial College).  
2.2.9.2 Symptomatic 
Additional medication was permitted post dosing for symptomatic relief, including 
bronchodilators and simple analgesia. 
In addition to any planned adjuvant treatment for patients in part B of the study; 
patients could also receive symptomatic treatment with ibuprofen and 
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paracetamol. This was prescribed on an ‘as-required’ basis according to patient 
request and symptoms (as long as drug or dose interval was not contraindicated by 
existing adjuvants).  
2.2.10 Adverse events and safety reporting 
Adverse events during the Run-In and Pilot study were collected on all patients 
from trial enrolment. Methods of identifying adverse events included patient 
report, patient symptom diary, together with review of clinical laboratory blood 
results. Serious adverse events (SAEs) and suspected unexpected serious adverse 
reactions (SUSARs) were reported to the trial Sponsor and relevant bodies.  
2.3 Outcome measures: Airway physiology 
This section includes methodology for airway physiology outcomes in the Run-In 
and Pilot studies. This includes extensive development work undertaken by the 
author to improve data quality and analysis for spirometry and LCI outcomes. 
Where results are presented to illustrate these quality and analysis issues, they are 
from the Run-In study Visit 1.  
2.3.1 Spirometry 
For both Run-In and Pilot studies, spirometry was performed on all subjects at trial 
enrolment and subsequent study visits according to ATS/ERS standards (51). An 
exception to this was in the six hour post gene therapy dose monitoring period in 
the Pilot study. During this acute monitoring period, repeated measurements were 
made hourly for a period of 6 hours as per protocol, however patients often found 
this exacerbating of any respiratory symptoms post dose and therefore we 
considered it acceptable that patients perform only a single blow.  
2.3.1.1 Equipment 
Spirometry was performed at each visit using an EasyOne® spirometer (ndd Medical 
Technologies, Zurich, Switzerland), with a single disposable mouthpiece and filter 
(spirette®, ndd Medical Technologies as above). The EasyOne® is a portable, 
battery operated spirometer which uses ultrasonic flow sensors. 
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2.3.1.2 Calibration 
A calibration check was performed on the day of test with the EasyOne® using a 3 
litre syringe, with acceptable results if -/+ 3%. Due to the ultrasonic flow detection 
system used by the EasyOne®, it does not require calibration by the researcher (this 
is because the ultrasonic transducers are external to the spirette® and therefore 
changing the spirette® does not alter the transducers, which also function 
independent of temperature, atmospheric pressure and humidity).  
2.3.1.3 Data collection 
Spirometry tests were performed by study personnel (physiologists, nursing staff, 
clinical research fellows) at London and Edinburgh sites. They were performed with 
the patient seated using an open circuit method. Patients were asked to wear a 
nose clip for testing. A minimum of three forced expiratory manoeuvres from 
maximal inspiration were undertaken by subjects at each visit. EasyOne® 
spirometers were prepared by selecting ‘best value’ and ‘Automated QC’ in the 
test settings menu. Patient data was entered with study number as identifier, date 
of birth and height. ‘FVC(expiration)’ was selected in test selection menu, prior to 
insertion of the spirette®. Baseline flow setting was performed with occlusion of 
the base of the spirette®, following which a ‘blast out’ prompt was displayed on 
the EasyOne® screen. With patients holding the EasyOne® spirometer, they were 
instructed to place the mouthpiece into their mouth and form a complete seal 
around it. Patients then performed a forced sustained expiratory manoeuvre from a 
maximal inspiration. Verbal encouragement was given to subjects during testing. 
Visual inspection of the flow volume curve on the EasyOne® screen after each blow 
was made by the researcher carrying out the test. Three forced expiratory 
manoeuvres were performed, with measurement of FEV1, FVC, and expiratory 
flows. 
The raw flow and volume measurements captured for each EasyOne® test included 
FEV1, FVC, MEF50, MEF25, MEF75, MEF25-75, and FEV6. Selection of FEV1, FVC and 
MEF25-75 was performed according to ERS/ATS standards (51). Within manoeuvre, 
each blow had to demonstrate an absence of artefacts (e.g. cough during first 
second) and satisfactory duration of expiration (at least 6 seconds (3 for children)). 
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Between tests, across 3 acceptable tests the two largest volumes for FEV1 and FVC 
had to be within 150 ml of each other (of 100ml if FVC < 1 litre). 
The highest acceptable FEV1 and FVC did not necessarily have to originate from the 
same blow (51). MEF25-75 was taken from an acceptable blow with the highest sum 
of (FEV1+FVC). Where two blows had identical sums of (FEV1+FVC) but different 
MEF25-75 values, the blow with the highest FEV1 contributed to the final data value 
for that visit.  
Parameters from all three acceptable forced expiratory manoeuvres were recorded 
in the patient’s case record form (CRF), with selection of the final result for FEV1, 
FVC and MEF25-75 at each visit according to ERS/ATS standards. In both Run-In and 
Pilot studies, raw values were written into the CRF from the EasyOne® screen or 
exported directly to a computer via USB connection. The former was only relied on 
where the electronic data was unobtainable. Connection of the EasyOne® to a 
computer by placing it in the EasyOne® cradle, and using EasyWare™ software 
resulted in an automatic upload of data. Print out of the collected data was kept 
for source data reference. The electronic data was imported from the EasyOne® 
software into Excel spreadsheets. 
2.3.1.4 Original spirometry reference source 
Raw values for FEV1 and FVC (litres) and MEF25-75 (litres/minute) were initially 
converted to % predicted values according to Rosenthal (<18 years) and Quanjer 
(≥18 years) reference equations (61;62). The reference equations used to 
determine the expected volumes for subjects according to these sources for FEV1 
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Reference 
source 
Relevant group Regression equation for % predicted FEV1 
<18 years: 
Rosenthal et al 
(62) 
M <162.6 cm (0.03425*standing height in cm) -2.78 
M >162.5 cm (0.0521*standing height in cm) -5.108 
F <152.6 cm (0.03316*standing height in cm) -2.734 
F >152.5 cm (0.04112*standing height in cm) -3.680 
≥18 years: 
Quanjer et al 
(61) 
M 18-70 years, 
height 1.55-1.95$ 
(4.3*standing height in m)-(0.029*age yrs)-
2.49 
F 18-70 years, 
height 1.45-1.80$ 
(3.95*standing height in m)-(0.025*age 
yrs)-2.60 
Table 2.3. Linear regression equations for calculation of FEV1 % predicted as 
used at start of Run-In and Pilot studies. M=male, F=female. $25 substituted for 
subjects between 18-25 years. ‘Relevant group’ refers to height and gender. Height is 
inserted into the relevant regression equation in centimetres for Rosenthal and metres for 
Quanjer reference equations respectively.  
 
2.3.1.5 New spirometry reference source  
During the time course of the Run-In study, published reference look-up tables 
spanning paediatric and adult age ranges became available (64). An Excel add-in 
downloaded from www.growinglungs.org.uk (and currently accessible from 
www.lungfunction.org) allowed conversion of raw spirometry values to % predicted, 
z scores for FEV1, FVC and MEF25-75  according to the reference source described by 
Stanojevic et al (64).  In Excel, data were analysed with columns designated for the 
variable of interest (e.g. FEV1), aligned with patient gender, decimal age and 
height (to nearest cm in Run-In and to nearest mm in Pilot study) at study visit. All 
lung volumes (litres) and flows (litres/minute) were recorded to 2 decimal places in 
the CRF. Using the macro in the add-in, conversion to % predicted values and z 
scores was performed for FEV1, FVC and MEF25-75. Height was measured on a single 
occasion at the start of the Pilot study as all participants were adults, therefore all 
% predicted and z scores were obtained from the same height measurement. As the 
Run-In study included children and adolescents, height was measured at each study 
visits for all participants.  
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2.3.1.6 Comparison between percent predicted values for FEV1 obtained with 
original and new reference source 
Comparisons between the percent predicted values obtained with the original and 
new reference source were investigated. Using the Run-In study data set at visit 1 
as an example, the differences in absolute FEV1 % predicted values according to 
original and new reference sources for the same raw data are plotted in Figure 2.2. 
  
 
Figure 2.2. Difference in absolute FEV1 % predicted values for identical raw 
data according to reference source at Run-In visit 1. Data on the left is the 
difference between Rosenthal and Stanojevic reference values for all patients aged <18 
years at visit 1 with each patient represented by a single point. Data on the right is the 
difference between Quanjer and Stanojevic reference values for all patients aged ≥18 
years at visit 1, with each patient represented as before. Lines represent mean and 
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Rosenthal and Quanjer FEV1 % predicted values were both significantly higher than 
the Stanojevic values calculated with the same raw data. For all patients at visit 1, 
Rosenthal and Quanjer equations resulted in FEV1 % predicted values on average 
2.6% greater in absolute % predicted terms (paired t-test p<0.0001). Divided 
according to paediatric and adult age ranges, the mean difference was 2.8% (95%CI 
1.9-3.7) for children with Rosenthal equations (p<0.0001), and 2.4% (95%CI 2.1-2.8) 
for adults using Quanjer equations (p<0.0001). This difference between equations 
was present across the range of severity in disease in the Run-In study, illustrated 
by the Bland Altman (104) plot in Figure 2.3 with mean bias and 95% limits of 
agreement shown. 




















Figure 2.3. Bland Altman plot for absolute FEV1% according to reference 
source. FEV1% predicted values are according to Rosenthal (<18 years) or Quanjer 
(≥18 years) compared to Stanojevic values for all patients (n=191) at Run-In visit 1 
in (graph A), patients <18 years at visit 1 (graph B) and patients ≥18 years at visit 1 
(graph C). The mean difference (bias) and 95% limits of agreement between 
Rosenthal and/or Quanjer vs. Stanojevic % predicted values are represented by 
dotted lines.  
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For patients aged <18 years at visit 1, the greatest difference between reference 
sources was seen for female participants with height <152.6cm at visit 1 (mean 
difference between Rosenthal and Stanojevic % predicted value = 6.2, paired t-test 
p<0.0001) although the number of patients in this bracket was small (n=13). Large 
discrepancies were also noticed between males aged <18 at visit 1 with height 
<162.5cm (n=31 patients, mean difference between Rosenthal and Stanojevic % 
predicted value = 3.7, paired t-test p<0.0001).    
A plot of FEV1 % predicted values calculated with the Rosenthal and Quanjer 
equations at visit 1 in comparison to the Stanojevic z score for FEV1 at visit 1 is 
shown in Figure 2.4A. Similarly the FEV1 % predicted values from the Stanojevic 
reference source in comparison to z scores are plotted in Figure 2.4B; as expected 
a tighter correlation was seen due to these measures being derived from the same 
data source. However, where discrepancies exist, this comparison demonstrates 
the additional benefit of using z scores to describe results as they take account of 
the expected normal distribution according to age, gender and height of the 
participant. 
 
Figure 2.4A      Figure 2.4B  
Figure 2.4. Comparison of FEV1 % predicted and z scores. In graph A, visit 1 FEV1 
% predicted values according to original reference (Rosenthal <18 years or Quanjer ≥18 
years) are plotted against Stanojevic z scores. In graph B, % predicted and z scores from 
the Stanojevic source are compared. Each patient is represented by a single data point on 
graph A and graph B.  
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2.3.1.7 Patients crossing their 18th birthday during the longitudinal study 
 
In view of the longitudinal nature of data collection in the Run-In study and the 
study population including both child and adult participants, it was expected that 
several patients would transition across their 18th birthday during the period of 
data collection. This occurred for 10 patients during the study, therefore crossing 
from Rosenthal to Quanjer reference sources at some point between visits 1 and 4 
with the original reference source. This transition was often met with a steep step 
down in % predicted FEV1 even in the presence of consistency with height and raw 
FEV1 volumes.  
For these 10 patients the FEV1% predicted values at the study visit either side of 
their 18th birthday according to Rosenthal (<18) and Quanjer (after 18th birthday) or 































1 109.0 98.0 10.9 100.7 97.3 3.4 
2 88.4 68.9 19.5 83.5 70.2 13.3 
3 102.6 94.3 8.3 96.0 91.9 4.1 
4 109.7 90.4 19.3 101.5 89.4 12.1 
5 86.0 81.5 4.4 79.4 80.9 -1.5 
6 79.0 72.5 6.4 74.3 72.3 1.9 
7 75.9 66.3 9.6 71.4 65.8 5.6 
8 35.8 30.7 5.1 35.6 30.4 5.2 
9 74.3 65.0 9.4 61.4 64.3 -2.8 
10 45.6 41.8 3.8 43.0 43.4 -0.4 
 
Table 2.4. FEV1% predicted values for the n=10 patients that crossed their 18th 
birthday during the first 4 visits of the Run-In study. Data shown are the % 
predicted values for the last visit before their 18th birthday, first visit afterwards, and the 
difference in absolute % predicted values between these visits according to Rosenthal to 
Quanjer (A) or Stanojevic (all ages) reference source (B). 
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The mean absolute drop in FEV1 % predicted values across the study visits spanning 
a patient’s 18th birthday was 9.7 absolute % points with Rosenthal to Quanjer 
equations in comparison to 4.1 absolute % points when Stanojevic reference values 
were used.  
The slope (‘m’) representing annual decline in absolute FEV1 % predicted values 
were calculated using the linear regression equation y=mx+ c for FEV1% predicted 
values at each visit, taking into account the interval between study visits. Using 
this approach, the annual decline in FEV1 % predicted values was significantly 
greater with Rosenthal/Quanjer than with Stanojevic reference source (paired t-
test p =0.0007) (Figure 2.5), largely due to an artefactual drop when switching 
from Rosenthal to Quanjer values at age 18.  
 
Figure 2.5. Annual change in absolute % predicted FEV1 for the 10 patients 
transitioning across their 18th birthday during the Run-In study.  Plotted 
according to linear regression analysis. Annual change is plotted according to the separate 
child and adult reference source (Rosenthal to Quanjer) or Stanojevic reference source 
alone.  
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2.3.1.8 Summary 
In view of the above results, which are particularly relevant for any longitudinal 
study involving paediatric and adult participants, all raw values from Run-In and 
Pilot tests were converted to percent predicted values and z scores using the 
Stanojevic ‘All Ages’ spirometry reference source (64). All final spirometry percent 
predicted values and z scores reported in the Run-In and Pilot study results 
chapters (Chapter 3 and 4 respectively) were those obtained using the ‘All Ages’ 
Stanojevic reference source (64).  
 
2.3.2 Lung clearance index 
This methodology section applies to both the Run-In and Pilot studies. The author 
was involved in performing many of the tests, although the majority of data 
collected from the London centre was by study physiologists. For Run-In study 
patients in Edinburgh the test was performed largely by the Clinical Research 
Fellows. The author has led in identifying and responding to quality control issues, 
and been extensively involved in optimising analysis parameters and performing 
data analysis.  
2.3.2.1 Equipment 
Lung clearance index (LCI) was measured using a multiple breath washout (MBW) 
technique with sulphur hexafluoride as the inert tracer gas. MBW was undertaken 
using an Innocor (Innovision, DK) machine adapted for testing according to the 
methodology described by Horsley et al (48). The Innocor was originally developed 
for measurement of cardiovascular parameters by inert gas rebreathing. 0.2% SF6 in 
air was used as the tracer gas (2000 ppb SF6/air 200bar, cylinder BOC 159499-L-PC). 
2.3.2.2 Calibration 
The Innocor machine was switched on at least 20 minutes prior to testing to allow 
the photoacoustic gas analyser to warm up. Flow gas delay calibration was 
performed prior to the first test each day and repeated after 4 hours if further 
testing was planned. This was performed with a filter (details below) present 
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within the calibration set up. The researcher performing the MBW test then 
performed a series of 11 manoeuvres involving slow expiration followed by rapid 
inspiration. Each breath was separated by a few seconds. Acceptability criteria 
included the variation in flow gas delay between breaths being not more than +/- 
20 milliseconds. Flowmeter calibration was also performed at intervals as above. 
This was performed with a filter in situ using a 3 litre calibration syringe. 
Repetitions of filling and emptying the syringe (at different flow rates – slow x 2, 
medium x 2, fast 2) were performed; differences were required to be within +/- 
2%. Measured syringe volumes were also required to be within +/- 2% accuracy.  
2.3.2.3 Performing the test   
The MBW test was performed at each clinical site (RBH, RHSC Edinburgh and 
Western General Hospital). The test was performed with subjects at rest, 
distracted using a DVD, seated with a nose clip occluding the nasal passages. Tidal 
breathing was required throughout.  
2.3.2.4 Wash-in phase  
A single use disposable filter (Bacterial/viral filer Air Safety Ltd, Adult: 4000/01 
Paediatric: 9070/01) was sited between the mouthpiece and flowmeter (Hans 
Rudolph Adult: 4700A, Paediatric: 4719). Subjects inhaled the gas mixture which 
was delivered via a T-piece flow past (Figure 2.6).  
 
Figure 2.6. Illustration of T-piece flow past for LCI measurement. A mouthpiece 
is connected to the filter (on left) prior to patient testing. The T-piece is 
illustrated by the blue arrow. The orange arrows represent the flow of SF6 in air in 
the tubing.  
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This was delivered at a rate of 10-15 litres/minute to ensure that expired gas was 
not re-inspired. With progression of the test, the difference in inspired and expired 
SF6 was reduced as expired concentrations equilibrated to those in the cylinder. As 
the Innocor determines the difference in concentration between the sampling inlet 
and an internal reference within the machine, measures were taken to minimise 
the presence of SF6 around the machine. These included opening doors and window 
(where possible) and use of a fan. The researcher was able to identify when wash-
in was complete by noting a difference of ≤0.003% in SF6 concentration for three 
breaths on the screen of the Innocor machine (this concentration difference was 
deliberately more strict than the criteria for acceptable wash-in at the data 
analysis stage, to be certain of reaching adequate wash-in prior to the washout 
phase).  
2.3.2.5 Disconnection 
When equilibrium between inspired and expired SF6 was reached, the ‘wash-in’ 
phase was complete and the subject was switched to breathing room air. The T-
piece (and therefore gas supply) was disconnected when the patient was in 
expiration with rapid removal of T-piece from the vicinity of the patient to prevent 
any additional further inspiration of test gas. Tidal breathing of room air continued 
until the test gas had been ‘washed out’ of the lungs. This point was identified by 
the researcher on the Innocor screen as the point at which the maximal SF6 
concentration was of ≤0.003% for 3 consecutive breaths. An example trace 
illustrating the wash-in and wash-out phases is shown in Figure 2.7. 
 
Figure 2.7. Multiple breath washout trace illustrating wash-in and wash-out 
phases of the test.  
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On each test date occasion, the procedures above were repeated until 3 tests had 
been performed.  
2.3.2.6 Data export 
Raw data from each test (1 file per washout) were identified by the format: 
[patient ID]-[Date]-[Time].ino and Innocor data files (.txt file extension). They 
were retrieved from the Innocor and saved on a network drive at each clinical site.  
2.3.2.7 Data analysis 
The process of data analysis for LCI evolved considerably during the Run-In and part 
A of the Pilot study in 2009-2010, due in large part to the work of the author. 
2.3.2.8 Original analysis 
At the start of the Run-In and Pilot studies, LCI tests were analysed using software 
written by Per Gustafsson (Queen Silvia Children’s Hospital, Gothenburg, Sweden) 
(no commercially supported software for the standard Innocor for LCI analysis is 
available). During both Run-In and Pilot studies, a number of technical problems 
were detected during data analysis. A key trigger for detailed investigation of the 
LCI results occurred as a result of two analysers sensing SF6 gas concentration 
reaching a different result for the same test, in combination with an unexpectedly 
high inter-visit variability for some patients in the Run-In study. Concerns with the 
quality and consistency of data analysis led to tests being re-analysed by a five 
member team across the two clinical Consortium sites. Between London (the 
author and VC (respiratory physiologist)) and Edinburgh (Clinical research fellows 
NB, HS and PR) sites, just under 2000 LCIs were reanalysed using the software 
written by Per Gustafsson. However, during this reanalysis process and on-going 
data collection it was also noted that not all traces had an end-inspiratory 
concentration of SF6 of zero at completion of a washout. This had great potential 
to influence the LCI result, but it was not possible to adequately address this 
within the original software used. In response, NB wrote a new software 
programme (‘SimpleWashout’) for analysing the LCI data, and in doing so we found 
that there was a small but likely important ‘offset’ between the start and end 
ambient SF6 concentration. Further investigation by NB with Innovision (Odense, 
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DK) confirmed that this was due to the methodology employed by the Innocor 
machine in determining gas concentrations relative to ambient (air) reference 
rather than from absolute values, thus it was not always possible to achieve a 
‘zero’ SF6 end expired gas concentration at the end of the washout.  
The problem with offsets was particularly relevant for the London site. During the 
period of data collection described, the clinical area for LCI tests within RBH 
changed on 2 occasions in response to the building of a new Clinical Research 
Facility within the hospital. Problems with room ventilation in the interim 
temporary accommodation were considered likely contributory to the offsets.  
2.3.2.9 Revised analysis for final LCI results 
The final values for LCI described for the Run-In and Pilot study in Chapters 3 and 4 
have been calculated using the SimpleWashout software (NB, University of 
Edinburgh). This programme was written using the IGOR Pro (WaveMetrics Inc) data 
analysis platform. The following parameters were entered into the SimpleWashout 
software window for calculation of the MBW parameters: Analyser, study, patient, 
visit, test, Flow gas delay and Height (m) – this allowed calculation of the minimum 
termination volume (2.9 x height(cm)-215, in mls) for aiding identification of the 
end of a washout. 
Data files were imported into the SimpleWashout software by first converting the 
.ino files to .txt files containing flow, SF6 and CO2 data using the accompanying 
‘Innofileconverter’. The SimpleWashout software was written to minimise input 
required on the part of the researcher (to minimise operator impact on LCI result). 
Therefore only minimal input was required, however these were important and 
included: 
1. Setting the disconnection point and grading the quality of disconnection 
(e.g. ensuring it had not taken place during inspiration). 
2. Ensuring that the position of the cursors for Cmax (concentration of SF6 at end 
of last inspiration before disconnection) and Cinit (average concentration of 
SF6 at the end of the last expiration before disconnection) were correct.   
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3. Verifying that the first breath and subsequent breaths had been correctly 
identified 
4. Checking the washout termination status 
5. Checking the SF6 offsets 
6. Checking Expired: Inspired gas volume ratio 
 
2.3.2.10 Calculating LCI 
Fall in concentration of SF6 in expired gas during tidal breathing of air, in 
combination with measurement of flow (and thus volume determination) is used to 
calculate the LCI. This is defined as the number of lung turnovers of functional 
residual capacity (FRC) taken to reduce the expired concentration of SF6 to 1/40
th 
of the ‘wash-in’ value.  
The following criteria were used to determine acceptable quality control for tests 
used: 
 Variability in concentration of test gas at wash-in was <0.008%  
 Minimum difference between MBW tests was acceptable if FRC within 11% 
(test excluded if >11% different). 
 Minimum difference between MBW tests within 21% for LCI (tests were 
excluded if >21% different) 
 Satisfactory disconnection and termination of MBW test 
 At least 1 other acceptable test on same test date (to allow calculation of 
average LCI and FRC). 
 Expiratory: Inspiratory volume ratio <0.8 or >1.3 
Repeat reanalysis of all Run-In LCI traces was performed with the NB 
SimpleWashout software, taking the above criteria into account to identify 
acceptable tests. Using this new software, 1961 Run-In traces were analysed 
between NB, GD, VC and PR, with HS performing the revised analysis of Pilot LCIs. 
Each Run-In and Pilot LCI test was then also subsequently been reanalysed by a 
second (different) operator to apply the offset and address any outstanding issues 
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regarding acceptability of data for inclusion in the study datasets. Inter-operator 
agreement was not formally investigated, as on the very rare occasion (since the 
process was largely automated) where a second analyser disagreed with the first, a 
consensus review process involving remaining members of the group determined 
the final outcome.  
The ‘SimpleWashout’ software allowed an ‘offset’ correction for any SF6 gas 
present in the room at the beginning of subsequent tests. The difference in LCI 
between tests performed at the London site with and without the Offset correction 
is displayed in Figure 2.8. The mean difference was negligible (0.02 LCI units). 
However, for individual patients the difference in LCI using the offset correction 
was more substantial. As extreme examples, one patient’s value changed from 9.26 
to 8.30 as a result of applying the offset and another from 12.18 to 13.58. These 
differences exceed changes that have been reported in response to clinically 
established interventions (69;70).  
 
Figure 2.8. Influence of Offset correction on LCI result. Graph shows the difference 
in LCI as a result of application of Offset correction for all Run-In LCI tests performed at 
the London site, with each test represented by a single data point. 
 
The results from the ‘Offset corrected’ LCIs are those contributing to the final 
values for Run-In and Pilot LCI and FRC results. Three tests were performed at each 
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Run-In or Pilot study visit, with the mean of 2 or more acceptable tests 
contributing to final LCI result. 
2.3.2.11 LCI data loss 
The process of data analysis described above led to the exclusion of tests not 
meeting the quality control criteria. These largely included failure to appropriately 
‘wash-in’ with test gas prior to disconnection, or tests terminating prematurely. 
This led to an incomplete LCI data set for a proportion of patients (Table 2.5).  
 All sites 
N (%) 
London   
N (%) 
Edinburgh    
N (%) 
Total number of expected LCIs 
from all Run-In study visits 
678 378 300 
Total number of acceptable LCI 
results 
568 (84%) 277 (73%) 291 (97%) 
Total number of excluded 
tests/absent LCI results 
110 (16%) 101 (27%) 9 (3%) 
 
Table 2.5. LCI data loss following SimpleWashout analysis and quality control 
review, according to Run-In study sites.  
The extent of data loss at the London site was disproportionate to loss of LCI test 
results performed in Edinburgh. It is likely this reflected factors beyond 
environmental influences in test gas measurement including an inadequate 
appreciation of the importance of adhering to the wash-in and washout criteria; 
which has since been resolved through further training and a more detailed 
standard operating procedure. However, also of note was a finding that tests across 
both sites were more likely to be excluded in patients with a visit 1 z score of <-2.5 
(the Run-In study population median FEV1 z score at visit 1). These patients 
accounted for 6/9 (67%) of the excluded tests from Edinburgh and 68/110 (62%) 
excluded tests from London; the author speculates this may in part be due to a 
longer period of time required to achieve adequate wash-in or washout.  
The exclusion of tests according to the quality control rules described above has 
ensured quality and confidence in the final dataset on which multiple comparisons 
with other Run-In study outcomes were made (Chapter 3). Due to parallel timelines 
of the Pilot study and visits 3 and 4 of the Run-In study, these problems with data 
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loss at the London site particularly affected the patients in Pilot part A, most 
notably the 20ml lung dose cohort (Chapter 4). 
2.3.3 Gas transfer 
Transfer factor of the lung for carbon monoxide (TLCO) (referred to as ‘gas 
transfer’ throughout this thesis) was measured for all patients receiving a lung dose 
of gene therapy in the Pilot study using a single breath technique. Gas transfer was 
not part of the Run-In study protocol.   
Irrespective of Pilot study dose cohort, testing was carried out on a single date pre-
dose, and on days 2, 14 and 28 post gene therapy. In Pilot part A, where the post 
dosing measurement on day 14 coincided with post dosing bronchoscopy gas 
transfer was always measured pre- bronchoscopy.  
Pilot study measurements were all performed using a Jaeger® Masterscreen PFTPro 
(CareFusion, Germany) by the trial physiologists. Volume and gas calibrations were 
performed prior to testing. Subjects were seated wearing a nose clip, and 
measurement undertaken using the diffusion single breath protocol. Patients were 
asked to exhale to residual volume, then take a maximal inspiration (required to be 
>90% vital capacity) of the test gas (medical air with 0.28% carbon monoxide and 
9% helium) prior to a breath hold of 10 seconds duration. Tests where the subject 
expired during this period (detected by a near patient shutter >3Kpa) were invalid. 
Following breath hold, the subjects were asked to breathe out smoothly.  
This procedure was repeated at least twice on each test day (minimal interval 
between tests 4 minutes).  Duplicate estimates of TLCO had to be within 10% or 
1.0mmol.min-1.kPa-1 (whichever greater) to meet requirements for test 
acceptability. At least 2 technically acceptable tests were obtained and the mean 
values used for test results.  Up to 10 measurements could be performed to obtain 
these reproducible values. The following values were recorded for each test: Single 
breath TLCO, Alveolar volume (VA), Transfer coefficient (KCO)(=TLCO/AV) and 
Inspiratory vital capacity (IVC). TLCO and KCO were corrected for haemoglobin 
(Hb); TLCOc and KCOc respectively; either from Hb on day/nearest day to test date 
using the following formulas (105):  
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Males: TLCOc = TLCO*(10.22+[Hb])/(1.7*[Hb])) 
Females: TLCOc = TLCO*(9.38+[Hb])/(1.7*[Hb])) 
The gas transfer results from the Pilot study were analysed as change in absolute 
values and % change from baseline at each post gene therapy test date.  
2.4 Outcome measures: Clinical, laboratory, structural and 
patient reported 
2.4.1 Physical examination and pulse oximetry 
2.4.1.1 Run-In  
Height was recorded at each study visit for both adults and children using a 
Leicester height measure and measured to the nearest centimetre. Readings of 
≥0.5cm were rounded up and <0.5cm rounded down to the nearest cm. Weight was 
measured with shoes and outdoor clothing removed in kilograms to the nearest 
100g. Blood pressure, heart rate and pulse oximetry were measured using a 
Dinamap ProCare monitor (GE Healthcare, US) and portable oxygen saturation 
monitor.  
2.4.1.2 Pilot  
Height was recorded (to the nearest mm) on a single occasion following enrolment. 
Weight in kilograms was recorded to the nearest 100g and measured at each study 
visit. Body temperature was recorded with a single use thermometer (Tempa 
DOT™, 3M, UK) to the nearest 0.1 degrees C. Change in temperature post dosing 
was assessed according to the following approaches:  maximum temperature post 
dosing, and objectively measured temperature 8 hours post start of dosing. Clinical 
examination at study enrolment and on dosing day was performed by a study 
doctor. At all other times, chest auscultation could be performed by either the 
study doctor or nurse.  
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2.4.2 Clinical laboratory blood tests and genotype 
2.4.2.1 Run-In 
Blood samples were taken at each visit for the clinical and research assays as 
summarised in Appendix 9.1. Outcomes discussed in this thesis (total white cell 
count, neutrophil count, C-reactive protein) were analysed by the hospital 
laboratories at the respective clinical sites according to usual hospital procedures. 
Analysis of the blood parameters from samples taken at each study visit was 
restricted here to routine clinical laboratory tests of inflammation, to allow 
comparison with the results following the single nebulised dose of gene therapy in 
the Pilot study (Chapter 4). 
 
Patients with incomplete CF mutation information at study enrolment (i.e. either 
single or both mutations unknown) had an EDTA blood sample sent for CFTR 
mutation analysis (ARMS29 mutation screen).  
 
2.4.2.2 Pilot 
Blood for electrolytes, renal function, inflammatory markers, full blood count and 
coagulation screen were taken at study visits according to trial protocol. They were 
processed by the RBH clinical laboratories in accordance with usual routine hospital 
practice. A coagulation screen was only performed on subjects in the invasive 
cohort of the study, as a safety precaution prior to bronchial biopsy at 
bronchoscopy (these patients were all in Pilot Part A). Blood was also processed for 
cytokine analysis, autoantibodies and lymphocyte analysis of anti-CFTR T-cell 
response to investigate any host immunological response to the gene therapy 
product; however, the results are not included within this thesis.  
2.4.3 Structural: Chest computed tomography (CT) scan 
2.4.3.1 Run-In 
A baseline CT chest was carried out at Run-In study visit 1 or 2 (or visit 3 in 
exceptional circumstances). Post menarchic female study participants were 
required to have a negative urine pregnancy test on the day of the CT scan. CT 
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scans performed for the Run-In study were volumetric high-resolution chest CT 
(inspiration, contiguous thin sections (1.25mm)) and interspaced high-resolution CT 
(expiration, 1mm sections at 10mm intervals) scanning from apices to bases.  The 
maximal total dose of radiation for the CT scan was 1.5 milli Sieverts. CT scans 
were anonymised by coding and scored by two independent radiologists according 
to a scoring system developed by Professor D Hansell, Royal Brompton Hospital.  
 
Scoring was carried out for the following variables: extent of bronchiectasis, 
severity of bronchiectasis, wall thickening, presence of small airway plugs, 
presence of large airway plugs and degree of air trapping. A score was given for 
each variable for each lobe (right upper, middle and lower lobes, left upper, 
lingual and lower lobes) by each radiologist. Where discrepancies of > 1 between 
scores existed, both radiologists reviewed the images and a consensus was agreed. 
Air trapping (on expiratory images only) was quantified as a percentage of the lobe 
involved to the nearest 5%. The final score entered into the CRF for each variable 
represented the mean for all lobes combined. CT scans were also assessed for the 
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Absent Mild Extensive    
Large airway 
plugs 
Absent Mild Extensive    
Air trapping  To nearest 5% 
 
Table 2.6. CT scoring grid used for analysis of Run-In chest CT scans. Scoring 
was performed by two radiologists, with a score given for each variable for each 
lobe (right upper, middle and lower lobes, left upper, lingual and lower lobes). Air 
trapping (on expiratory images only) was quantified as a percentage of the lobe 
involved to the nearest 5%. Final CT scores for each outcome (e.g. wall thickening) 
represented the mean for all lobes combined. 
 
No other chest CT scans were performed for the Run-In study between visits 1-4; 
therefore there was only a single CT time point for data analysis for each patient. 
The second intended time point for CT in the Run-In study was either at a 
subsequent study ‘exit’ visit, or following recruitment to the multidose trial. As the 
latter is on-going at the time of writing this thesis, I have not included any data 
from paired scans. 
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2.4.3.2 Pilot 
In part A of the Pilot study, patients underwent limited cut high resolution CT chest 
(without contrast) at intervals according to study protocol. Cuts were made every 
30mm with seven images per CT scan. One pre-dose scan (<7 days pre-dose), and 
three post dose scans were performed (day 2, 14 and 28). The total number of 
chest cuts for the entire study was therefore 28 per patient. This was equivalent to 
an estimated maximum total radiation dose of 1.6 milli Sieverts. Female trial 
participants underwent urine pregnancy testing on date of each CT scan in 
accordance with usual clinical practice for radiological imaging.  
CT scans were analysed by Professor Hansel (Consultant Radiologist, RBH) for signs 
of toxicity following nebulised gene therapy. As they were included as a safety 
measure (rather than efficacy), scans were not reported according to the scoring 
system described for the Run-In study. 
2.4.4 Patient reported: Quality of life questionnaire 
2.4.4.1 Run-In study 
Quality of life was measured with the disease specific CFQ-R questionnaire 
(106;107), using the CFQ-UK (Revised) version (2005, Bryon & Stramik CFQ-UK 
English language version 1). This was completed at the start of each study visit. 
The CFQ-R measures functioning during the past two weeks and contains generic 
and CF specific responses. Children <14 years completed the child questionnaire. 
Adolescents and adults completed the adult questionnaire. Where transition across 
the 14th birthday occurred during the study, patients transferred to the adult 
questionnaire. All CFQ-R responses were converted to scores for the questionnaire 
domains by Dr Su Madge, Royal Brompton Hospital. According to questionnaire 
responses, a numerical score (out of 100) was given for each of the domains with 
higher scores implying greater quality of life. There are 12 domains in the adult 
and 8 in the child questionnaire, these are listed in Table 2.7.  
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CFQ-R Domains 
Adult and Child questionnaire Adult questionnaire only 
Respiratory Role  
Physical functioning Vitality 
Eating disturbances Health perceptions 





Table 2.7. Adult and paediatric domains for the CF Quality of Life questionnaire 
(CFQ-R) 
 
Scores from adult and child questionnaires were combined for analysis (108). Data 
analysis has concentrated on the Respiratory Symptoms domain. The questions 
from the CFQ-R which contribute to the Respiratory Symptoms domain score are 
displayed in Table 2.8. A minimal clinical difference for the Respiratory Symptoms 
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 Child version of CFQ-R questionnaire Adult version of CFQ-R questionnaire 
“Tell me how often in the past two 
weeks”: 
 You coughed during the day*  
 You woke up during the night 
because you were coughing* 
 You had to cough up mucus* 
 You had trouble breathing* 
Indicate how you have been feeling 
during the past two weeks: 
 Have you been congested?** 
 Have you been coughing during 
the day?** 
 Have you had to cough up 
mucus?** 
How often during the past two weeks: 
 Have you been wheezing?* 
 Have you had trouble 
breathing?* 
 Have you woken up during the 
night because you were 
coughing?* 
 
Table 2.8. Questions in CFQ-R contributing to the Respiratory Symptom 
domain score. Questions are shown according to questionnaire version (child or 
adult). Potential responses are on a four point Likert scale: 
*Always/Often/Sometimes/Never. **A great deal/Somewhat/A little/Not at all.  
  
2.5 Functional efficacy outcome measures: Potential 
difference measurements in the upper airway 
This section describes the methodology for measurement of nasal PD in the Pilot 
study. Basic equipment required for nasal PD testing includes electrodes, a high 
impedance voltmeter, a perfusion set up, and data capture. The details of 
hardware vary according to manufacturer and test variability is also introduced 
with experimental technique (e.g. anatomical site of measurement) and 
experience of the operator. In both the US and in Europe, attempts have been 
made over recent years to standardise conditions between centres (94;109). 
However, although the technique is not difficult, it is one for which familiarity is 
essential and results can be affected by methodology such as times for solution 
  91 
perfusion etc. Ahrens et al reported considerable variability in nasal PD results 
between centres (84) and therefore attention to detail in methodology and data 
analysis is essential.  
The equipment set up at our centre (RBH) has been developed in our centre over 
the past 15 years. Several changes were required prior to trial onset, in order that 
it complied with all aspects of Good Clinical Practice. A Standard Operating 
Procedure was written by the author and followed by the researchers undertaking 
testing throughout the Pilot study (GD/JD), a detailed description of methods 
within this is given in section 2.5.2 below. A novel approach to nasal PD is also 
described. 
2.5.1 Measurement of nasal PD: overview 
Our methodology measures transepithelial nasal PD using a set-up involving an 
exploring electrode sited within an adapted Foley catheter and a reference 
electrode sited on the subject’s forearm. The integration of a voltmeter into this 
‘circuit’ permits measurement of PD A photograph of the nasal PD set up is shown 
in Figure 2.9.  
 
 
Figure 2.9. Nasal PD equipment set up. Photograph of nasal PD set up including nasal 
PD catheter with recording electrode, skin reference electrode on forearm connected to 










PD solutions  
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2.5.1.1 Nasal PD measurements in vivo 
The transepithelial PDs generated are detected by a voltmeter and displayed in 
real time on a laptop computer.  
The nasal PD perfusion protocol includes the following solutions, the composition of 
which is to be found in Appendix 9.4: 
1. Ringers solution (physiological; designed to reflect basal [non-stimulated, 
resting] PD) 
2. Ringers with Amiloride (RA) 
3. Zero Chloride solution with Amiloride (ZCA) 
4. Zero Chloride solution with Amiloride and Isoprenaline (ZCAI) 
Perfusion steps 1 and 2 are considered to measure sodium ion (Na+) transport; steps 
3 and 4 chloride (Cl-) ion transport. Step 4 assesses CFTR specific (cAMP-activated) 
chloride transport. In CF, the basal nasal PD is higher (more negative), there is a 
profound depolarisation (becomes less negative) in the presence of amiloride (ENaC 
blocking agent), and absent or minimal evidence of Cl- secretion in response to 
zero-chloride containing solutions and isoprenaline in contrast to the 
hyperpolarisation these solutions induce in non-CF individuals. Example 
representative traces from a non-CF and CF PD test are shown in Figure 2.10.  

































Figure 2.10B  
Figure 2.10 Nasal PD traces in normal and CF subject.  
Example nasal PD measurement trace from non-CF subject (2.10A) and CF patient 
(2.10B). Red arrows denote start of change in perfusion solution. R = Ringers 
solution, RA = Ringers amiloride, ZCA = zero chloride amiloride, ZCAI = zero 
chloride amiloride with Isoprenaline solution. Blue dashed line represents PD post 
RA perfusion, to compare with baseline PD during Ringers perfusion and post ZCA / 
ZCAI perfusion. Basal PD in CF is greater (more negative), as is change in PD post 
RA perfusion (c>a). PD increases in response to ZCA/ZCAI solutions in normal 
subjects (b) but remains flat or depolarises in CF (d). Vertical depolarisation spikes 




RA ZCA ZCAI 
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In addition to specific equipment and solutions, nasal PD requires technical 
expertise. Training on non-CF volunteer subjects was undertaken by GD prior to 
supervised (by JD, approximately 10 years of nasal PD experience) measurements 
during the Pilot study. Once competence had been achieved, all nasal PDs were 
performed by either JD or GD.  
2.5.2 Patient testing and detailed description of set-up 
All patients in Pilot part A and all patients in the nasal cohort of Pilot part B had 
nasal PD measurements performed. Intervals were determined by study protocol. 
This was open-label, designed to be iterative and underwent several amendments 
during the trial. In some cases, additional (off-protocol) tests were carried out to 
further quantify the duration of observed responses. Three nasal PD measurements 
were planned pre-dose of gene therapy because of the known variability within 
measurements between patients on different days. Post dose nasal PDs were 
performed until day 28, or longer in some cases if any PD changes persisted.  
2.5.2.1 Preparation of Foley catheters 
For the first time, there is now a commercially available double lumen catheter 
designed specifically for these measurements (http://www.marquat.com/). This 
was not available at the start of the trial and so our in house methodology of 
adapting a Foley catheter (Rusch, Teleflex Medical) was employed. Foley catheters 
have two channels but in their usual use as urinary catheters the purpose of one 
channel is to be able to inflate the balloon to keep the catheter in a patient’s 
bladder. The catheter for nasal PD measurement requires two lumens throughout 
its length and the balloon is not required. Catheters were therefore adapted by the 
author by removing the balloon section and replacing the catheter tip, before 
creating a new side hole which allows an electrical connection between the surface 
epithelium and the ‘exploring’ lumen, which is filled with electrode cream (diluted 
1:1 with Ringers solution) prior to use. The hole extends through the entire 
catheter, allowing the second lumen to perfuse solutions onto the nasal 
epithelium. Markings to a distance of 7cm (1cm intervals) from the side holes along 
the length of the catheter were made to guide appropriate placement during the 
repeated measurements made during the Pilot study. An ‘adapted’ Foley catheter 
is shown in Figure 2.11. 
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Figure 2.11. Photograph of adapted Foley catheter. There are two patent lumens 
throughout the length of the catheter. The first (‘exploring’) lumen is filled with electrode 
cream. An electrode is secured into place within this cream-filled lumen with tape which, 
for the purposes of illustration, is not shown. The second lumen is for solution perfusion, 
with a 3-way tap attached as shown.  
 
For the first measurement in each subject, the PD catheter was inserted along the 
floor of the patient’s nasal cavity and secured in place so that the exploring side 
hole sits at the site of highest (most negative) PD. Subsequent nasal PDs within the 
same subject were performed at the same site, unless there was a reason why this 
was not possible.  
2.5.2.2 Solutions 
To comply with Good Clinical Practice (GCP) and hospital pharmacy requirements, 
solutions for PD measurement were produced off site by an approved pharmacy 
manufacturing unit (St Georges Hospital, London). Prior to the Pilot trial, solutions 
had been made in-house and were based on a HEPES buffering solution. 
Requirement for superior grade of reagents meant that the change was made to 
comply with the US TDN solution characteristics, based on Ringers solutions (110).  
Stock solutions (in 100ml volumes, ethyl vinyl acetate (EVA) bags) were produced 
from the individual chemical reagents (Spectrum, US) and couriered to our centre 
in batches following production. Solutions were stored refrigerated prior to day of 
use, in a temperature mapped fridge. The stock solutions for nasal PD were 
Ringers, Ringers Amiloride and Zero Chloride Amiloride solution.  
The effect of storage in plastic EVA bags was assessed by Quality Control testing 
carried out by the pharmacy production unit at St Georges Hospital. They 
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confirmed stability of storage of each stock solution type with refrigeration over a 
three month period (previously untested in EVA storage).  
Solutions were removed from the refrigerator on the day of requirement and were 
allowed to reach room temperature before use. They were not warmed prior to 
perfusion. Each bag of stock solution could be kept for a period of 24 hours from 
opening prior to expiry (recommended from a microbiological rather than active 
substance perspective).  
The fourth perfusion solution (containing isoprenaline) was prepared immediately 
prior to PD testing by adding isoprenaline (as isoprenaline sulphate) to a zero 
chloride amiloride stock solution. Solutions containing isoprenaline had an expiry 
time of two hours after preparation. 
Documentation of solutions including batch number and expiry dates were 
completed on pharmacy-prepared worksheets for each nasal PD. A list of batch 
number and expiry date of each solution used was also placed in the patient’s 
hospital medical records at conclusion of the trial, to comply with hospital 
pharmacy requirements for traceability.  
2.5.2.3 Equipment 
The high impedance, low resistance voltmeter used for making the PD 
measurements was model LR4 (Logan Research, UK). This was connected to a 
laptop computer (Toshiba) via a USB connection, with appropriate internal 
electrical isolation. The laptop power supply plug used was a Medline EXM80 80w 
AC/DC Wall plug adaptor (Powerbox, Craftec, UK). This was required in order to 
comply with safety regulations regarding appropriate electrical isolation for near-
patient testing, with class II double isolation and approval for use with electrical 
medical equipment (standard IEC60601-1). Electrical safety testing involving the 
combined components of LR4 voltmeter, laptop and power supply was carried out 
by the BioMedical Engineering department at RBH. The electrodes (two per nasal 
PD) were silver/silver chloride (Ag/AgCl) 7mm discs (commonly used in 
electrophysiology studies including electroencephalograms (EEGs))(Biosense 
Medical, UK). 
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2.5.2.4 Offset and correction 
The offset of a pair of electrodes used for measurement was checked prior to use 
in a nasal PD test. Offset describes the potential difference generated by creating 
a ‘circuit’ with the electrodes and conducting cream alone and is an indication of 
the suitability of electrodes for testing. To measure offset, electrodes were placed 
into a 20ml universal container containing 10ml electrode cream and 10ml Ringers 
(diluted 1:1) and voltage recorded by the LR4 as displayed on the laptop screen.  
Because of the small mV values being recorded, tight acceptability criteria were 
used for electrode offset. Acceptability criteria were met if the (uncorrected) 
offset was <5mV. This offset was then corrected to zero using the Logan Research 
LR4 software (‘offset correction’ button within software). If an offset ≥5mV was 
obtained, the electrode pair was not used and a different electrode selected until 
an offset <5mV was achieved.  
2.5.2.5 Data recording  
Patient ID, visit date, nostril used for testing and distance into nostril were 
recorded on a paper proforma. This was also used to record skin PD. Nasal PD data 
files were saved on the laptop computer and subsequently backed up to USB and 
network drive. No identifiable patient details were saved, files were saved 
according to by study ID, visit name and nostril side (e.g. 030D28R for patient 
1SD030 day 28 visit, right nostril).  
2.5.2.6 The measurement tubing ‘circuit’ 
The tubing ‘circuit’ essential for perfusion of solutions onto the nasal epithelium 
was created using a series of plastic tubing connectors connected with 3-way taps. 
Each perfusion solution in a 50ml syringe was mounted in an infusion pump (Alaris® 
Syringe Pump) and connected to the tubing circuit, to allow the sequential 
perfusion steps to take place.  
2.5.2.7 Preparation of nasal PD catheter 
The adapted Foley catheters (prepared as described above), were single use and 
filled with the diluted electrode cream at the time of testing. The widest lumen of 
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the catheter was filled with diluted electrode cream (1:1 ratio with Ringers 
solution) using a 2ml syringe, taking care not to create air bubbles during filling. 
Air bubbles result in loss of electrical conductivity and disruption to the 
measurement ‘circuit’.   
The Ag/AgCl disk electrode (the ‘exploring’ electrode) was inserted into the same 
lumen of the cream-filled catheter at the large port end, and taped with Sleek to 
secure in position and prevent escape of electrode cream. The electrode plug was 
connected to the positive (red) port of the LR4 voltmeter as described previously.  
2.5.2.8 Forearm (reference) electrode 
It has been shown that the subcutaneous space in the forearm is isoelectric with 
the submucosal space of the airway (111). Access to this can be achieved by 
removing the epithelial skin layer; at our centre this is achieved by skin abrasion. 
We do not use the agar filled needle inserted subcutaneously into the forearm for 
the reference electrode utilised in the US TDN nasal PD protocol (110).  
The skin was cleaned using an alcohol wipe. A skin abrasion was made by carefully 
using a sterile dental drill burr. This was applied to the forearm surface until a 
sheen on the skin was seen. A piece of tape (sleek) was placed over the reference 
electrode and a hole made through the tape into electrode with the tip of the 
dental burr. This was placed exactly over abraded skin site and secured using tape.  
A 2ml syringe was filled with diluted electrode cream, and this was ‘injected’ into 
a hole in the tape (created using a needle sheathed with a sterile pipette tip 
attached to the syringe) to completely fill the dead space between electrode disk 
dome and skin. This created good electrical contact between the abraded skin and 
electrode itself.  
The skin electrode was connected to the negative (black) port of the LR4 voltmeter 
as described above.  
2.5.2.9 Skin PD  
Following identification of a satisfactory pair of electrodes by offset testing and 
catheter/tubing set up prepared, and siting of forearm electrode, skin PD was 
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measured. This was undertaken by placing the prepared nasal PD catheter (with 
recording electrode attached) on the index finger tip. This enabled confirmation 
that the integrity of the electrical circuit and skin contact was good. Measurements 
in vivo are typically between -30 and -60 mV (with values in CF > non-CF); and if 
skin PD was <30mV the circuit was reviewed and forearm skin preparation process 
repeated.  
Skin PD was confirmed prior to commencing nasal measurements for each subject 
on each test occasion.  
2.5.2.10 Nasal measurement   
The nasal PD test was performed with the subject seated at a table (adjustable 
height) and we incorporated a chin rest (Double screw clamp chin rest, 6011R, 
Richmond Products, NM, US) into the set up to aid head stability and comfort 
during testing. The head rest was adjusted to ensure that the head tilted slightly 
forward so that solutions dripped out of the patient’s nostril rather than trickled 
down their nasopharynx.  
To insert the nasal PD catheter, the subject was asked to lift their head off the 
chin rest so that the researcher had an optimal view of nasal passages. The PD 
catheter was inserted slowly along nasal floor whilst watching mV readings in real 
time on computer screen. The final site of catheter placement was that at which 
the PD was highest (most negative). The nostril and distance inserted was recorded 
(in centimetres). The PD catheter was taped in place using tape strips (Steri-
Strip™, 3M, Bracknell UK) wrapped around the catheter and taped to the nose. 
Additional catheter site security was provided by taping the catheter to the head 
rest. The same nostril and distance into nose was used for all subsequent 
measurements involving that subject, unless readings could not be achieved at 
subsequent tests. On the rare occasion this occurred (e.g. unable to tolerate 
catheter in particular nostril due to pain) it was documented.    
2.5.2.11 Solution perfusion  
Prior to commencing the sequence of solution perfusion the subject’s head was 
positioned on the chin rest. A drip tray was placed on the table to retain used 
  100 
perfusate. Solutions were perfused according to the following timescale at a flow 
rate of 4ml/minute (240ml/hour), in accordance with previously described optimal 
flow rates for testing:  
 •  Ringers until stable (<1mV change in PD) for 30-60 seconds   
•   Ringers Amiloride for at least 3 minutes but until stable (defined as above)  
•   Zero Chloride Amiloride solution for 5 minutes  
•   Zero Chloride Amiloride with Isoprenaline for 5 minutes 
To mark the time point at which a solution change occurred, the calibration switch 
on the voltmeter was used as a marker by creating an artefact reading. This was 
easily identifiable on the computer screen as a large spike on the PD trace out of 
keeping with true transepithelial measurements. 
Any other relevant details, e.g. patient coughing or moving during procedure were 
recorded on the paper proforma completed for each PD measurement.  
Millivoltages detected by the LR4 were displayed graphically in real time whilst 
testing. Each PD test continued until the sequence of perfusions was complete, 
unless patient factors or technical factors (e.g. loss of electrical contact) 
precluded test completion.   
2.5.2.12 Infection control 
Royal Brompton Hospital policies on infection control were followed for patient 
isolation and testing equipment. A new Foley catheter was used for each test and 
disposable plastic tubing used for solution perfusion. Hard surfaces including the 
chin rest used for head placement during testing were cleaned with disinfectant 
wipes (Clinell Universal Wipes, Steroplast Healthcare, UK) between patients. An 
electrode was designated the skin electrode for each patient for the duration of 
the trial, with no cross contamination of skin electrodes between patients. If an 
existing skin electrode did not comply with ≤5mV offset at subsequent test dates, a 
further new skin electrode was designated to that patient.  
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2.5.2.13 Generating data files 
Files generated from the Logan Research LR4 software were prop.binary data files 
with extension (.dat). Text files were created by clicking on ‘DataDump’ in the file 
menu within the LR4 software, automatically creating a file with extension .txt. 
These files could be imported into Microsoft Excel, for subsequent data analysis. 
2.5.3  Methods: data analysis 
Formal nasal PD data analysis took place following completion of data collection in 
the Pilot study. Nasal PD traces were analysed independently by the author (GD) 
and JD prior to combining the analysis as described below.  
2.5.3.1 Generating text export files for analysis 
Raw data files (.txt) were imported into Microsoft Excel. Each row of data on the 
spreadsheet represented the mV recorded in 1 second intervals from start of data 
capture to end of recording.  
2.5.3.2 Blinding of test identification  
During PD analysis, GD and JD were blinded to patient identification and timing of 
test including whether the traces represented pre- or post dosing measurements. 
The author achieved this by attributing a random 4 digit code number to the PD 
test and removing all features relating to patient study code and visit date. 
Random numbers were generated using the Random Number generator in Microsoft 
Excel.  
2.5.3.3 Analysis parameters 
Export of files to spreadsheet in Excel allowed detection of the mV and 
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 Basal PD:  
Basal PD was identified according to a period of stability on the PD trace during 
perfusion with Ringers solution. The value taken for basal PD represented the 
average (mean) of 20-30 seconds’ mV values.  
 Amiloride response:  
The amiloride response was defined as the delta between the start and end of 
Ringers Amiloride perfusion. The start value was taken as the basal PD unless the 
PD following marker artefact (created using calibration switch as described above) 
differed substantially from this. The mV at the end of RA perfusion was taken 
where the mV had plateaued out, again taking the average of around 30 data 
points. The delta for Ringers Amiloride response was the difference between the 
start and end of Ringers Amiloride perfusion. 
 Zero chloride amiloride (ZCA) response 
The zero chloride amiloride response was defined as the delta between the start 
and 5 minutes post start of ZCA perfusion. The starting mV was taken as the 
plateau of the amiloride response unless the PD immediately following marker 
artefact (to mark switch to ZCA solution) substantially differed from this. The mV 
value at the end of 5 minutes perfusion was the average of preceding 30 data 
points. The delta was the difference between the mV at the start and end of ZCA 
solution.  
 Zero chloride amiloride isoprenaline (ZCAI) response 
This was calculated using the same methodology as described for ZCA response, for 
the ZCAI perfusion stage. The sum of the change in mV (delta ZCA + delta ZCAI) 
was also calculated, representing total chloride transport.   
2.5.3.4 Combining two nasal PD analyser results 
Nasal PDs from patients receiving the preliminary 1ml nasal dose (n=3 patients) 
were analysed solely by GD as this was a small safety subgroup which preceded the 
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full trial. All nasal PD results from patients receiving the 2ml nasal dose were 
analysed by GD and JD. Following independent analysis, analyses were then 
combined to determine ‘final agreed’ PD values for each variable of interest. 
To determine final agreed PD values, acceptability criteria were pre-defined for 
maximal allowed differences between the two analysers’ values. The final agreed 
mV value for each parameter was determined as follows: 
 The differences between values calculated by GD and JD for each analysis 
parameter were calculated. Values for each analyser were automatically 
accepted if the difference between GD and JD were within the following 
range (in millivolts (mV)): 
o Ringers: 2mV 
o Ringers amiloride delta: 2mV 
o Zero chloride amiloride delta: 1mV 
o Zero chloride amiloride isoprenaline delta: 1mV 
 Tests where the difference between GD and JD was greater than these 
maximum values were discussed. Where, following review of plotted values, 
both JD and GD values were considered equally valid, the mean of both 
values was calculated.  
 For tests where disagreement out with the above criteria existed, PD traces 
were reviewed by JD and GD and a consensus opinion was agreed about final 
values or requirement for further review.  
 Tests that were deemed non-analysable by both analysers were excluded 
from the final values for data analysis. 
 Where a disagreement out with the above criteria persisted following repeat 
analysis, PD traces were reviewed by JD and GD and a consensus was agreed 
about final values. 
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The final mV values for each of the PD analysis parameters for each nasal PD were 
calculated by obtaining the mean of GD and JD analysis values. 
Zero chloride responses (deltas) were calculated for the ZCA stage and ZCAI stage 
separately, and also by summing the two deltas for a mV result to represent total 
chloride secretion.  
2.5.3.5 Pre-dosing tests 
The Pilot protocol included more than one pre-dose nasal PD per patient, with all 
patients scheduled to have at least two, and up to 3, measurements pre- nasal 
gene therapy. In order to benchmark post dosing measurements to those taken pre-
dose, mean pre-dosing values were calculated. These were calculated using the 
final agreed values (calculated as per GD/JD as above) to obtain a mean value for 
all pre-dosing tests per patient. Average pre-dosing measurements were calculated 
for the following variables: basal, and deltas for amiloride, zero chloride amiloride 
and zero chloride amiloride isoprenaline responses to allow comparison with post 
dose results. Each individual pre-dose test result was also considered individually 
for the calculation of chloride secretion ‘response’ according to the methods 
described in section 2.5.3.6 below.    
2.5.3.6 Defining efficacy response 
There is no ‘gold standard’ method to define change in sodium or chloride ion 
transport in response to a novel therapeutic intervention such as gene therapy. For 
each section of the nasal PD tests, within-patient variability in pre-dose tests was 
investigated.  
The optimal way of classifying evidence of chloride secretion on nasal PD results is 
unknown. It was the responses to zero chloride with amiloride (ZCA) solutions that 
were shown to change post CF gene therapy in the Lancet study (35). For Pilot 
results, intrinsic chloride secretion (ZCA delta), stimulated chloride secretion (ZCAI 
delta) and total chloride secretion (sum of ZCA and ZCAI deltas) were calculated 
for each PD test. Evidence of chloride transport on post dosing nasal PDs was then 
analysed by the author in accordance to the following three definitions:  
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Method 1: Evidence of chloride secretion on post dose test greater than any 
pre-dose test for that individual 
For individual patient results, the method involved defining ‘response’ according to 
evidence of chloride secretion on a post dose test greater than any pre-dose test 
for that individual. This was investigated for intrinsic chloride secretion (ZCA 
delta), stimulated chloride secretion (ZCAI delta) and total chloride secretion (ZCA 
delta + ZCAI delta) for each test. 
Method 2: Chloride secretion relative to mean pre-dosing results 
Response was defined as a post-dose test with a sum representing chloride 
transport ≥5mV relative to mean pre-dosing test results for that individual. This 
was performed for intrinsic chloride secretion (ZCA delta), stimulated chloride 
secretion (ZCAI delta) and total chloride transport (ZCA delta +ZCAI delta). Total 
chloride transport >5mC relative to pre-dosing tests has been used previously in CF 
clinical trials (96;97).  
Method 3: ‘Normal’ chloride secretion 
Finally, chloride secretion was assessed according to whether ≥ -5mV of total 
chloride transport was achieved (irrespective of the magnitude of pre-dose 
results). This cut off was used for total chloride transport at it is considered to 
represent normal (non-CF) levels of chloride secretion (112). In addition to 
performing this for total chloride transport (ZCA delta +ZCAI delta), results were 
analysed according to having ≥ -5mV in intrinsic chloride secretion (ZCA delta), and 
similarly for stimulated chloride secretion (ZCAI delta).  
2.5.3.7 Relationship with other Pilot outcome measures 
The relationship between change in nasal PD and the presence of vector specific 
CFTR mRNA on nasal brushings was assessed, with methods as described in section 
2.7. Relationships with genotype and other patient characteristics were also 
investigated.  
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2.5.4 Statistics 
Intra-class correlations (ICC) were calculated to assess inter-reporter agreement 
between nasal PD values for each section of the test (e.g. basal PD) as calculated 
by GD and JD. This was undertaken in several phases: 
 Initial agreement between GD and JD for all 2ml nasal PD analysed values 
 Final agreement between acceptable tests following consensus between GD 
and JD 
ICCs were calculated using SPSS Statistics version 21.0 (IBM), using a two way 
mixed effects model for absolute agreement. Final PD values for each section of PD 
(mean of accepted GD and JD result) were combined to analyse group differences 
between pre- and post- measurements. Comparison between groups was performed 
using paired t-tests or Wilcoxon signed rank tests with significance at p<0.05.   
Time points for post dosing tests were determined by trial protocol. In addition, it 
became apparent early in the trial that if a change was seen at last time point 
defined in the protocol, it would be useful for further off-protocol measurements 
to be made until the end of trial (day 28 post dosing, or post day 28 in the 
presence of any persisting evidence of change).  
Mean-pre and a single time point post dosing measurements (e.g. day 14) for basal, 
and deltas for ringers amiloride, zero chloride amiloride and zero chloride 
amiloride isoprenaline were compared using paired Students t-tests or paired non-
parametric tests.  
2.5.5 Patient inclusion in nasal dosing cohort 
At the start of the Pilot study, we had less strict inclusion criteria for the nasal 
dosing cohort in terms of evidence of chloride secretion on pre-dosing nasal PDs. A 
minority of patients recruited early in the trial process had ≥5mV chloride secretion 
on pre-dosing tests but were not excluded from nasal dosing, yet we adopted a 
stricter policy for inclusion in the latter stages of the trial once the safety 
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parameters were becoming clearer in an effort to further define the nature of PD 
results. 
2.5.6 Novel approach to nasal PD testing 
A novel approach to PD testing was investigated which was hypothesized to 
improve the quantitative detection of change in PD in response to CF gene therapy.  
2.5.6.1 Novel voltmeter and clamp 
Standard nasal PD measurements take advantage of the change in electrical 
potential difference as a result of a chemical load. As described for the nasal PD 
perfusion protocol in the Pilot study, a change in PD is measurable as a result of 
exposing the nasal epithelium to the sodium channel blocker amiloride. This can be 
considered a chemical challenge or ‘load’ for the airway cells at the site of 
measurement. An alternative approach would be to subject the airway to an 
electrical challenge or ‘load’. The potential advantages would potentially include 
being able to apply and then remove the ‘load’ instantaneously to evaluate 
response within seconds and negate the need for perfusion stages in the PD 
protocol.    
The hardware for a unit to evaluate this hypothesis was developed by Logan 
Research Ltd (Rochester, UK). It incorporates a voltmeter set-up similar to that 
used for standard nasal PD testing, but has an additional capability of being able to 
apply a high resistance ‘load’, of variable magnitude, at intervals during testing to 
the PD generated across the respiratory epithelium. This artificial manipulation of 
the PD essentially applies a resistance in parallel to the (parallel) electrical circuit 
created by the PD across the epithelial cells themselves. No additional voltage or 
‘electricity’ is being given to the patient, rather the clamp load(s) are applied and 
recovery to baseline PD is assessed.  
It was hypothesised that the magnitude of PD change in response to an electrical 
load and rate of return to baseline PD may be different depending on the 
proportion of cells expressing CFTR. It was considered that following the 
application of a high resistance load to the ‘circuit’, the proportion of cells with 
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functioning chloride channels would determine the rate of recovery of PD to pre-
clamp values.   
This method has never been applied in vivo to respiratory epithelial PD 
measurements. As a novel standalone piece of equipment, the hardware voltmeter-
based unit (‘LR5’) was tested by the BME department at the RBH to ensure it 
complied with electrical safety testing prior to testing on human subjects in vivo. 
In addition, as it has no CE mark, standard procedures were followed to permit this 
unit to be evaluated within the Royal Brompton and Harefield NHS Foundation 
Trust.  
2.5.6.2 Experimental set up 
The LR5 was attached to a standard laptop computer (Toshiba, Windows XP 
operating system) via USB connection. A double insulated power pack (Craftec) 
replaced the proprietary laptop mains AC adaptor to comply with electrical safety 
testing appropriate for near-patient use. Frequency of signal filtration was 
manually selected on the front panel of the LR5. This included the following: Notch 
(50Hz) and WB wideband 1KHx low pass, Wide band (no notch filtering) 1 KHz low 
pass, Medium filter 10Hz low pass (F1 setting on LR5), Low filter 1Hz low pass (F2 
setting on LR5).PD (in millivolts) was recorded every 0.03 seconds (33Hz). The 
clamp was applied during basal PD measurement in the absence of solution 
perfusion, with a load between ‘1’ and ‘9’. Setting ‘1’ represented no load; 
(maximal resistive component) 9 (maximal load; lowest resistive component). 
Clamp duration was manually adjustable between 1 – 10 seconds. The point at 
which the clamp is applied was seen graphically on the laptop screen in real time, 
as a pale blue line indented at 1 second intervals. This line has been set arbitrarily 
by the manufacturer at -69mV, and decreases to -59mV when the clamp is applied.   
The electrode set up for the LR5 was similar to the usual LR4 voltmeter used for 
our existing nasal PD set up, however the LR5 uses a 3-electrode rather than 2-
electrode set up. Two silver/ silver chloride electrodes were used to make 
electrical measurements across the respiratory epithelium. An electrode overlying 
abraded skin on the forearm was connected to the negative port of the LR5 as per 
conventional testing with the LR4 voltmeter. The nasal electrode (either in direct 
contact with airway surface or within an electrode cream filled Foley catheter 
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depending on experimental set up) was connected to the positive port of the LR5. 
In addition, a press-stud electrode attached to the anterior chest wall with a 
standard ECG electrode gel pad (Skintact® CT-601, Leonhard Lang Ltd) was used to 
provide an electrical ground reference. At the end of each test, files were saved as 
a data file extension (.dat) file. A corresponding ascii text file was generated by 
clicking ‘datadump’ within the LR5 software programme. These were imported into 
a Microsoft Excel spreadsheet for analysis.  
2.5.6.3 Clinical investigation of LR5 device 
To investigate the ability of the LR5 to manipulate the transepithelial PD, the 
magnitude of load, clamp time, signal filtration and type and set-up of recording 
electrode were assessed. 
Measurements across the nasal epithelium and skin were initially made in healthy 
volunteers (n=2) and in CF subjects (n = 4) taking part in the Pilot gene therapy 
trial. The CF patients were enrolled into the nasal cohort of the gene therapy study 
and timing of LR5 measurements coincided with standard nasal PD testing as 
determined by trial protocol.  
Comparison between non-CF and CF nasal PD responses to electrical load were 
made by analysing rate and magnitude of change in PD and recovery to baseline PD 
between subjects (expressed as % pre-clamp values).  As stated, CF patients were 
evaluated with the LR5 post standard nasal PD testing. Therefore their respiratory 
epithelium had been exposed to the sequential perfusion steps with Ringers, 
Ringers amiloride and Zero chloride amiloride solutions immediately prior to LR5 
evaluation. Due to the preliminary nature of the investigation, the author accepted 
this as a limitation of testing. No pre-perfusion tests with the LR5 were carried out 
on CF patients in order to maintain constant experimental conditions for the 
standard nasal PD as an outcome measure in the Pilot study. However, testing with 
the LR5 in non-CF subjects (n=2) both pre- and post standard nasal PD testing (with 
perfusion protocol) was undertaken to ensure this did not influence the responses 
seen.  
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2.6 Functional efficacy outcome measures: Potential 
difference measurements in the lower airway 
Although any functional CFTR assessment would ideally be performed repeatedly, 
this is not feasible in the lower airway for both practical and ethical reasons. The 
nose is often used as a surrogate because of similarities in respiratory epithelium 
and accessibility to testing. However, there are differences with regards to drug 
delivery (which is much easier in the nose than in the airway, particularly when the 
latter is diseased) and local environment (e.g. presence of airway secretions) that 
may affect measurement. Direct PD measurement in the lower airway is thus 
relevant and important, despite the limitations of infrequent testing. Such 
measurements are technically more challenging than in the upper airway. Prior to 
the Pilot study, although lower airway measurements had been performed, these 
techniques would not have complied with current standards of Good Clinical 
Practice (GCP). Therefore initial work concentrated on methodology to develop an 
appropriate measurement set up (designed largely by the author), which was then 
utilised for in vivo measurements in the Pilot study.  
2.6.1 Previous methodology and rationale for changing existing set 
up 
Lower airway PDs have previously been undertaken within our department in adults 
(35) and children (113) and the method now described aimed both to address GCP 
compliance issues and to overcome some of the problems previously identified. The 
group originally used a double lumen PD catheter through the suction channel of an 
adult sized bronchoscope (35). One lumen was used for PD solution perfusion and 
the other was primed to the tip with Ringers and used as an electrical bridge to 
connect with the exploring electrode for lower airway PD measurements. This fluid 
interface required the use of glass Calomel half cell electrodes. The reference 
electrode in this set up was connected to an intravenous catheter. This set up was 
similar to the original methodology described by Knowles et al (74) for measuring 
upper (and lower) airway PD. 
The bronchial PD set up described by Davies et al (113) included modification from 
a double to single lumen catheter to fit down the smaller channel of the paediatric 
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bronchoscopes. A single lumen polyethylene catheter was primed to the tip with a 
zero chloride solution. Basal PD measurements were recorded through this fluid 
column to the exploring electrode, prior to perfusion with a low chloride solution 
to assess chloride secretion. 
Both of these techniques (35;113) provided technically acceptable readings 
however there were several relevant technical and regulatory issues. Use of 
Calomel half cell electrodes was problematic particularly due to microbubbles 
interrupting the fluid filled conduction circuit and the glass electrode interface 
required for PD measurement. Both set ups also required the presence of an 
intravenous line to connect with the reference electrode, again at a fluid-glass 
interface which needed to be bubble free. There were also considerable issues with 
meeting appropriate equipment sterilisation requirements. Therefore, for the 
current CF gene therapy Pilot study, circuit modification has been undertaken.  
We chose to use the same silver/silver chloride (Ag/AgCl) 7mm disc electrodes as 
used for nasal PD measurement (Chapter 2, section 2.5). In addition, we were no 
longer able to source simple sterile double lumen or single lumen polyethylene 
tubing of clinical grade. Instead, we used a single lumen catheter sourced by using 
the tubing from the casing of a standard bronchoscopy cytology brush (the brush 
was discarded)(Olympus, UK).   
No system for measuring lower airway PD with solid Ag/AgCl electrodes with the 
inclusion of basal PD measurements and a perfusion protocol has previously been 
described. Fajac et al (114) describe the development of a Ag/AgCl electrode 
technique for measuring PD in the human lower airway but their technique allows 
no perfusion so only basal measurements can be obtained. In previous CF gene 
therapy clinical trials, it is the response to zero or low chloride solutions perfusion 
that has been shown to change (rather than basal measurements) and therefore it 
was critical to develop an experimental set up and measurement protocol for 
assessing bronchial PD which could measure chloride secretion. 
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2.6.2 Methods and initial early phase results 
2.6.2.1 Early modification to bronchial PD set up: electrodes 
Incorporation of Ag/AgCl electrodes into the PD set up required consideration of 
the interface between the electrode and the remainder of the PD ‘circuit’. 
Whereas Calomel electrodes form a fluid interface by direct contact of their glass 
wall to a fluid column, Ag/AgCl electrodes are solid metal discs. Therefore, a 
system to ‘connect’ the Ag/AgCl electrodes with the fluid column measuring lower 
airway PD was required. The author chose to investigate this using agar as an 
interface. 4% agar Noble in 3 molar (M) potassium chloride (KCl) was chosen 
because it is often used as an electro- conductive bridge for in vitro and in vivo 
transepithelial PD measurements (110;115). In seeking to optimise this, the 
following conditions were explored: 
2.6.2.1.1 Condition 1: electrode embedded in agar  
 The electrode offset was checked on a pair of Ag/AgCl electrodes; accepted 




Electrode offset is mV measured by placing two Ag/AgCl electrodes in electrode 
cream and connecting to a voltmeter. 
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 One of the pair was embedded in 2ml 4% agar in 3M KCl in a 5ml syringe 
(with plunger removed); this was allowed to solidify at room temperature 
for four hours (n=4 tests).  
 Circuit offsets were retested by placing the syringe tip containing solid agar 
into Signacreme (electrode cream)(Parker Laboratories, US). The free end of 
the embedded electrode was inserted into the positive port of a high 
impedance voltmeter. The second Ag/AgCl electrode was placed directly 





Offset is mV generated between electrodes including an agar/electrode cream 
interface. 
 
Figure 2.13. Development of electrode interface for bronchial PD circuit: testing 
offsets with electrode embedded in agar.  
 
 
 Electrode offset was tested and defined as the difference (mV) between the 
two electrodes.   
Outcome: Offsets were high (mean -48.0 mV, SD 8.0 mV). This indicated a 
significant conduction problem within the circuit, so whilst it would be technically 
possible to adjust for this, such an adjustment would lead to sensitivity problems in 
subsequent measurements.  
 
 
5ml syringe with plunger removed 
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2.6.2.1.2 Condition 2: agar and conducting cream interface  
The author considered that the contact between the solidifying agar and the 
electrode was likely suboptimal and responsible for this problem. The author next 
tested a system she devised involving both agar and electrode cream (repeated for 
n=4 tests). 
 1ml volume of 4% 3M KCl agar was inserted (when liquid) into a 5ml syringe 
with the plunger removed.  
 Once this had solidified, electrode cream (approximately 2ml) was placed on 
top of the agar 
 The ‘exploring’ Ag/AgCl electrode was placed in to this electrode cream and 
secured in place. 
 A separate Ag/AgCl electrode was placed directly into a separate pot of 
electrode cream, and into the negative port of voltmeter. The tip of the 
syringe containing agar (with exploring electrode) was also placed in to this 








Figure 2.14. Development of electrode interface for bronchial PD circuit: testing 




5ml syringe with plunger removed 
1ml 4% agar in 3M KCl 
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 Electrode offset was tested and defined as the difference (mV) between the 
two electrodes.   
Outcome: Offsets were not affected by the presence of agar column (mean offset 
=-2.4mV, SD 0.7 mV) and were identical to those achieved when both electrodes 
were placed in electrode cream alone.  
This electrode set up was subsequently used for all bronchial PD measurements in 
the Pilot study. Connection to the remainder of the PD circuit and overall offsets 
for the entire circuit are described in the following sections.   
2.6.2.2 Initial bronchial PD set up: tubing and connections 
The voltmeter (LR4), computer and software used for lower airway measurements 
were the same as those used for upper airway measurements in the Pilot study 
(section 2.5).  
Solutions for bronchial PD are listed in Appendix 9.5 and the perfusion protocol is 
described below.  Stock Ringers and Zero chloride solutions were stored 
refrigerated until use. For bronchial PDs undertaken with this ‘initial’ set up, 
solutions were taken out the refrigerator on the morning of use.  
The tubing connections, cytology brush sheath and other components forming the 
bronchial PD circuit are shown in Figure 2.15. Preparation of the circuit involved: 
 Removal of bronchoscopy cytology brush from casing; brush discarded 
and casing retained.  
 Joining T-piece connectors with the use of 3-way taps to permit inclusion 
of a perfusion step with zero chloride isoprenaline solution as well as 
basal measurements.  
 Priming a T-piece connector adjacent to a 3-way tap with zero chloride 
solution (without isoprenaline). 
 Connecting the agar containing syringe to this primed T-piece connector. 
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 Adding 2ml Signacreme electrode cream to agar as described above 
 Placing Ag/AgCl exploring electrode disc in Signacreme. 
 Priming the remaining measurement circuit to the tip of the cytology 
brush sheath with Ringers solution.  
 Performing basal measurements and first of three distal measurements 
before changing perfusion solution to zero chloride with isoprenaline.  
 
 
Figure 2.15. Schematic representation of initial bronchial PD set up. PD 
catheter (cytology brush sheath) is connected to two three way taps via an Abbocath 
catheter. T-piece connectors are used to connect the Ringers and Zero Chloride 
solution syringes, and the syringe containing Agar and electrode cream. Transepithelial 
measurements are made across the bronchial epithelium with the recording electrode 
embedded in electrode cream. An Agar-fluid interface conducts through the Ringers 
fluid column within the PD catheter to the apical surface of the respiratory epithelium 
down a flexible bronchoscope. The single channel PD catheter is also used to perfuse 
Zero Chloride (with isoprenaline) solution during continual PD measurement, with 
three-way taps facilitating change from Ringers to Zero Chloride solution. Reference 
electrode is placed over an area of abraded skin with contact optimised with electrode 
cream. Recording and reference electrodes are connected to a voltmeter and PD is 
recorded on a laptop computer.  
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2.6.3 Evaluation of the novel set up and use in Pilot study 
Circuit integrity and ability to perform measurements in the nose of healthy 
volunteers (n=2 subjects, 3 perfusions undertaken) using the bronchial PD set up 
was confirmed prior to the first trial patient bronchoscopy with a representative 

















Figure 2.16. Initial bronchial PD set up tested in the non-CF nose. The lower 
airway PD catheter was applied to the nasal epithelium. Nasal PD was measured (indicated 
by navy coloured line) during perfusion with Ringers (‘R’) and then with Zero Chloride 
isoprenaline solution (ZCI; the start of ZCI perfusion is marked with the corresponding 
arrow) using the initial bronchial PD set up. The light blue dashed line represents the basal 
PD (in Millivolts) during perfusion with Ringers solution. The response to ZCI solution after 
5 minutes is indicated by the change in PD (delta) between start and end of ZCI perfusion, 
indicated by ‘e’.   
 
This test set up demonstrated ability to achieve stable basal measurements with 
Ringers solution and to assess change in PD as a consequence of Cl- secretion in 
response to the zero chloride solution perfusion. This system was then used for 
lower airway PD measurements in the Pilot study. 
ZCI R 
e 
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All patients undergoing bronchoscopy were in Pilot part A, as detailed in section 
2.2. To briefly summarise, all patients received a 20ml nebulised lung dose and all 
had both nasal and lower airway PD measurements performed at time points as 
defined in the trial protocol. Bronchoscopies were performed by JD (n=21) and AB 
(n=3) with bronchial PDs performed by GD (n=21) and JD (n=3). All bronchoscopies 
were done under general anaesthetic as per trial protocol with written informed 
consent obtained pre-procedure.  
Skin PD was measured using the tubing set up primed to the tip with Ringers 
solution once the patient was anaesthetised to check integrity of the bronchial PD 
measuring ‘circuit’. The cytology brush sheath re-primed with Ringers was then 
inserted into the bronchoscope in preparation for lower airway measurements.  
Basal bronchial PD measurements were made after a minimum of 20 seconds 
stability during perfusion with Ringers solution at 100ml/hr at both lateral surfaces, 
anterior and posterior surfaces of the main carina. Basal PD was then measured in 
the first of three distal (approximate 5th generation bronchi) sites. Once a stable 
trace had been achieved, perfusion was switched to zero chloride isoprenaline 
solution at 100ml/hr for five minutes. The sheath was then removed from the 
bronchoscope and the circuit purged with 2.5mls of Ringers solution to eliminate 
the column of zero chloride solution; second and third distal basal and perfusion 
measurements were performed in the same way. All distal measurements were 
performed on the same side. The decision to make measurements in either the left 
or right lung was based largely on the macroscopic appearances including presence 
of secretions which could potentially interfere with measurement.   
2.6.3.1 New problems encountered  
Two patients underwent bronchoscopy with the initial set up described above. 
However, several problems were identified which were not apparent from the 
initial tests carried out in healthy volunteers using the nasal epithelium as 
described. 
1. The circuit set up for both these patients was characterised by high offsets 
(-27.6 and -23.0 mV) and difficulty in obtaining accurate traces due to the 
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frequent intermittent loss of electrical contact and an inability to achieve a 
stable basal measurement.  
2. Visible small bubbles were trapped within the circuit soon after drawing up 
the solutions.  
3. Loss of electrical contact occurred during PD perfusions as a result of 
bubbles within the circuit. 
It became apparent that additional bubbles were also forming during the PD 
measurements; these could not have been prevented as they were not present at 
the time of circuit preparation. 
The author hypothesized that the appearance of new bubbles related to the rising 
temperature of the refrigerated solutions. To investigate this further, syringes and 
tubing from the second bronchoscopy were kept at room temperature until the 
following day by which point thousands of tiny bubbles were distributed throughout 
the tubing and lining the syringe walls. The author reasoned that such bubbles may 
not form if the solutions were warmed prior to being drawn up into syringes and 
then allowed to cool to room temperature. This hypothesis was confirmed in the 
laboratory: no bubbles formed within tubing or syringes if the PD tubing circuit was 
prepared with pre-warmed solutions.  
The three-way taps within the tubing circuit also appeared to contain air bubbles 
when switching between open ports. Their opaque centre meant that it was not 
possible to visualise the entire fluid columns within the circuit.  
2.6.4 Further development and use in Pilot study 
Further modification of the circuit was therefore undertaken (Figure 2.17) to tackle 
high offsets and bubble formation: 
1. Solution warming: Solutions were warmed in the RBH operating theatres’ fluid 
warmer to approximately 37 degrees C (stock PD solutions were removed from the 
refrigerator and placed in the warmer on the afternoon before the test). 
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2. Slow and careful drawing up of solutions into 50 ml syringes from EVA stock PD 
solution bags. 
3. Minimising connections: All three-way taps were removed from the circuit. 
Instead, T-piece connectors with rubber bungs (Medex, Smiths Medical) allowed a 
‘3-way’ connection by a primed needle piercing the bung and clamping until 
required. This preserved the ability to perfuse sequential solutions independently.  
A diagram summarising the modified circuit is shown in Figure 2.17.  
 
 
Figure 2.17. Schematic representation of the modified bronchial PD set up. All 
solutions were warmed prior to circuit preparation. PD catheter (cytology brush sheath) is 
connected to t-piece connector via an Abbocath catheter. A needle pierced through the t-
piece connector bung is used as a three way connection to allow perfusion with zero 
chloride isoprenaline solution once baseline Ringers measurements have been performed 
(no 3-way taps are in the circuit). The transition between Ringers and Zero chloride 
isoprenaline solutions during PD measurements is made by clamping off the relevant t-
piece connector.  
 
This modified circuit was used to perform all PD measurements in patients (n=10) 
with pre- and post gene therapy bronchoscopies, and a further two patients with a 
single pre- bronchoscopy who withdrew from the Pilot study prior to dosing. Offsets 
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with the modified circuit were substantially lower than those prior to circuit 
optimisation: the mean (SD) offset for pre-dosing tests was -3.2 (2.1) mV and -3.5 
(2.0) mV for post dosing tests. The Offsets were corrected to zero prior to making 
measurements of skin PD and through the bronchoscope. 
All patients with bronchial PDs undertaken with the modified circuit had carinal 
and distal measurements made successfully. On occasion, a stable distal baseline 
was not achieved. Where this occurred, that site was abandoned and an additional 
site tested so that all patients had three perfusion results. Taking three distal 
measurements each with a subsequent perfusion stage enabled the calculation of a 
delta to quantify chloride secretion at each site which could be averaged to take 
account of variability.  
2.6.5 Data recording and analysis in Pilot study 
A proforma was used to record the timing of all basal measurements and start and 
end of perfusion solutions (in seconds post start of data recording). This was crucial 
to guide the subsequent analysis of results. Timing of basal and perfusion 
measurements was documented at each site. 
Data files for each test were saved according to patient code and PRE or POST 
denoting status in relating to gene therapy dose. Creation of the .txt files was 
undertaken as per nasal PD (Chapter 2, section 2.5).  
Data analysis of all traces was undertaken following completion of Pilot study data 
collection. The method of creating a display of data in Excel was identical to that 
described for nasal PD in (Chapter 2, section 2.5).  
For blinded data analysis carried out by the author, filenames identifiable with 
patient code were replaced with a 3 digit random number (generated with Excel 
random number generator). All identifying features including patient ID and 
relationship to dosing (pre/post) were removed. Analysis was then performed using 
the time points recorded in real time during bronchoscopy for each site and 
start/end of perfusion on anonymised bronchial PD proformas.  
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To identify the PD at each point of interest (at the designated time points for 
measurement (as defined on the proforma) and corresponding visual analysis of the 
trace (displayed graphically in Excel)), a mean of up to 20 values (20 seconds) of 
mV recording were used to identify the mV result at each time point. The number 
of time points averaged by the author depended on stability of the trace at the 
specified time point. For example, where an equal (bidirectional) variation in mV 
was seen n=20 time points were used, whereas if the trace appeared to be on an 
incline a smaller number of data points (<20) were averaged according to visual 
perception of ‘true’ mV value at that point. Use of mean values calculated 
electronically rather than isolated single mV (single second) readings were used to 
improve accuracy of the PD.   
For each analyser (the author (GD) and JD), mean basal carinal measurement 
(average of anterior, posterior, right and left lateral surfaces), mean distal basal 
PD (average of the three measurements), and mean delta chloride response 
(average of the three deltas) were calculated.  
The data from all patients with paired pre- and post bronchial PD measurements 
were analysed independently by the author and JD prior to combining analyses and 
consensing on final PD values for each PD variable of interest. This is described in 
more detail below. 
2.6.5.1 Combining two lower airway PD analyser results 
The final agreed mV value for each parameter was determined as follows: 
 Difference between GD and JD mV values for mean carinal basal, mean 
distal basal and mean of the n=3 distal delta chloride responses was 
calculated 
 Values for each analyser were automatically accepted (and not other 
technical concerns about the trace) if the difference between GD and JD 
was within following pre-defined range: 
o Mean carinal basal measurement: 2mV maximum difference allowed 
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o Mean distal basal measurement: 2mV maximum difference allowed 
o Mean Zero chloride isoprenaline delta: 1mV maximum difference 
allowed 
 Tests where difference between GD and JD was greater than these allowed 
values were discussed on a test-by-test basis with visual analysis of the trace 
(still anonymised and blinded) in combination with the time points recorded 
on proforma during bronchoscopy. If, following review of plotted values, 
both JD and GD were considered equally valid, both were accepted and the 
mean calculated.  
 Tests deemed non-analysable by both analysers were excluded from final 
data analysis 
 Where disagreement out with the above criteria existed, PD traces were 
reviewed by JD/GD and a consensus was agreed about final values for data 
analysis.  
2.6.5.2 Final lower airway PD values 
All results presented here are from the final GD/JD combined values.  
Although post dosing bronchoscopies were performed at one of two different time 
points post dosing (day 6 or 14), to allow comparison between pre- and post-, 
measurements bronchoscopies performed on either date were combined for data 
analysis.  
2.6.5.3 Analysis of final lower airway PD and comparison with other outcome 
measures 
The following analyses and comparisons were undertaken using the final lower 
airway PD results including: 
- Comparison between basal measurements obtained proximally (carina) and 
distally 
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- Change in mean basal (mV) PD measurements between pre and post dosing 
at proximal and distal sites.  
- Change in response to zero chloride/ isoprenaline perfusion between pre- 
and post dosing. This was analysed on a within patient and between group 
(pre vs. post dose bronchoscopy) basis. 
- Comparison of bronchial PD with nasal PD pre- and post dose:  accepting 
differences between sites (drug delivery, disease manifestation and 
structure), this was undertaken to determine whether there is any 
relationship in terms of ion transport and whether one can be used as a 
surrogate for the other.  
2.6.6 Statistics 
2.6.6.1 Agreement between analysers 
Intraclass correlation coefficients (ICCs) were calculated to assess agreement on 
the lower airway PD values as calculated by GD and JD using SPSS software as 
described in Chapter 2, section 2.5. This was undertaken in two phases, using the 
same approach as nasal PD: 
 Initial agreement between all lower airway PD analysed values 
 Final agreement between acceptable tests following consensus opinion 
between GD and JD. 
ICCs were calculated using SPSS Statistics version 21.0 (IBM), using a two way 
mixed effects model for absolute agreement. Final PD values for each section of PD 
(mean of accepted GD and JD result) were combined to analyse group differences 
between pre- and post- measurements. Comparison between groups was performed 
using paired t-tests with significance at p<0.05. Pearson correlation coefficients 
were used to describe associations between continuous variables. 
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2.7 Functional efficacy outcome measures: molecular 
evidence of CFTR gene transfer 
In the Pilot study, in addition to airway PD measurements, molecular evidence of 
successful CFTR gene transfer was also investigated. This was undertaken in the 
upper and lower airway for patients receiving a nasal or lung dose of gene therapy 
respectively. 
2.7.1  Nasal brushing for molecular CFTR assays 
Nasal brushings were performed pre- and post, or post dosing only for subjects 
receiving a nasal dose of CF gene therapy. All nasal brushings were performed by 
JD. Interdental brushes (Dent-o-care, London, UK) were used for sample collection 
dipped in phosphate buffered saline (PBS) first, with samples taken from under the 
middle or inferior turbinate under direct vision and immediately placed in 800 
microlitres PBS. Cells were removed from the brush by passing it back and forth 20 
times through a wide pipette tip into the PBS. A sample was taken from both 
nostrils, and combined, before being split three ways for subsequent analysis for 
immunocytochemistry, percent positive cells (PPC) and RNA extraction. Cells 
obtained from nasal brushing were counted using light microscopy for differential 
cell numbers. Molecular testing was carried out by Consortium researchers in 
Oxford for detection of vector-specific CFTR mRNA and DNA. Percent positive cells 
were analysed using the Taqman(R) Gene Expression Cells-to-CTTM Kit.  
2.7.2 Bronchial brushing for molecular CFTR assays 
Samples for molecular CFTR testing (DNA and mRNA) were obtained from lower 
airway brushings obtained at bronchoscopy. All bronchoscopies were performed at 
the RBH under general anaesthetic. The sequence of tests performed whilst a 
patient was anaesthetised included: lower airway potential difference 
measurements, bronchial brushings, and endobronchial biopsy. Bronchial brushings 
were processed and tested as described for nasal brushings above. Bronchial 
brushings were taken using disposable cytology brushes (BC-202D-5010, Olympus 
UK, Southend on Sea, UK). Ten brushings were taken per patient per bronchoscopy.  
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In addition to the bronchial brushing samples which were taken for the purposes of 
assessing efficacy, two endobronchial biopsies were taken per patient at each 
bronchoscopy using disposable single-use forceps (FB-231D, Olympus UK, as 
before). Biopsies were immediately fixed in formaldehyde. Histological analysis for 
presence of inflammation or evidence of remodelling was carried out by the 
histopathology department at the RBH according to standard hospital procedures 
for analysis of endobronchial specimens.   
Where time allowed for same-visit nasal PD to be performed pre-bronchoscopy, 
nasal brushing was also performed under anaesthetic to minimise discomfort for 
the patient. Patients were observed and monitored as in patients at RBH for a 
minimum of six hours post bronchoscopy. 
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3 Results: Run-In study  
This chapter describes the results from the first four Run-In study visits. This 
includes description of the study population and results (cross-sectional and 
longitudinal) for airway physiology, structural, patient reported outcomes and 
systemic markers of inflammation.  
3.1 Patient recruitment and characteristics of study 
population 
192 patients were recruited to the Run-In study, with 191 patients completing 1 or 
more study visits (n=111 at London site, n= 80 Edinburgh). Figure 3.1 shows the 
number of participants over the duration of the 4 visits. 
 
Figure 3.1. Number of patients (N) participating in each Run-In study visit.  
Trial enrolment (n=192) 
Visit 1 N=191 
 
 
Withdrawn after visit 1 
N=17 
 
Visit 2 (N=174) 
Withdrawn after visit 2 
N=11 
Visit 3 (N=163) 
Withdrawn after visit 3 
N=12 
Missed visit 4 N=1 
Visit 4 (N=150) 
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The subject attrition rate between visits 1-4 was linear (the average decline 
between visits was n=13 subjects, or 7% loss in study population; linear regression 
r2 =0.99). 
3.1.1 Subject characteristics 
At visit 1, the median (IQR) age was 18.7 (14.0-28.7). Ninety one subjects were 
aged <18 years at enrolment (London n=50, Edinburgh n=41), with the youngest 
patient aged 10 years. The oldest patient recruited was 59 years. Other baseline 
characteristics of Run-In patients are summarised in Table 3.1.  
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Table 3.1. Baseline characteristics of Run-In study participants 
 
The median FEV1 % predicted for the group as a whole at visit 1 was 71.0 % 
(Interquartile range (IQR) 53.5-84.8), which corresponded to a median FEV1 z score 
of -2.5. Patients recruited at the London site had more severe disease (as assessed 
by FEV1) than those in Edinburgh (median (IQR) 63.1 (48.5-78.2) % and 78.4 (63.4-
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90.4) % respectively, Mann Whitney test p<0.0001). The patients recruited at the 
London site appeared to be older however there was no statistically significant 
difference between their age and those of the Edinburgh patients at visit 1 (Mann 
Whitney test p=0.08). There was no difference in gender split between sites (52% 
male in London, 60% male in Edinburgh; Chi square test p=0.2).   
Almost fifty percent of the study patients were homozygous for the p.Phe508del 
mutation. Genotypes from all patients in the Run-In study are summarised in Table 
3.2.  
 p.Phe508del Other Unknown 
p.Phe508del 95 (49.7) 62 (32.5) 20 (10.5) 
Other  9 (4.7) 4 (2.1) 
Unknown   1 (0.5) 
 
Table 3.2. Genotypes from Run-In study participants. CF mutations are represented 
in grid format, mutation combinations in study patients are summarised according to 
number of patients (N (%)) with each combination.  
 
 
3.1.2 Interval between visits 
The number of days between study visits is summarised in Figure 3.2. The interval 
between visits 1 and 2 was significantly shorter than between visits 3 and 4 
(median 113 vs. 182 days; Wilcoxon test p<0.0001). This pattern was observed in 
both London and Edinburgh sites and reasons are described in the Discussion 
(section 3.7.2).  
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Figure 3.2. Interval between study visits 1-4. Results are summarised as Box and 
Whisker plots.  
 
 
3.2 Description of data 
The Run-In data provide opportunities to a) look at the variability of assays over 
time during periods of stability; b) question how these assays correlate with others, 
both within and across categories (e.g. physiology, inflammation, radiology), and c) 
observe directional change over time. Sections 3.3-3.5 focus on the first two of 
these as ‘interval independent’ analyses. A subsequent section (section 3.6) 
describes changes over time. For consistency, the data in section 3.3 are presented 
for those patients with results for a particular assay at every one of the 4 study 
visits. The assays described and the number of patients with all 4 data values 
available are summarised in Table 3.3. For many of the analyses described in this 
chapter, visit 1 data are used, whereas for others, particularly when looking at 
repeatability, the group of patients with data from all 4 study visits was used. To 
confirm whether these two groups were similar in baseline characteristics, Table 
3.3 includes visit 1 data from both groups. With the exception of LCI, there was no 
overall difference between subjects with results at every one of the study visits 
and those in the entire study population (Table 3.3); the potential reasons for this 
difference are described in the Discussion (section 3.7.4).  
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result at V1 
Mean (SD) 
assay 




Physiology   
FEV1 z score 150 -2.45 (1.67) 191 -2.57 (1.62) p=0.51 
FVC z score 150 -1.51 (1.52) 191 -1.59 (1.45) p=0.64 
MEF25-75 z 
score 
150 -2.60 (1.76) 191 -2.72 (1.71) p=0.52 
LCI 92 10.03 (2.57) 168 10.75 (2.73) p=0.04 
Inflammation   
Total white 
cell count 
137 9.16 (2.86) x 
109/L 





137 6.05 (2.64) x 
109/L 
186 6.20 (2.74) 
x 109/L 
p=0.65 
CRP 137 6.40 (10.91) 
mg/L 
186 6.55 (10.15) 
mg/L 
p=0.90 








Table 3.3. Comparison of visit 1 outcomes from patients with assay result at 
every one of the 4 study visits with the initial study population. The visit 1 (V1) 
outcomes from patients with valid results for an assay at all 4 study visits are compared to 
the entire study population with a valid assay result at visit 1. FEV1, FVC and MEF25-75 
values are for z scores. Unpaired t-tests were used to compare V1 results for patients with 
data from all 4 visits to the entire study population, with p values as shown.    
 
In the following sections, I will present i) a summary of the results for each 
outcome variable at the first study visit and its subsequent variability across visits 
for patients with data from all 4 visits available (section 3.3), ii) cross-sectional 
correlations within category (e.g. physiological outcomes) (section 3.4) and iii) 
cross-sectional correlations between categories (e.g. FEV1 z score with Respiratory 
domain of CFQ-R) (section 3.5). For the purposes of consistency, as a CT was 
performed only at one visit, all cross-sectional analyses are performed on data 
from that visit. 
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3.3 Summary data and variability  
3.3.1 Physiology: Spirometric values 
A Box and Whisker summary plot of the % predicted values and FEV1 z scores at 
each study visit from all patients with data for all 4 visits are shown in Figure 3.3.  
  
Figure 3.3A      Figure 3.3B 
Figure 3.3. FEV1 % predicted values and z scores across all 4 study visits. FEV1 
% predicted values are shown in 3.3A and z scores in 3.3B. Data are summarised in 
Box and Whisker plots. 
 
The median inter-visit coefficient of variation in FEV1% predicted values was 6.04%. 
Patients with an FEV1% predicted in the lowest quartile (V1 FEV1 < 54.5%) had 
greater variability than those in the highest quartile (V1 FEV1 ≥87.1%), with a 
median coefficient of variation of 7.83% vs. 5.10% respectively, Mann Whitney 
p=0.02). Using a cut off of -1.64 z scores for FEV1 as the lower limit of normal (LLN) 
(116;117) (approximately equivalent to an FEV1 of 80% predicted), Figure 3.4 
illustrates the inter-visit coefficient of variation for patients with results at each 
visit. Patients with a normal FEV1 z score at visit 1 appeared to show a lower 
variability in results but this was not statistically significant.  
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Figure 3.4. Coefficient of variation in FEV1% predicted according to visit 1 FEV1 
z score. Each patient is represented by an individual data point. A z score of -1.64 
was the cut off between normal and abnormal lung function at visit 1; coefficient 
of variation (CV) was plotted for each group. Mann Whitney test p=0.1.  
 
Using the same format as for FEV1, the results for FVC and MEF25-75 % predicted and 
z scores, and ratio of FEV1/FVC are shown in Figure 3.5. The median inter-visit 
coefficient of variation in MEF25-75 predicted values was 13.97%. Patients with a 
higher inter-visit coefficient of variation in FEV1 % predicted also had a higher 
coefficient of variation in MEF25-75 % predicted (r= 0.73, p<0.0001). For a patient 
with an inter-visit FEV1 % predicted coefficient of variation of ‘x’, their 
corresponding coefficient of variation for MEF25-75 % predicted was approximately 
‘2x’ (linear regression analysis: slope 2.10, 95% CI for slope 1.96-2.24). In other 
words, a patient with a 10% coefficient of variation for FEV1% predicted was likely 
to have had a 20% coefficient of variation in MEF25-75 % predicted values across the 
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Figure 3.5A  % Predicted FVC   Figure 3.5B  FVC z score 
  
Figure 3.5C  MEF2575 % predicted  Figure 3.5D  MEF2575 z score 
 
Figure 3.5E  Ratio of FEV1/FVC 
Figure 3.5. Summary data for spirometry outcomes at each study visit. Data for 
all 4 visits summarised as previously described for the outcome indicated on graphs A-E. 
The summary data for FEV1 is shown in Figure 3.3. 
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3.3.2 Physiology: Lung clearance index 
The summary final LCI results are summarised in Figure 3.6. The dataset was less 
complete for LCI than other outcome measures, reflecting the processes in data 
analysis and quality control described in Chapter 2, section 2.3.  
 
Figure 3.6. Summary data for lung clearance index (LCI) at each study visit. 
 
Only seventeen patients had a normal LCI at visit 1 according to the Upper limit of 
normal (ULN) as defined by Horsley (ULN 7.5 in adults and 7.3 in children ≤16 
years) (48). The median inter visit coefficient of variation in LCI was 6.4%. The 
relationship between severity and variability was explored. Patients in the top 
(most severe) quartile for visit 1 LCI had greater variability than those in the 
bottom (mildest) quartile (Mann Whitney p=0.03) (Figure 3.7). Similarly, those with 
a normal LCI at visit 1 had less variability over subsequent visits than those with an 
abnormal LCI (Mann Whitney p=0.04) (data not shown), although for the group as a 
whole, there was no correlation between baseline (visit 1) LCI and coefficient of 
variation across the 4 visits (r=0.10, p=0.4). 
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Figure 3.7. Variability in LCI between study visits according to quartile of visit 1 
LCI in Run-In population. The inter-visit coefficient of variation (CV) for each patient in 
the lowest (<25th) and highest (≥75th) quartile is represented by an individual data point. 
Mann Whitney test p=0.03.   
 
3.3.3 Structure 
180 baseline chest CT scans were performed for the Run-In study. Of these, 178 
have been formally scored (data not available for 2 patients). Scores are available 
on 131 scans performed at visit 1, 45 at visit 2, and two at visit 3. Eleven patients 
had not undergone a CT chest scan according to the CTEU database: 7 patients in 
this group withdrew after visit 1 and therefore did not have opportunity for CT at 
later visits. The reason for the absence of CT data for the other 4 subjects is 
unknown. 
The Run-In CT data are summarised in Table 3.4. Only 27/178 (15.2%) patients had 
no evidence of bronchiectasis on their CT scan (CT score <1 for extent of 
bronchiectasis).  These patients tended to be young (median (IQR) age 13.4 years 
(11.0-17.7)), had mild disease according to spirometry measurements (median 
(IQR) FEV1% predicted 89.3 (81.9-96.1)), and have normal or near normal LCIs 
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2.7 1.5-3.4 0-4 4 
Severity of 
bronchiectasis 
2.0 1.2-2.3 0-3.5 4 
Wall thickening 2.0 1.6-2.1 0.9-3.8 5 
Small airway 
plugs 
0.6 0.2-0.8 0.0-1.8 2 
Large airway 
plugs 
0.6 0.2-1.0 0.0-1.8 2 
Air trapping (%) 59.6 54.6-65.4 31.7-90.8 100 
 
Table 3.4. Summary results from chest CT scans. Summary results from n=178 
patients at a single time point scored according to the methodology described in 
Chapter 2, section 2.4.3. 
 
3.3.4 Inflammation 
The results for total white cell count, neutrophil count and C-reactive protein for 
patients with results at 4 visits are summarised in Figure 3.8. The median inter visit 
coefficients of variation for these measurements for all patients with results at all 
4 visits are summarised in Table 3.5 (section 3.3.6). The increased variability of 
CRP compared to white cell count likely reflects the very small normal range (<10 
mg/L) and the potential for very high values in inflammatory conditions. A small 
number of patients had high CRP values despite the presence of clinical stability as 
assessed by symptom questionnaire performed at study visit. The 75th centile for 
CRP was normal (<10mg/l) and consistent between study visits (7- 8 mg/L) however 
the maximal result for CRP (in any study patient) decreased between visit 1 and 4 
from 109 to 38mg/L.  
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Figure 3.8A Total white cell count  Figure 3.8B Neutrophil count 
 
Figure 3.8C C-reactive protein 
Figure 3.8. Blood markers of systemic inflammation. Summary plots are shown for 
blood total white cell count (Figure 3.8A), neutrophil count (Figure 3.8B) and C-reactive 
protein (Figure 3.8C).  
3.3.5 Quality of life questionnaires 
Results were combined for scores from adult and paediatric questionnaires, with 
one questionnaire per visit. 141 adult and 49 paediatric questionnaires were 
completed at visit 1 (results from 1 paediatric patient are unknown). The summary 
results from all study patients each questionnaire domain at visit 1 is shown in 
Figure 3.9. The median score was greater than 90 for the following domains at visit 
1: Physical, Role, Eating disturbances, Weight (the maximum score possible for any 
domain is 100).  
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Figure 3.9. CFQ-R scores for each questionnaire domain at Run-In visit 1. 
 
The ‘Respiratory symptoms’ domain scores at each study visit are summarised in 
Figure 3.10; the median inter-visit coefficient of variation for this domain was 
8.7%. 
 
Figure 3.10. CFQ-R Respiratory domain score summary data at each study 
visit. 
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Nine patients transitioned between the paediatric and the adolescent/adult 
questionnaire over the study period. There was no clear directional bias to change 
in score between visits when transitioning between paediatric and adult 
questionnaire versions. The median inter-visit coefficient of variation for these 
adolescents across all 4 visits (i.e. including responses from both paediatric and 
adult questionnaires) was 9.8%. The variability in inter-visit Respiratory symptom 
domain score from the CFQ-R was significantly greater in those patients with an 
abnormal FEV1 z score at visit 1 (Mann Whitney test p= 0.03).   
3.3.6 Summary 
In summary, this section has described the results and variability over time for the 
physiology, inflammatory and patient reported outcomes described in this chapter. 
For comparison in variability between outcomes, the median inter-visit coefficient 
of variation for each is summarised in Table 3.5.  
Outcome measure Median CV (%) 
Physiology 
FEV1 % 6.0 
FEV1 z score N/A 
FVC % 4.5 
FVC z score N/A 
FEV1/FVC  3.5 
MEF25-75 % 14.0 
MEF25-75 z score N/A 
LCI 6.4 
Inflammatory 
Total white cell count 14.8 
Blood neutrophils 21.7 
CRP 31.6 
Quality of Life 
CFQ-R Respiratory domain 8.7 
 
Table 3.5. Mean inter-visit coefficient of variation (CV) between visits for the 
outcome of interest. CV was not calculated for z scores due to the proximity to zero and 
presence of both positive and negative values. 
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3.4 Cross-sectional correlations within categories 
To allow a greater understanding of the clinical importance of the outcomes 
investigated, the relationships between them has been explored. This section 
describes cross-sectional correlations of outcomes within each category (e.g. 
airway physiology). These relationships help understand whether outcomes reflect 
similar or ‘additional’ information. The latter may either be due to increased 
sensitivity to detect disease or differences in site of airway under test, allowing a 
clearer understanding of disease pathology and which level of airways the different 
assays are representing. As patients only had one CT, all measurements included in 
this analysis are from that visit (1st, 2nd or 3rd as described above). 
3.4.1 Airway physiology  
Correlations between spirometry measurements (FEV1, FVC and MEF25-75) and LCI (% 
and z score) are summarised in Table 3.6 for measurements performed at the CT 
visit. The strength of correlation between FEV1, FEV1/FVC and MEF25-75 with LCI 
were virtually identical despite FEV1/FVC and MEF25-75 considered as reflecting 
different sites of the airway (Table 3.6 and Figure 3.11) (larger vs. small airways). 
To investigate sensitivity, the results for FEV1 z score vs. LCI and MEF25-75 vs. LCI 
have been plotted with reference to a line separating normal and abnormal 
measurements (Figure 3.11). For both FEV1 z score and MEF25-75, LCI was more 
sensitive outcome measure. Conversely the number of patients with an abnormal z 
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Figure 3.11A     Figure 3.11B 
Figure 3.11. Spirometry and LCI correlations. Each patient is represented by a single 
data point. Dotted lines separate normal from abnormal results. This is plotted at -1.64 z 
scores for FEV1 (Figure 3.11A) and MEF25-75 (Figure 3.11B) and at 7.5 to differentiate normal 
from abnormal LCI in both figures. Abnormal results are defined as FEV1 or MEF25-75 <-1.64 z 
scores or an LCI >7.5. 
 
  143 
  FVC z score FEV1/FVC MEF25-75  z score LCI 
FEV1 z score 180 0.86 <0.0001 180 0.76 <0.0001 180 0.91 <0.0001 156 -0.72 <0.0001 
FVC z score       180 0.35 <0.0001 180 0.61 <0.0001 156 -0.46 <0.0001 
FEV1/FVC ratio             180 0.89 <0.0001 156 -0.75 <0.0001 
MEF25-75  z score                   156 -0.78 <0.0001 
Table 3.6. Correlations between airway physiology outcomes at study visit when CT carried out. For each main variable (e.g. FEV1 z 
score), columns are divided into 3 sub-columns. From left to right for each, these columns represent the number of patients contributing to the 
analysis, Correlation coefficient (r) from Pearson correlation, and corresponding p value. In view of multiple comparisons, a statistically significant 
result was considered when p<0.0001.
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3.4.2 Structure 
As expected, there was a strong correlation between the extent and severity of 
bronchiectasis (Spearman r =0.89, p<0.0001), (Figure 3.12). To investigate the 
extent of disease affecting different airway sites (e.g. proximal vs. distal sites), 
relationships between other CT variables are summarised in Table 3.7. Airway wall 
thickness (a component of bronchiectasis, and therefore as expected) correlated 
strongly and similarly with both bronchiectasis scores (extent and severity). Large 
(and to a lesser extent, small) airway plugging were similarly correlated with 
bronchiectasis scores. In contrast, air trapping correlated only weakly (correlation 
coefficient < 0.5) with all other parameters, suggesting either that this may be an 
independent feature uncoupled from other measures, or that the scoring of this 
feature is less accurate than others. 
 
 
Figure 3.12. Severity and extent of bronchiectasis on CT scan. Each patient is 
represented by an individual data point, Spearman r= 0.89, p<0.0001. 
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  Severity bronchiectasis Wall thickness Air trapping Small airway plugs Large airway plugs 
Extent of 
bronchiectasis 
178 0.89 <0.0001 178 0.7 <0.0001 177 0.47 <0.0001 178 0.61 <0.0001 178 0.73 <0.0001 
Severity of 
bronchiectasis 
      178 0.73 <0.0001 177 0.38 <0.0001 178 0.57 <0.0001 178 0.74 <0.0001 
Wall thickness             177 0.37 <0.0001 178 0.54 <0.0001 178 0.7 <0.0001 
Air trapping                   177 0.35 <0.0001 177 0.36 <0.0001 
Small airway plugs                      178 0.65 <0.0001 
Table 3.7. Correlations between component of CT score and remaining CT outcomes.  For each CT variable, columns are divided into 3 
sub-columns. From left to right for each, these columns represent the number of patients contributing to the analysis, Correlation coefficient (r) 
from Pearson or Spearman rank correlation, and corresponding p value. In view of multiple comparisons, a statistically significant result was 
considered equivalent to p<0.0001.   
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3.4.3 Inflammation 
As the total white count reflected predominantly neutrophils, comparison was 
restricted to blood neutrophil population and level of serum CRP. For the 175 
patients with results for these outcomes at the CT visit (on which all cross-
sectional comparisons have been made), there was a weak but significant 
correlation between neutrophil count and CRP (r=0.33, p <0.0001).  
3.4.4 Quality of life 
Data analysis focused on the CFQ-R Respiratory domain score, and therefore no 
‘within category’ comparisons were performed.   
3.5 Cross-sectional correlations between categories  
To explore relationships, this section compares outcomes between categories (e.g. 
physiology vs. structure). Again, an investigation of these relationships helps 
understand issues relating to sensitivity and site of airway or systemic ‘readout’. As 
before, all measurements included in this analysis are from the visit at which CT 
was performed. 
3.5.1 Physiology vs. structure 
FEV1 z scores, MEF25-75 and LCI all correlated significantly with all CT parameters; 
for all physiological measures, the strongest correlation was seen with 
bronchiectasis and the least strong with gas trapping; mucus plugging was 
somewhere in between. LCI correlated more strongly with all CT parameters than 
did any of the spirometric values (Table 3.8). There was no indication from these 
data that MEF25-75 was reading out a different level of the airway than was FEV1. 
LCI was superior to FEV1 in correlating with degree of air trapping. The ratio of 
FEV1/FVC was almost equivalent to LCI in terms of strength of correlation with air 
trapping on CT, and was superior to MEF25-75 (which is conventionally considered to 
read out small airways).  
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For all spirometry measures, including MEF25-75 large airway plugging was more 
strongly correlated than small. For LCI, correlations with large and small plugs 
were much more similar. To investigate the sensitivity of LCI vs. FEV1 or MEF25-75 to 
detect structural change (as assessed by extent of bronchiectasis), the data was 
plotted as previously described for comparison within physiology outcomes. Again, 
LCI was superior in terms of sensitivity to detect change on CT than either FEV1 z 
score or MEF25-75 (Figure 3.13). 
 
Figure 3.13A     Figure 3.13B 
 
    Figure 3.13C 
 
Figure 3.13. Extent of bronchiectasis and FEV1, MEF2575 and LCI. Figure 3.13A is 
for extent of bronchiectasis with FEV1 z score; 3.13B with MEF2575 z score and 3.13C with 
LCI respectively. Each patient is represented by a single data point. Reference lines 
delineating normal and abnormal results are present at LCI =7.5, FEV1 or MEF2575 z score <-
1.64 and a score for extent of bronchiectasis of 1 or more. 
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  Extent bronchiectasis Severity bronchiectasis Wall thickness Air trapping Small airway plugs Large airway plugs 
Physiology       
FEV1 z score 178 -0.68 <0.0001 178 -0.66 <0.0001 178 -0.58 <0.0001 177 -0.42 <0.0001 178 -0.55 <0.0001 178 -0.64 <0.0001 
FVC z score 178 -0.54 <0.0001 178 -0.55 <0.0001 178 -0.47 <0.0001 177 -0.31 <0.0001 178 -0.44 <0.0001 178 -0.5 <0.0001 
FEV1/FVC ratio 178 -0.61 <0.0001 178 -0.58 <0.0001 178 -0.48 <0.0001 177 -0.48 <0.0001 178 -0.48 <0.0001 178 -0.57 <0.0001 
MEF25-75 z score 178 -0.67 <0.0001 178 -0.63 <0.0001 178 -0.56 <0.0001 177 -0.44 <0.0001 178 -0.53 <0.0001 178 -0.62 <0.0001 
LCI 154 0.82 <0.0001 154 0.78 <0.0001 154 0.65 <0.0001 153 0.5 <0.0001 154 0.64 <0.0001 154 0.68 <0.0001 
Inflammation       
Blood neutrophils 176 0.35 <0.0001 176 0.4 <0.0001 176 0.35 <0.0001 175 0.22 0.004 176 0.33 <0.0001 176 0.39 <0.0001 
CRP 174 0.33 <0.0001 174 0.39 <0.0001 174 0.41 <0.0001 173 0.27 0.0003 174 0.22 0.0029 174 0.35 <0.0001 
Quality of Life       
Respiratory domain 
CFQ-R 
178 -0.44 <0.0001 178 -0.42 <0.0001 178 -0.4 <0.0001 177 -0.29 <0.0001 178 -0.35 <0.0001 178 -0.4 <0.0001 
 
Table 3.8. Correlations between physiology, inflammatory and quality of life outcomes with CT outcomes, at study visit when CT 
carried out. For each CT variable, columns are divided into 3 sub-columns. From left to right for each, these columns represent the number of 
patients contributing to the analysis, Correlation coefficient (r) from Pearson or Spearman rank correlation, and corresponding p value. In view of 
multiple comparisons, a statistically significant result was considered equivalent to p<0.0001.  
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3.5.2 Physiology vs. inflammation 
There were weak but statistically significant correlations between FEV1 and LCI 
with measures of systemic inflammation (Table 3.9). However significant 
correlations were not consistently seen across other spirometry outcomes.  
3.5.3 Physiology vs. Quality of life 
Significant correlations were seen between all spirometric outcomes and LCI with 
the CFQ-R respiratory domain score (Table 3.9). The strength of correlation 
between the respiratory score from CFQ-R and spirometry outcomes and LCI was 
similar to those seen with structural changes. It was greatest for FEV1, MEF25-75 and 
LCI.  
3.5.4 Structure vs. inflammation 
Blood neutrophil count and CRP measurements were associated with CT outcomes 
however the relationships were weaker than those described above for airway 
physiology measurements (Table 3.8). The strongest association between CRP and 
CT outcome was seen for airway wall thickness. Both blood neutrophil count and 
CRP were also associated with severity of bronchiectasis on CT scan, and with the 
degree of air trapping on CT however although remained statistically significant 
was weaker. A greater association was seen between neutrophil count and severity 
of bronchiectasis on CT than for wall thickness or air trapping (Table 3.8).  
3.5.5 Structure vs. Quality of life 
Lower CFQ-R Respiratory symptom domain scores were associated with extent of 
bronchiectasis on CT (Table 3.8). The relationship between quality of life scores 
and CT outcomes was greatest for extent of bronchiectasis (in comparison to air 
trapping and wall thickness). 
 
 




FEV1 z score FVC z score FEV1/FVC  MEF25-75  z score LCI 
Inflammation 
Blood neutrophils 178 -0.3 <0.0001 178 -0.22 0.003 178 -0.29 <0.0001 178 -0.28 0.0001 154 0.39 <0.0001 
CRP 176 -0.34 <0.0001 176 -0.27 0.0002 176 -0.28 0.0002 176 -0.31 <0.0001 152 0.38 <0.0001 
Quality of Life 
Respiratory domain CFQ-R  180 0.41 <0.0001 180 0.33 <0.0001 180 0.36 <0.0001 180 0.4 <0.0001 156 -0.4 <0.0001 
 
Table 3.9. Correlations between physiology outcomes and measures of systemic inflammation and quality of life at study visit 
when CT carried out. For each physiology outcome (e.g. FEV1 z score), columns are divided into 3 sub-columns. From left to right as before, these 
columns represent the number of patients contributing to the analysis, Correlation coefficient (r) from Pearson or Spearman rank correlation, and 
corresponding p value. In view of multiple comparisons, a statistically significant result was considered when p<0.0001 
 
  Blood neutrophils CRP 
Quality of Life 
Respiratory domain CFQ-R 178 -0.26 0.0006 176 -0.24 0.0015 
 
Table 3.10. Correlations between quality of life and measures of systemic inflammation. The format and statistical significance as 
defined above.  
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3.5.6 Inflammation vs. Quality of life 
There were no significant correlations between markers of systemic 
inflammation and the Respiratory domain score from the CFQ-R. Although the 
results appeared to show a weak association between lower domain scores and 
higher populations of neutrophils or CRP in blood these did not achieve 
statistical significance (Table 3.10). 
3.6 Longitudinal analysis: change over time 
For any medium to long term study of CF, the progressive nature of the disease 
and thus the potential for directional change independent of any intervention 
needs to be considered. For the majority of outcome measures in CF, the degree 
of such directional change has not been defined. This section describes 
longitudinal data taking into account the number of days between individual 
study visits. Unless otherwise described, analysis has been performed on patients 
with results for the outcome of interest at every one of the 4 study visits. 
The median number of days between visit 1 and visit 4 for all 150 patients 
attending 4 study visits was 426 days (interquartile range 399 to 479 days). The 
minimum and maximum number of days between visit 1 and 4 were 329 and 875 
days respectively.    
3.6.1 Physiology 
3.6.1.1 Spirometric values 
 
The mean (95% CI) change in FEV1 % predicted per year was -1.1% (-2.2 to +0.02) 
in absolute % predicted values, which approached statistical significance. Mean 
change in FEV1 z score was -0.1 z scores per year. The change in % predicted 
values per year are plotted in Figure 3.14, with each patient represented by a 
single data point.  
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Figure 3.14. Change in FEV1% predicted per year. Lines represent mean and 




There was no significant change in FVC over time (-0.41% (-1.43 to 0.61) per 
year) and the corresponding change in FVC z score was -0.04 (-0.14 to 0.05) per 
year. The mean change in MEF25-75 % predicted and z scores per year was -1.3% (-
3.67 to 1.04) and -0.08 (-0.20 to 0.05) z scores per year respectively, however 
again this was not statistically significant. There was also no change in the ratio 
of FEV1 to FVC over the study period (mean change -0.01% (-0.02 to 0.00) per 
year). The change in % predicted values per year for FVC and MEF25-75, and 
change in ratio of FEV1/FVC are plotted in Figure 3.15.  
   
Figure 3.15A FVC % predicted   Figure 3.15B MEF2575 % predicted  
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Figure 3.15C Ratio of FEV1/FVC 
Figure 3.15. Annual change in FVC and MEF25-75 % predicted and ratio of 
FEV1/FVC. Presentation of data in graphs A-C as before, lines for mean are largely 
obscured by the proximity to the x-axis indicating no significant change over time. 
  
3.6.1.2 Lung clearance index 
LCI did not change significantly over the study period. The mean (95% CI) change 
in LCI per year for the n=92 patients with LCI results at each visit was +0.07 (-
0.12 to 0.27), summarised in Figure 3.16.  
 
Figure 3.16. Annual change in LCI. Each patient is represented by a single data 
point as before. Lines represent mean and standard deviation, with no evidence of 
change over time. 
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3.6.2 Inflammation  
Neither blood total WCC, neutrophils or CRP changed significantly over time. 
The mean (95% CI) annual change in total WCC, neutrophils and CRP were -0.14 
(0.53 to 0.24) x 109 /L, -0.04 (-0.44 to 0.35) x 109 /L and -0.44 (-1.67 to 0.79) 
mg/L (Figure 3.17).  
  
Figure 3.17A Total white cell count Figure 3.17B Blood neutrophil count 
 
Figure 3.17C  C-reactive protein 
Figure 3.17. Annual change in blood total white cell count, neutrophils and 
C-reactive protein. Data is presented as before, however lines for mean change 
overlie the x-axis at y=0.  
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3.6.3 CFQ-R Respiratory domain 
There was no change in patient reported outcomes over time as assessed by the 
CFQ-R respiratory domain score. The mean (95% CI) change for patients with 
results from all 4 visits was +0.3 (-1.41 to 1.97) score points per year. Results are 
displayed in Figure 3.18.  
 
Figure 3.18. Annual change in the Respiratory domain score of the CFQ-R. 
Data is presented as previous graphs with lines representing mean and standard 
deviation. Resp = Respiratory. 
 
 
3.6.4 Influences on longitudinal change  
Despite an absence of significant change over time in the outcome measures 
investigated for the entire study population with data at each of the 4 study 
visits, the patient population was diverse in terms of disease severity. Change 
over time. within subgroups was investigated according to visit 1 disease severity 
(FEV1 z scores) and age of patient.  
The rate of change in FEV1 was related to the patient’s lung function at visit 1. 
Patients with normal lung function at visit 1 (defined using a FEV1 z score cut off 
of -1.64) demonstrated a steeper decline in FEV1% predicted than those with an 
abnormal visit 1 FEV1 z scores (Figure 3.19). Those with normal lung function 
(n=59) had a mean (95% CI) annual change in FEV1 of -3.4% (-5.6 to -1.3) in 
absolute % predicted values compared to a change of +0.22% (-0.9 to 1.4) for 
those with an abnormal FEV1 at visit 1 (n=97); unpaired t-test p=0.001. This 
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relationship was also observed when the Run-In study patient population was 
divided into two approximately equal groups using a z score cut off of -2.5. Using 
this divisor, the annual change in FEV1 was -2.4% (95% CI of mean -4.05 to -0.72) 
in absolute % predicted values (n=78) for patients in the milder group (z score ≥ -
2.5) compared to +0.4% (95% CI of mean -0.97 to 1.68) for those in the more 
severe group (z score < -2.5) (n=72); unpaired t-test p =0.01 (Figure 3.19).  
 
Figure 3.19A     Figure 3.19B 
Figure 3.19. Annual change in FEV1% predicted according to FEV1 z score at 
visit 1. The annual change in FEV1 % predicted is plotted according to a lower 
limit of normal z score for FEV1 (-1.64)(Figure 3.19A) and a z score cut off of -2.5 
(Figure 3.19B)(which divided the Run-In population into two approximately equal 
halves). The rate of change in FEV1 % predicted was greater in both milder 
groups of patients (unpaired t-test p=0.001 for cut off of -1.64 z scores, and  
0.01 for -2.5 z score cut-offs respectively).  
 
There appeared to be a greater rate of decline in FEV1 z score in patients age < 
18 years at visit 1, but this did not reach statistical significance (unpaired t-test 
for change in z score for patients <18 years vs. ≥18 years at visit 1, p= 0.13). 
However, there was no difference between the trends of LCI or CFQ-R 
Respiratory domain score over time according to the presence of a normal or 
abnormal FEV1 z score at visit 1. The unpaired t-test for mean rate of change in 
LCI over time according to normal or abnormal FEV1 z score at visit 1 was not 
significantly different between groups (p= 0.6), nor was it for trends in change in 
Respiratory domain score over time  (p= 0.3). 
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3.6.5 Correlation of longitudinal change between outcome 
categories 
If outcome in a clinical trial is assessed according to change in one parameter, 
this may not be mirrored by ‘improvement’ in another category. To explore 
relationships in directional change between one outcome with another over time 
within individuals, the slopes resulting from the regression analyses were 
compared.  
The annual change in FEV1 z score was negatively correlated with the annual 
change in LCI (Pearson r = -0.34, p=0.0009; n=92) (Figure 3.20), and therefore 
both consistent with a directional change of more severe disease.   
 
Figure 3.20. Annual change in FEV1 and LCI. The slope representing annual 
change in FEV1 z score against change in LCI per year is plotted for each patient. 




To determine whether rate of change over time in physiological outcomes was 
related to baseline airway structural abnormalities, comparisons were made with 
baseline CT parameters. There was no significant correlation between the 
annual change in FEV1 z score or LCI and the severity of bronchiectasis score on 
chest CT (Spearman r= 0.1, p= 0.2 and r=-0.05, p=0.6 respectively). Similarly 
there was no association between trends in FEV1 z scores and extent of air 
trapping or bronchial wall thickness on CT. Although direction and magnitude of 
change in physiological outcomes correlated with each other, they also did not 
reflect any change in the CFQ-R respiratory domain score over time. There was 
no correlation between the direction and rate of change in FEV1 z score or LCI 
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and direction of change in the Respiratory Symptom domain score of CFQ-R  
(Pearson r = -0.07, p=0.4 and r=-0.17, p=0.1 respectively), (Figure 3.21). Any 
within-patient trends over time in spirometry or LCI were not reflected by 
similar trends in inflammatory markers (CRP, white cell count and neutrophil 
count) (data not shown). 
 
Figure 3.21. Annual change in Respiratory domain score of CFQ-R and FEV1 
z score. Format of graph is as presented for other comparisons. No significant 




3.6.6 Change over time with data from < 4 study visits 
Inclusion of data from patients with 2 or more study visits (as opposed to 4) 
increased the ‘n’ number of subjects per outcome measure but also increased 
the variability of change over time when included in the regression analyses. 
Therefore results with <4 data points have not been described within this 
section. An example of the potential problems with a small (n=2) number of data 
points to plot a ‘best fit’ line to represent change over time is illustrated by the 
CFQ-R respiratory domain score results.  The change per year for all patients 
with 2 or more visit results according to regression analyses is shown in Figure 
3.22. This suggests an annual change beyond the potential maximal value 
possible for this outcome (for example by having data from 2 visits only and a 
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CFQ-R respiratory domain score of e.g. 33 at visit 1 and 68 at visits 2 separated 
by a 3 month interval) and is therefore invalid.  
 
Figure 3.22. Annual change in Respiratory domain score of CFQ-R 
calculated according to slope derived from 2 or more (rather than 4) study 
visits. The resultant ‘change’ in score over time for the outliers is implausible 
(maximum domain score =100). Respiratory is abbreviated to ‘Resp’; Lines represent 
mean and standard deviation as previously.  
 
3.7  Discussion 
The outcome measures described for the Run-In study have included data 
analysis from two perspectives: 1) results at each visit in order to describe 
variability in different outcome measures over time, and 2) results according to 
the actual visit interval in order to investigate rate of change in outcome over 
time (sections 3.3 and 3.6 respectively). Interest in the former is important to 
guide suitability as outcome measures for clinical trials and to guide power 
calculations. The second allows an investigation of directions change over time 
indicating progression of lung disease. Results from cross-sectional comparisons 
both within and between categories of outcome measures have also been 
described (section 3.4 and 3.5), allowing investigation of their relationship with 
each other.  
Several themes are worthy of further discussion. These are related both to 
general issues of longitudinal study design and specific issues to the outcome 
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measures described, including methodology as described in Chapter 2, section 
2.3-2.4.  
3.7.1 Airway physiology analysis methodology 
The results for the Run-In study airway physiology outcomes in this chapter are a 
consequence of refinements initiated as part of the UKCFGTC clinical 
programme as described in Chapter 2, section 2.3. Through involvement in both 
data collection and data analysis, the author was able to identify several issues 
within physiology outcomes that were being collated and speculate on their 
likely cause. Collectively, the processes employed have provided opportunity to 
investigate the impact of variables on final outcomes which contribute to data 
analysis for clinical trials. These include reference equations, test software and 
hardware, and other external factors which can influence final results. 
Unexpected results, including discrepancies on repeated analyses of the same 
test (as identified for LCI) or exaggerated longitudinal trends over time (as 
identified for FEV1 % values) initiated the process of review. As a result of the 
exhaustive team effort between physiologists and research fellows at the London 
and Edinburgh sites in LCI reanalysis, we were collectively able to identify 
additional problems with quality of test data which led to refinement in 
methodology, and detailed revision of standard operating procedures. The cost 
was data loss – most significantly at the London site – but the resultant data 
surviving quality control measures can be analysed with greater confidence as a 
consequence. Horsley reported that > 85% of CF subjects performing an Innocor-
measured LCI were able to complete testing and obtain reproducible 
measurements (48). The 97% rate for LCI test acceptability at the Edinburgh 
sites were therefore impressive and, in combination with a standardised 
approach and environmental improvements in London testing conditions, is 
encouraging for superior dataset completeness in the ongoing multidose trial.   
Moving forward, it will be important to determine whether the finding that a 
greater proportion of LCI tests are rejected in patients with more severe disease 
holds true. If so, this is crucial information for planning power calculations for 
any CF clinical trial including LCI as an outcome measure in patients with 
moderate or severe lung disease. Within-patient variability in LCI during 
longitudinal data collection is described in section 3.3.2; higher coefficients of 
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variation were observed for the most severe quartile of Run-In patients. 
Collectively these issues suggest that as an outcome measure LCI is better suited 
to those with early stage disease, or at least consideration should be given to 
determining an appropriate treatment effect size in interventional trials 
according to the underlying severity of disease. 
During the process of data analysis for the Run-In study, the author became 
aware that the use of the two separate spirometry reference sources (Rosenthal 
and Quanjer) was introducing unacceptable additional variability into 
longitudinal assessment of change in % predicted values over time (Chapter 2, 
section 2.3). Presentation of the comparative data detailed below to the 
UKCFGTC Strategy Group led to the adoption of Stanojevic ‘All ages’ approach 
for interpretation of spirometry values for both the Run-In and Pilot studies, and 
this continues to be used in the current multidose trial. The conversion of 
spirometry data to % predicted values highlighted the challenges introduced by 
an external reference source, particularly with separate, non-continuous 
reference ranges for children and adults. For studies in a disease such as CF 
which may include participants in their teenage years, use of discontinuous 
reference ranges across child- and adulthood can have significant implications 
for data interpretation and clinical decision making. For longitudinal studies 
including this patient group a continuous reference source is essential. The 
opportunity to take account of expected distributions within a population by 
defining results according to z scores is also attractive, as the implications of a 
particular % predicted value are not static with age. In the future the author 
anticipates similar ‘all age’ reference sources being crucial to appropriate LCI 
interpretation as exists for spirometry (64) currently. 
3.7.2 Recruitment and retention 
Interestingly, the rate of patient withdrawal between Run-In study visits was 
consistent, demonstrated by the almost perfect regression line across data 
points representing patient numbers at each visit (section 3.1.2). The interval 
between study visits was not constant, increasing with later Run-In visits (Figure 
3.2). This reflects the difference in perceived vs. real timelines that were 
encountered in preparation for the UKCFGTC Pilot study (single dose safety trial, 
see Chapter 2, section 2.2) and multidose gene therapy trial and a resultant 
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spacing of Run-In visits. Maintaining patient enthusiasm for on-going 
participation in longitudinal studies is a challenge. Although its wider 
applicability is unknown, the linear relationship between visit number and 
patient retention is a useful observation for non-interventional studies leading to 
patient selection for a future (interventional) trial such as intended by Run-In 
study and its relationship with the multidose trial.  
3.7.3 Defining clinical stability 
In the Run-In study, a definition of clinical stability was based on patient history 
and a crude (in-house designed) symptom score. Patients were only allowed to 
continue with the study visit if the symptom score was compatible with no or 
little change from baseline clinical status. Despite this, it is interesting that 
individual patients can be identified as significant outliers for certain tests. For 
example, the serum C-reactive protein (CRP) results demonstrate a relative 
stability over time, however on a single occasion an individual patient had a CRP 
above 100mg/L. Other examples of significant outliers observed within the 
results included scores for the Respiratory symptom domain of the CFQ-R from a 
single visit being well outside those from the other 3 visits analysed. 
Therefore it is possible that other outcomes measured at the same visit may not 
represent that patient’s ‘true’ baseline status, and may artificially affect the 
expected variability of a test. Ultimately, a pragmatic approach has to be taken 
and in accordance to data presented and discussed in this chapter, an inclusive 
approach has been undertaken. All data were analysed, irrespective of the 
presence of a significant outlier.  
3.7.4 Data availability 
The author has chosen to concentrate longitudinal analysis on those patients 
with a complete data set (results from 4 visits) for the outcome of interest. This 
inevitably meant that not all patients were represented in the analysis. This was  
due either to patient withdrawal from the study prior to visit 4, or to absent 
data as a result of missing test results or exclusion of results prior to inclusion on 
the CTEU database as a result of quality control processes (e.g. as occurred for 
LCI, described in Chapter 2, section 2.3). Comparison of the visit 1 results from 
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these patients with the entire study population at visit 1 demonstrated that they 
were not significantly different at baseline, with the exception of LCI. This was 
significantly higher in the overall study population. Although there were no 
differences in other outcomes, it is possible that concentrating on complete 
datasets excluded patients with more severe disease and this is an important 
consideration when considering change over time, however the additional 
variability introduced by including patients with incomplete datasets meant that 
this was an accepted limitation. However, it may be that the difference is 
artefact, as a higher proportion of LCIs from patients with more severe disease 
were ineligible for the final Run-In LCI dataset (Chapter 2, section 2.3).  
3.7.5 Coefficient of variation 
The measure ‘coefficient of variation’ (CV, which is calculated by dividing the 
standard deviation by the mean) has been calculated for the longitudinally 
collected outcome measures reported in this chapter (section 3.3). The median 
coefficient of variation between visits was 6.0% for FEV1% predicted values and 
6.4% for LCI. Tests with low expected values, irrespective of the units, are 
subject to large coefficients of variation. Therefore results which are maintained 
in a ‘normal’ range during periods of stability can still experience wide 
variability (and high coefficients of variation) between visits. This was illustrated 
by the results across visits 1-4 for white cell count and CRP. Coefficients of 
variation, as a reflection of variability of an outcome over time, are also not 
suitable for assessing variability in z scores between visits as they contain both 
positive and negative values. Another difficulty with this summary measure is 
that an outcome with a small unit of measurement and an apparently ‘low’ CV 
(%) can result in an expected variability in the outcome which is equivalent or 
near to the magnitude of treatment effects seen in response to a therapeutic 
intervention. For example, a CV of 7.0% on the basis of an LCI of 10 is equivalent 
to an absolute value of 0.7. This is near to the size of treatment effect with 
RhDNase in the study reported by Amin et al (70) (LCI was measured in 17 
patients in a cross over trial involving RhDNase or placebo; mean (SD) 
improvement in LCI on RhDNase = 0.9 (1.44)). CVs do however provide useful 
information about the variability of outcomes over time within the patient 
population and can help guide power calculations for determining appropriate 
sample sizes in interventional clinical trials.  
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3.7.6 Ceiling effect 
The results from the CFQ-R demonstrate the problem of ceiling effects with 
outcome measures. The CFQ-R domains for physical functioning, role, eating 
disturbances and weight were particularly affected by this with over half of all 
study participants attaining a score >90 (maximal score 100), as shown in Figure 
3.9. Furthermore, for 7/12 domains in the adult questionnaire, the 75th centile 
was >90. If the patient population of interest has a maximal or near maximal 
score when well during periods of stability, there is little opportunity to observe 
a treatment effect. This is even more the case with CFQ-R results than lung 
function measurements, as the latter are based on a continuous numerical scale 
with no maximum value in comparison to an absolute maximum of 100 for each 
CFQ-R domain. These ceiling effects also reduce the validity of plotting the 
domain score against a continuous variable such as FEV1% predicted, as linear 
associations become invalid if the scores are saturated at the top of the scale. 
As scores from the Respiratory domain were not all saturated at the top of the 
scale, linear correlations were made in this thesis. Other potentially useful 
domains in the CFQ-R to explore further in this dataset include Vitality, Social, 
Health perception, and Treatment burden. An association between these 
domains and disease severity in CF using the CFQ has been reported in the 
literature (106).  
3.7.7  Change in outcome measures over time 
Data analysis of repeated measures from individual subjects was undertaken in 
order to identify change over time (section 3.6). Whereas the assessment of 
variability was undertaken independent of visit interval (as Run-In visits were 
undertaken at times of clinical stability defined by symptom score undertaken at 
study visit), trends in change over time were undertaken by taking the visit 
interval into account.  
The assessment of change over time was performed with linear regression for 
each outcome independently. However, relationships presented here suggest 
there would be merit in performing sophisticated statistical modelling analysis to 
identify the interdependence of the different outcomes investigated throughout 
this chapter. Such models could also take into account patient characteristics 
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including airway microbiology, concurrent medications, and infective 
exacerbation rate requiring admission for intravenous antibiotics over the data 
collection period.  
Despite some wide variations in ‘slopes’ from the regression equation 
(representing change over time) from particular outcome measures between 
individual patients, for the study population there was little change in the 
results from airway physiology tests, blood markers of infection and 
inflammation, and quality of life over the duration of the first 4 Run-In study 
visits. The mean decline in FEV1% predicted values per year in the Run-In 
population was consistent with reports in annual decline in FEV1 for patients 
with CF described in the literature (46). Steeper rates of decline in FEV1 in the 
Run In study were observed in patients with milder disease (as assessed by FEV1) 
at visit 1. This is in keeping with the findings of Konstan et al where high 
baseline FEV1 was an independent risk factor for decline in FEV1 % predicted in 
children and adolescents (118). The comparatively lower rate of decline in FEV1 
over time in patients with more severe disease is also an important 
consideration for CF clinical trials when the primary outcome is decline in z 
scores or % predicted values for FEV1 over time.  The use of a continuous 
reference source for paediatric and adult patients (as described in Chapter 2, 
section 2.3) has allowed a more appropriate investigation of change over time 
than if two discontinuous reference sources were used – longitudinal change in % 
predicted FEV1 must not be assessed with the latter. Use of separate paediatric 
and adult reference ranges for % predicted values from the Danish CF Registry 
have recently been used to model the rate of decline in FEV1 % predicted values 
according to baseline FEV1 % (119). I suggest that any prediction model 
developed from this discontinuous dataset should be interpreted with caution.  
Of interest was the finding that the direction of change (in terms of slope of 
regression line) for FEV1 did not correlate with the annual change in Respiratory 
symptom domain score for CFQ-R on an individual patient basis. This provides 
evidence for the importance of measuring multiple outcomes in clinical studies 
involving CF patients. It is possible that the change over time would better 
conform to expected direction of change with longer periods of follow up. Data 
collection over a more prolonged period of time (spanning multiple years, if not 
decades) is needed to evaluate a more realistic description of annual rate of 
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change than possible with the data analysed here.  However, from a clinical trial 
perspective this is impractical. 
3.7.8 Relationship between structural change on CT and other 
outcomes 
Even when corrected for multiple comparisons, statistically significant 
correlations were seen between measures of disease severity as assessed with 
airway physiology tests (spirometry and LCI) and structural assessment of the 
airway with CT including assessment of bronchiectasis, airway wall thickness and 
degree of air trapping. However, the strength of these associations was not 
uniform. Due to the multitude of ‘significant’ p values resulting from correlation 
of CT outcomes with spirometry, the reader is directed instead to the strength 
of association suggested by the correlation coefficients. Consistent with the 
literature, LCI was superior to FEV1 and other spirometry indices in the 
correlations with structural change as assessed on CT (120). It was more 
sensitive than either FEV1 or MEF25-75, and in support of the study by Gustafsson 
et al we also found that a normal LCI almost excludes the presence of 
bronchiectasis on CT (120). The author did not perform a sensitivity analysis on 
the degree of air trapping with physiology outcomes as all CT scans performed 
were scored as having at least 30% air trapping. This is the % cut-off often used 
for defining abnormality (121) and was used as the threshold for abnormal gas 
trapping in the sensitivity analyses between airway physiology and CT outcomes 
performed by Gustafsson (120).  
The strength of correlation seen between FEV1 and structural assessments on CT 
were similar to MEF25-75 for all CT outcomes. Therefore there was no indication 
from these data that MEF25-75 was reading out a different level of the airway 
than was FEV1. For all spirometry measures, including MEF25-75 (which is thought 
to read out small airways), large airway plugging was more strongly correlated 
than small. For LCI, correlations with large and small plugs were much more 
similar. The highly statistically significant correlations between LCI and severity 
of bronchiectasis on CT support its role in detecting structural lung disease in 
CF.  
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3.7.9 Patient reported outcomes  
In the Run-In study, there were significant correlations between the Respiratory 
domain of CFQ-R and all CT outcomes, and similarly with all airway physiology 
outcomes.  In comparison there was no correlation between the change over 
time in Respiratory domain score from CFQ-R and airway physiology outcomes. 
This was perhaps not unexpected as one is a patient reported outcome and the 
other a surrogate marker of the underlying pathology within the lung. This 
highlights the importance of including patient reported outcomes and supports 
the use of both in clinical trial design (2).  
3.7.10 Variability according to disease severity 
In CF the ‘optimal’ outcome measure is different for different stages of disease. 
For example, LCI was superior to FEV1 in relation to the detection of disease on 
CT, however of interest was the suggestion of greater variability with increasing 
severity of disease. The increase in variability of the CFQ-R Respiratory domain 
scores were related to disease severity as defined by FEV1 z scores, again an 
important finding for clinical trials. These findings are important for any power 
calculations aiming to determine sample size for a particular effect change in 
the outcome measure of interest.  
3.7.11 Ability to detect change 
The airway is not a single entity and therefore it is important that clinical trials 
include tests that can detect changes at different airway sites. The relationship 
between patient reported outcomes and airway physiology tests in longitudinal 
study is likely to be complex. Scores for the Respiratory domain of CFQ-R have 
been reported in the literature to be associated with disease severity (106) (and 
significant correlations with CT parameters, spirometry outcomes and LCI have 
been reported here for the Run-In study), however the absence of any 
relationship between direction of change over time for quality of life and 
spirometry or LCI outcomes was striking. The duration of the Run-In study was 
not sufficient to investigate whether there is a measurable time lag between 
physiology and patient reported outcomes.  
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3.7.12 Moving forward to multidose trial 
A review of the Run-In data by the trial statistician and UKCFGTC strategy group 
was undertaken in order to identify the most appropriate outcome measures 
(and most appropriate patients) to take forward to multidose trial. This led to 
the selection of relative change in % predicted FEV1 after 12 monthly doses of CF 
gene therapy or placebo as the primary outcome for the multidose trial. 
However, all outcome measures described in this chapter are being collected at 
intervals throughout the multidose trial. In combination with results from the 
Pilot study (Chapter 4), this will provide extensive further opportunity to 
investigate the associations observed between outcomes in the Run-In study and 
how they change in relation to one another as a result of a novel therapeutic 
intervention. 
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4 Results: Single dose Pilot study 
This chapter describes patient demographics, baseline clinical status and safety 
outcomes from the Pilot study. All results from measurements of airway 
potential difference (PD) in the Pilot study from the upper and lower airway are 
described in Chapters 5 and 6 respectively.   
4.1 Recruitment  
Patient enrolment in the Pilot study commenced in February 2009. The final 
patient was enrolled in May 2011. Forty two patients were enrolled in the study 
and 36 received a dose of CF gene therapy and completed the trial. Six patients 
withdrew from the study prior to receiving the gene therapy dose or did not 
meet clinical stability required for dosing during the time course of the trial.  
4.2 Baseline characteristics 
Thirty five patients received a single lung dose of gene therapy and n=22 
received a nasal dose. With the exception of one patient, all those receiving a 
nasal dose were also in the lung cohort. This patient did not meet the inclusion 
criteria for the lung cohort, hence participation in the nasal cohort alone. 
4.2.1 Lung gene therapy patients 
The median age of all patients receiving a lung dose of gene therapy (n=35) was 
27.4 years (range 16.4 – 61.6 years), 34.3% were female. At enrolment, all 
patients had an FEV1 % predicted >60% according to Quanjer or Rosenthal (<18 
years) reference values (61;62). The median (IQR) FEV1 % predicted values at 
enrolment was 72.1 (66.2-86.8) % according to the Stanojevic reference source 
(64). 
Table 4.1 summarises the baseline characteristics of the patients receiving a 
nebulised dose of gene therapy.  
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Yes N (%) No N (%) 
Pancreatic insufficient? 29 (82.9) 6 (17.1) 
Nebulised antibiotics? 28 (80) 7 (20) 
RhDNase 14 (40) 21 (60) 
Hypertonic saline 8 (22.9) 27 (77.1) 
Daily (long term) azithromycin 23 (65.7) 12 (34.3) 
CF related diabetes on insulin 6 (17.1) 29 (82.9) 
Regular inhaled steroids 16 (45.7) 19 (54.3) 
Table 4.1. Baseline characteristics of the n=35 patients receiving a nebulised 
dose of CF gene therapy. 
 
The genotype of patients in the lung cohort was as follows: 
 20/35 (57.1%) were homozygous for the p.Phe508del mutation. 
 14/35 (40.0%) had one known p.Phe508del mutation, with: 
o N=7 another CF disease causing mutation 
o N=7 an unknown mutation.  
 One patient had two other (non p.Phe508del) disease-causing 
mutations.  
4.2.2 Nasal gene therapy patients 
The median age of the n=22 patients receiving a nasal dose of gene therapy was 
26.8 years (range 16.4 – 61.6 years), 37.5% were female. Sixteen patients in the 
nasal dose cohort were dosed during part A and 6 in part B of the Pilot study.  
All patients in the nasal cohort had at least one p.Phe508del mutation. The 
genotype of patients in the nasal cohort was as follows: 
 12/22 (54.5%) were homozygous for the p.Phe508del mutation. 
 10/22 (45.5%) had one known p.Phe508del mutation, with: 
o N=5 another CF disease causing mutation 
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o N=5 an unknown mutation.  
4.3 Dose delivery and duration 
The time taken to deliver each 5ml aliquot of gene therapy to the lung via 
nebulisation was consistently around 25 minutes when delivered at a ‘standard’ 
rate.  The proportion of complex administered via nebulisation (lung dose) for 
each dose cohort is shown in Figure 4.1. The mean (SD) volume administered for 
patients in the 20ml cohort was 17.8 (0.35) ml. Similarly for the 10ml cohort 
mean volume was 8.74 (0.23) ml and for the 5ml dosing cohort 4.47 (0.23) ml. 
The proportion of intended dose administered was consistent across the 20ml, 
10ml and 5ml dose cohorts (mean 87-89% for each group; ANOVA p=0.21).  
 
 
Figure 4.1. Proportion of nebulised gene therapy complex administered 
according to dose cohort. The proportion of dose administered was determined 
according to change in weight of nebuliser pot pre- and post administration; lines 
represent mean values, ANOVA p=0.21.  
 
For patients prescribed a 1ml nasal dose (n=3), container weights pre and post 
dosing were available for 2 patients, allowing determination of delivered 
volume. They received 1ml and 0.8ml respectively. No weights were available 
for the first patient dosed as the decision to weigh nasal containers in addition 
to the nebulisers (which had been planned a priori to determine actual 
nebulised volume administered) was made following this. Weights were available 
to calculate the nasal volume administered for 18/19 patients prescribed a 2ml 
nasal dose. The mean (SD) volume administered was 1.89 (0.3) ml. The 
proportion of complex administered for each dose cohort is shown in Figure 4.2. 
  172 
The variability in actual volume administered was large (as it was based on 
number of (patient) administered sprays rather than absolute change in weight). 
For one patient, despite delivering the 24 nasal sprays (as per protocol for 2ml 
dose), the actual volume administered was only 0.97ml. The maximum nasal 






Figure 4.2. Proportion of nasal gene therapy dose administered according to 
dose cohort. The proportion of dose administered was determined according to 




4.4 Post dose follow up 
4.4.1 Pilot A: 10ml lung dose/1ml nasal dose patients (n=3) 
For all three patients, lung and nasal dosing was well tolerated acutely, with 
report of throat discomfort only. Spirometry immediately post dosing 
demonstrated a mean drop in FEV1 of 15% in comparison to immediate pre-dosing 
values, but this was accompanied by minimal chest symptoms.  There was a 
further decline in FEV1 and FVC noted within the 6 hours of post-dosing 
observations, accompanied by findings of crepitations on chest auscultation but 
no wheeze.  There were small drops in oxygen saturation but no patient required 
supplementary oxygen.  Systemic symptoms included low-grade fever, headache, 
muscle ache and tiredness.  A raised white cell count with a predominant 
neutrophilia was detectable by 8 hours post dosing in all patients. All 3 patients 
were discharged home the following day (day 1) after elective overnight 
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observation. The maximal rise in the acute phase protein CRP (as a measure of 
systemic inflammation) was detected at day 2. Summary graphs of clinical, 
airway physiology and systemic inflammatory outcomes are presented later in 
section 4.5, with all patients grouped according to volume of lung dose received.  
4.4.2 Pilot A: 20ml lung dose/ 2ml nasal non-invasive lung dose 
patients (n=3)  
Due to the post-dosing profile experienced by the three 10 ml patients, an 
amendment to the trial protocol (version 5, 06 April 09) was submitted in order 
that the first three 20 ml patients would not undergo a post dosing 
bronchoscopy, which could interfere with our understanding of the host response 
to the agent.  
The spectrum of symptoms and decline in lung function was as observed for the 
10 ml patients, but was of a greater magnitude.  Decline in respiratory status 
and systemic inflammatory response was more marked (maximum drop in FEV1 
around 40%, maximum temperature post dosing 39.5 degrees C). Again, the 
clinical picture was of crepitations rather than wheeze and there was little 
response to bronchodilators (as may have been expected as there was a 
concomitant drop in FVC). In comparison to the objective measures of lung 
function drop, the report of respiratory-related symptoms by the patients was 
less notable. All three were discharged home the following day (day 1).  
A day 2 post dosing CT scan on one of these patients detected small areas of 
‘ground glass’, not present on pre-dosing scans. This was considered likely to 
represent a small patch of either alveolitis or very distal bronchiolitis.  In view 
of this, and the unknown natural history of its resolution, a decision was made 
by the Data safety monitoring board (DSMB) to withhold further gene therapy 
dosing until these 3 x 20ml lung dose patients had completed the study protocol.  
We noted a longer ‘tail’ of symptoms in the 20 ml patients, with symptoms of 
tiredness persisting longer than seen in those given 10 ml.  The CT changes seen 
at day 2 in the one isolated patient had resolved by day 14, and inflammatory 
markers had also normalized by this time point (peak CRP at day 2).  
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4.4.3 Pilot A: 20ml lung/ 2ml nasal invasive cohort (n=10)  
Following discussion of the safety profile of the 3 initial 20ml patients, 
permission from the DSMB was granted to proceed to the invasive 
(bronchoscopic) arm of the study.  Due to the now familiar post dosing 
inflammatory profile seen, a further amendment was requested (protocol 
version 6, 15/07/09) from the regulatory authorities to change the timing of the 
post dosing bronchoscopy from day 2 and day 14 (originally planned for n=12 in 
each group) to day 6 and day 14.  This was changed to prevent patients 
experiencing a likely post-gene therapy inflammatory process from being further 
compromised by a bronchoscopy under general anaesthetic at the same time 
point.  
Ten patients were dosed in this arm of the study. A consistent pattern of clinical 
and laboratory responses as observed in the 20 ml non-bronchoscopic patients 
was seen, although the magnitude of change in clinical and laboratory markers 
between patients was variable. The clinical response and logistics (e.g. distance 
lived away from hospital) dictated whether individual patients were discharged 
home or remained in hospital until the following morning. Treatment with 
ibuprofen and/or paracetamol was given in response to systemic symptoms or 
fever (see section 4.7). No further post dosing changes were seen on any CT 
scans. In addition to the raised inflammatory markers, there were small rises 
detected in serum creatinine and unconjugated bilirubin in the 24 hours post 
dosing, which then returned to pre-dosing levels. The change in serum creatinine 
and unconjugated bilirubin remained within the normal range across all 
measurements for the vast majority of patients despite this small rise from pre-
dosing levels, and are considered likely to reflect clearance mechanisms of the 
gene therapy product. Due to the adverse events noted in the 20ml group post 
dosing, the 20ml invasive bronchoscopic cohort was limited to 10 patients.  
4.4.4 Pilot B: dose cohorts 
As described, the aim of part B of the study was to find an optimal dose to take 
forward to multidose trial. Lung dosing strategies included: 
 10ml lung dose (slow delivery), 20ml lung dose (slow delivery) 
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 20ml lung dose with adjuvant prednisolone or ibuprofen 
 Further standard rate dosing with 10ml and 5ml volumes 
 10ml or 5ml lung doses with adjuvant paracetamol 
Patients in Pilot B experienced the same pattern of symptoms and changes in 
laboratory markers post dosing as those described for part A although the 
magnitude of this response was related to the dose received for most markers. In 
part B, n= 3 patients were given their lung dose at a slow delivery rate; n=2 
receiving a 20ml lung dose and n=1 receiving a 10ml lung dose. Slowing the rate 
of delivery made no difference to clinical or laboratory outcome parameters and 
the results from these subjects have therefore been combined with patients 
receiving standard rate nebulisation. All 5ml patients received the dose 
delivered at standard rate.  
4.5 Summary post-dose results according to cohort 
To allow comparison between dose cohorts (according to nebulised volume) and 
the influence of adjuvant therapy, result from patients from part A and B were 
combined according to lung dose irrespective of the rate of delivery. A summary 
of the safety outcomes for all patients without planned adjuvant therapy (which 
are discussed separately below) are summarised here.  
4.5.1 Clinical 
The maximum temperature was plotted at 8 hours post dose according to dose 
cohort (Figure 4.3). This was performed as not all patients stayed overnight post 
dosing and therefore there was an incomplete data set for day 1 results; 
additionally, for most patients, this was the period of maximal fever. 
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Figure 4.3. Temperature 8 hours post start of lung dosing according to dose 
cohort. Each patient is represented by an individual data point; patients with 
planned adjuvant therapies are not included. The temperature post dosing was 
significantly different between dosing groups (Krusksal-Wallis test p=0.006).  
 
4.5.2 Physiology 
Spirometry demonstrated a dose dependent difference in maximal decline in 
FEV1 post nebulised gene therapy (Figure 4.4), which was detectable 4-6 hours 
post start of dosing. The subjective report of symptoms by patients did not 
mirror the magnitude of drop in lung function, even for 20ml patients with a 40% 
drop in FEV1 volumes.  
 
Figure 4.4. Maximum drop in FEV1 (as % of raw volume) on dosing day. There 
was a significant difference between dosing cohorts (Kruskal-Wallis test p=0.03) 
 
The ratio of FEV1/FVC remained largely unchanged, suggesting that the 
underlying processes were causing a restrictive rather than obstructive lung 
defect. A significant decline from baseline in gas transfer was present on day 2 
in patients receiving a 20ml lung dose (paired t-test p<0.01)(Figure 4.5). This 
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had resolved by day 14; there were no significant differences between baseline 
measurements and those at day 14 or 28 (paired t-test p=0.26 and 0.69 
respectively). No significant changes were seen between baseline and post 
dosing KCOc results for the 10ml or 5ml dose cohorts (paired t-test p>0.05 for all 
tests).  
 
Figure 4.5. Change in KCOc between baseline and day 2 according to dose 
cohort. There was a significant reduction in KCOc between baseline and day 2 
test for the 20ml group (paired t-test p<0.01) but not for the 10ml or 5ml dose 
cohorts. 
 
The LCI signal from the 20ml dose cohort was suggestive of an adverse response. 
In contrast, patients in the 5 and 10ml dose cohorts showed a reduction in LCI 
over the study period (mean pre-LCI in 5ml and 10ml dose cohort combined vs. 
day 28 LCI p=0.039)(Figure 4.6). The paired t-test for mean pre- LCI in 5ml 
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Figure 4.6. Change in LCI according to dose cohort. Results for the 5ml lung dose 
cohort are in Figure 4.6A, and 10ml patients in 4.6B, with mean pre-dose LCI and LCI at 
each test date. Figures A&B are plotted irrespective of whether the patients received 
planned adjuvant paracetamol. All patients with a valid LCI test for both mean pre-dose 
and day 28 are summarised in Figure 4.6C. This is a plot of change from mean pre-dose 
LCI to day 28 result, the direction of improvement in LCI is towards negative values on 
the graph. This includes the separation of results according to whether the patients 
received planned adjuvant paracetamol (para = paracetamol). No 20ml patients 
received planned adjuvant treatment with paracetamol.  
4.5.3 Inflammation 
The post dose systemic inflammatory response as detected by laboratory 
markers (CRP, total white cell count (WCC)) is summarised in Figures 4.7 
according to dose cohort. Results are presented for the maximal time points at 
which change was detected; for CRP this was day 2 post dose and for total WCC 
at 8 hours post dose. 
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Figure 4.7A CRP result at day 2  4.7B  Total WCC 8 hours post dose 
Figure 4.7. Change in CRP and white cell count post dose. A) Maximum CRP 
post dose according to lung cohort on day 2 post dose. Although a trend was seen 
towards lower maximum values with lower volumes, the difference was not significant 
(Kruskal- Wallis p=0.38). B) Change in blood total white cell count from immediate pre-
dose to 8 hours after the start of dosing. Similar trends were seen according to dose 
group as with CRP but the difference was non significant (KW p=0.59). Each patient is 




For all lung dose patients combined, there was no correlation between maximum 
CRP and maximum drop in FEV1 (absolute %) post dosing (r=0.22, p=0.19) and 
similarly with change in total white cell count post dose (r=0.3, p=0.07). There 
was a significant correlation between the temperature measured 8 hours post 
dose and the maximal drop in FEV1 (absolute %), r=0.39 and p=0.02.    
4.5.4 Post dose follow up to day 28 
Patients were seen for study visits according to protocol for their dosing cohort. 
In Pilot part A, ten patients that had had a pre-dose bronchoscopy underwent a 
subsequent post-dose bronchoscopy to look for molecular and functional 
evidence of successful gene transfer (n=4 on day 6 post dose; n= 6 at day 14), 
(see Chapter 6). Follow up for all patients in the Pilot study was until day 28, 
however additional visits were permitted. Reasons included further dates for 
nasal PD measurement (n=4) (for patients with on-going changes suggestive of 
efficacy at day 28, as described in Chapter 5), and pulmonary exacerbation 
coinciding with final scheduled trial visit (n=1).  
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4.6 Post hoc comparison of lung dose cohorts 
To allow investigation of differences in safety outcome between dose groups, a 
post hoc analysis was undertaken to compare the characteristics of patients in 
each dosing cohort. There was no difference in enrolment FEV1 % predicted 
between dose groups, or between age and dose group (Figure 4.8).  
            
Figure 4.8A     Figure 4.8B 
Figure 4.8. FEV1% predicted values and age at recruitment according to lung 
dosing cohort. Each patient is represented by an individual data point in Figure 4.8A 
for FEV1% predicted and Figure 4.8B for age. There was no difference between groups 
for FEV1% predicted or age (Kruskal Wallis test p = 0.81and p=0.32 respectively).  
 
The baseline status in terms of usual management and co-morbidities of patients 
in each dose cohort is summarised in Table 4.2. 
 







Pancreatic insufficient (%) 88.2 80 75 
Nebulised antibiotics (%) 82.4 70 87.5 
RhDNase (%) 29.4 60 37.5 
Hypertonic saline (%) 23.5 20 25 
Long term azithromycin (%) 70.6 70 50 
CF related diabetes on insulin (%) 23.5 10 12.5 
Regular inhaled steroids (%) 35.3 70 37.5 
 
Table 4.2. Characteristics of patients according to lung dosing cohort. Values 
in the table represent the % patients in each dose cohort with baseline status according 
to disease status or usual clinical management. Patients receiving planned adjuvant 
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4.7 Adjuvant therapy: ‘As required’ and planned 
The majority of patients in pilot part A or pilot B without planned adjuvant 
therapy took paracetamol or ibuprofen on an ‘as required’ basis for symptomatic 
treatment post dosing (Table 4.3) although anti-pyretics were less commonly 
requested by patients in the 10 and 5 ml cohorts than by those receiving 20mls.  
Lung dose Paracetamol Ibuprofen 
Inhaled 
bronchodilators 
20ml 13/15 (87%) 13/15 (87%) 10/15 (67%) 
10ml 5/6 (83%) 1/6 (17%) 2/6 (33%) 
5ml 3/6 (50%) 1/6 (17%) 2/6 (33%) 
 
Table 4.3. Proportion of patients receiving additional medication on an ‘as 
required’ basis post dosing, according to lung dose cohort. This table excludes 
all patients with planned adjuvant treatment post dosing.  
In total n=8 patients received planned adjuvant treatment with prednisolone 
(n=1), ibuprofen (n=1) or paracetamol (n=6). Patients receiving planned 
prednisolone or ibuprofen received a 20ml lung dose. The six patients receiving 
planned adjuvant therapy with regular paracetamol administration included n=4 
patients receiving a 10ml dose and n=2 patients with a 5ml dose (none received 
the 20ml lung dose).  
4.7.1 Ibuprofen 
The post dosing profile for the patient receiving a 20ml lung dose with planned 
adjuvant ibuprofen was no different to the rest of the 20ml cohort. In addition 
to ibuprofen, he also received paracetamol for symptomatic relief in the 
immediate post dosing period. There was no evidence of a reduction in systemic 
inflammatory markers and a potential transient adverse impact on renal 
functioning meant that no further dosing with adjuvant ibuprofen was 
undertaken.  
4.7.2 Prednisolone 
In an alternative strategy to reduce the systemic inflammatory response, one 
patient received a 20ml lung dose with planned administration of prednisolone 
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as adjuvant therapy. This patient also received paracetamol and inhaled 
bronchodilators on an ‘as required’ basis in the period 48 hours post dosing. 
Again, lack of evidence for an impact on inflammatory response in combination 
with concern about the addition of prednisolone to the dosing schedule for any 
future multidose trial (including those relating to gene transfer efficacy and 
implications for placebo group) meant that this avenue was not pursued further. 
4.7.3 Paracetamol 
The post dosing profiles belonging to the n=6 patients receiving planned 
adjuvant treatment tended to have a lower rise in inflammatory markers post 
dose, although numbers are small for any statistical comparisons. No patients 
receiving this paracetamol dosing schedule requested ‘as required’ ibuprofen in 
the period 48 hours post dosing. The more favourable post dosing profiles 
observed in patients taking planned adjuvant paracetamol have led to its 
incorporation in the multidose trial for both active and placebo groups in an 
effort both to minimise adverse effects and aid with blinding.  
4.7.4 Bronchodilators 
All patients received pre-treatment with bronchodilators pre- nebulised gene 
therapy as per protocol. Overall, 16/35 (45.7%) patients received inhaled 
bronchodilators (either salbutamol or terbutaline) post dosing on an ‘as-
required’ basis in the period up to 48 hours post dose (n=15 on dosing day, n=1 
on day 2). Patients receiving a 20ml lung dose accounted for the majority of this 
group (n=11 for 20ml lung dose, n= 3 for 10ml lung dose, n= 2 for 5ml lung dose).  
In patients taking planned adjuvant paracetamol or ibuprofen (total n=7), only 
one received additional ‘as required’ bronchodilators in the period 48 hours post 
dose (administered on day 2). However, from the data available it is not possible 
to determine whether this is a treatment effect of these agents or a reflection 
of the lower lung doses (10ml and 5ml only) administered to these patients. 
Patients reported little symptomatic improvement in response to bronchodilators 
and there was no obvious impact on spirometry.  
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4.8 Efficacy outcomes 
4.8.1 CFTR molecular results 
The mRNA results for the detection of vector specific CFTR from nasal brushings 
taken pre- and post dosing are summarised in Table 4.4. As anticipated, no pre- 
dose samples were positive for the vector specific CFTR mRNA. Overall, 21/22 
patients had a post dose nasal brushing (one patient refused the test), the 
majority of which were also negative. Three post dose tests (14%) were positive 
for the presence of mRNA but in all cases the result was below the level deemed 
‘quantifiable’. All positive results were obtained either at day 14 or 28, with 
none at earlier time points.  Patient 030 had two brushings as was being 
followed up beyond the initial day 28 protocol due to evidence of ongoing 
chloride secretion on post dosing nasal PDs (Chapter 5). The mRNA results were 
negative on both occasions.  
Patient Nasal dose of 
gene therapy 




Day of post 
dose test 
1SD001 1ml N Not detected 2 
1SD002 1ml N Not detected 2 
1SD004 1ml N Not detected 2 
1SD003 2ml Y Not detected 2 
1SD005 2ml Y Not detected 2 
1SD020 2ml N Not detected 2 
1SD014 2ml Y Not detected 6 
1SD015 2ml Y Not detected 6 
1SD023 2ml Y Not detected 6 
1SD017 2ml Y Not detected 6 
1SD010 2ml Y Not done N/A 
1SD021 2ml Y Positive: NQ 14 
1SD022 2ml Y Not detected 14 
1SD007 2ml Y Not detected 14 
1SD011 2ml Y Positive: NQ 14 
1SD012 2ml Y Not detected 14 
1SD028 2ml N Positive: NQ 28 
1SD029 2ml N Not detected 28 
1SD030 2ml N Not detected 28 and 114 
1SD031 2ml N Not detected 28 
1SD034 2ml N Not detected 28 
1SD041 2ml N Not detected 28 
 
Table 4.4. Vector specific CFTR mRNA results from nasal brushings for all 
patients in the nasal cohort. For each patient, the nasal dose is shown along with 
whether there was a pre-dose sample taken (Y=yes, N=no). For post dose mRNA results, 
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Not detected= no vector specific CFTR mRNA detected; Positive: NQ= detected but not 
quantifiable.    
 
 
Similarly the mRNA results from lower airway brushings taken during the pre- 
and post- dose bronchoscopy are summarised in Table 4.5. Post dose bronchial 
brushings were obtained on day 6 (n=4) and day 14 (n=6). Again the majority of 
post dose measurements were negative, with only 2 patients (20%) having vector 
specific CFTR mRNA detected. 




Post dose test 
result 
Day of post 
dose test 
1SD014 20ml No data Not detected 6 
1SD015 20ml Y Not detected 6 
1SD023 20ml Y Positive: NQ  6 
1SD017 20ml Y Not detected 6 
1SD010 20ml Y Not detected 14 
1SD021 20ml Y Not detected 14 
1SD022 20ml Y Not detected 14 
1SD007 20ml Y Positive: 2.39% 14 
1SD011 20ml Y Not detected 14 
1SD012 20ml Y Not detected 14 
 
Table 4.5. mRNA results from bronchial brushings for all patients in the 
bronchoscopic cohort (Pilot part A). For each patient, the lung dose is shown along 
with whether a pre-dose brushing was tested (Y=yes, No data=no sample analysed). For 
post dose mRNA results, ND= no vector specific CFTR mRNA detected; Positive: NQ= 
detected but not quantifiable.   Not detected: no vector specific CFTR mRNA detected; 
NQ: not quantifiable. One patient had a positive quantifiable result, with the value 
(2.39%) representing the proportion of vector specific CFTR mRNA copies / human CFTR 
mRNA copies by TaqMan RT-PCR assay 
 
 
Patients in the bronchoscopic cohort had their post dose nasal brushing on the 
same date. No patient had a positive mRNA result on both nasal and bronchial 
brushings. Comparisons between molecular evidence of efficacy and the results 
of functional assessment of CFTR (airway PD measurements) are described in 
Chapter 5 (nasal PD) and Chapter 6 (bronchial PD) respectively.  
4.9 Serious adverse events  
Two serious adverse events (SAEs) was reported during the trial (one was 
reported as a suspected unexpected serious adverse reaction (SUSAR), see 
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below). One SAE was reported following a pre dose bronchoscopy. This patient 
experienced severe throat pain post bronchoscopy which, on examination was 
found to be the result of a pressure area on the uvula from a malpositioned 
endotracheal tube. He was observed overnight in hospital in case of airway 
compromise however remained well and was discharged the following morning. 
No intervention except simple analgesia was required. He was discharged home 
the following morning and agreed to undergo subsequent post-dosing 
bronchoscopy as per protocol, which was uneventful. 
One patient in the first 10ml nebulised/1ml nasal cohort, who had been well at a 
day 6 follow up visit, was admitted to a local hospital for acute pancreatitis 
prior to his day 14 follow up visit (which he therefore did not attend).  Although 
we considered it unlikely to be related to the administered gene therapy 
product, this event was reported as a SUSAR.  Despite never having been 
diagnosed formally as having a history of pancreatitis, we subsequently noted 
that he had had several previous admissions for abdominal pain and vomiting 
over the preceding years; on none of these occasions was a serum amylase 
measured. Following this, serum amylase levels from all other 10ml patients 
(and all subsequent 20ml trial patients) were measured and all were 
unremarkable.  
4.10 Discussion 
The Pilot study was undertaken to assess the safety and functional efficacy of 
the CF gene therapy product pGM169/GL67A. The evolution of the Trial protocol 
in response to safety outcomes reflected the ‘first-in-man’ nature of the trial 
and the complexities associated with evaluating outcome and determining 
tolerated delivered dose. This process has also allowed an investigation of the 
outcome measures in the Pilot study, and has raised a number of themes for 
discussion. 
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4.10.1 Trial design 
4.10.1.1 Recruitment 
The Pilot study included a large number of outcome measures, in part reflecting 
the dual purpose of assessing safety and functional efficacy. Prior knowledge of 
the most appropriate time points for data collection (for either safety or 
efficacy measures) would have allowed tailoring of the trial protocol at the 
design stage to reflect this. However, this is not necessarily possible with early 
phase clinical trials. Guidance was sought from pre-clinical studies and the 
previous Lancet study (35). However, the gene therapy plasmid was different 
(having been optimised for duration of expression and removal of CpG repeats as 
described in Chapter 2, section 2.2.1) and so the time points appropriate for 
efficacy in the Lancet study were not necessarily appropriate for Pilot. 
Furthermore, mice are not human: the administration of pGM169/GL67A to mice 
in a pre-clinical study prior to trial onset did not result in a systemic 
inflammatory response (100). 
The Pilot post dosing schedule, particularly in part A, required a high level of 
commitment from participants both in terms of number and length of study 
visits. This may explain the relatively large number of patients enrolled in the 
study withdrawing prior to dosing (section 4.1).  
4.10.1.2 Inclusion criteria and pre-dosing visits 
As the Pilot study was primarily a safety study and not designed to test clinical 
efficacy, the concept of ceiling effects for outcome measures described in the 
Run-In discussion (Chapter 3, section 3.7.6) is less relevant. There was no 
maximum cut off for lung function in terms of % predicted FEV1 at recruitment, 
however studies investigating clinical efficacy using FEV1 as a primary outcome 
measure would need to consider this. It is important that safety studies do not 
recruit a patient population considered ‘unsuitable’ for subsequent efficacy 
trials to ensure results are representative. Therefore it was appropriate that the 
minimal FEV1% predicted at enrolment for the Pilot study was 10% lower than for 
the Lancet study (35). 
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4.10.1.3 Number of pre-dose time points 
The Pilot study design was strengthened by collection of serial measurements for 
certain outcome measures (such as spirometry, LCI, blood markers and nasal PD) 
pre- gene therapy dose. The Run-In data (Chapter 3) has described the 
variability of airway physiology tests and systemic markers of inflammation over 
time (Chapter 3, section 3.3). However, for other assays, only a single time 
point of data collection existed pre dose. This reflected either trial design (e.g. 
single measurement only for gas transfer measurement pre dose), or significant 
additional trial burden with incorporation of a second pre-dose bronchoscopy or 
CT scan (including potential excess morbidity from general anaesthetic and 
radiation exposure). Whether comparisons should be made according to a single 
(e.g. initial visit) or mean pre-dose values is important as it can influence the 
magnitude of any effect size. For example, the results profile for LCI data in 
Pilot could appear significantly ‘improved’ by comparing only initial pre-dose LCI 
with post dose measurements, rather than mean pre- values. Therefore in the 
results described within this chapter only mean pre dose results were shown for 
comparison with post dose results (Figure 4.6).   
Multiple pre-intervention study visits have not commonly been incorporated into 
clinical trial protocols for CF gene therapy or other novel treatments. However, 
this may be important to consider depending on the study populations, 
particularly if variability in outcome measures is increased with greater severity 
of underlying disease as suggested by analysis of the Run-In airway physiology 
and patient reported outcomes (Chapter 3, section 3.3.5).  
4.10.1.4 Dose administration 
Reference to dose cohorts according to volume of the lung dose of gene therapy 
(20ml, 10ml etc.) has related to the intended dose prescribed. However, 
weighing of the nebuliser and nasal spray bottles demonstrated that this was not 
equivalent to the actual dose administered (section 4.3). Reassuringly, the 
proportion of actual administered dose was equivalent for the 20ml, 10ml and 
5ml cohorts.  The variability of dose received was lower for lung than nasal 
dosing (as described previously) and within-dose cohort differences in volumes 
were minimal. However, any differences in breathing technique may have led to 
hypothetical discrepancies in the amount of product reaching the distal airways. 
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The majority of patients were used to taking at least one nebulised therapy 
(antibiotics, RhDNase or hypertonic saline) as part of their usual CF care and 
therefore the concept of a nebulised therapy was not new.  
It was surprising that the volume of gene therapy delivered using the nasal spray 
bottle was so variable between patients (Figure 4.2), although patient technique 
and method of pressing the nasal spray bottle mechanism, despite supervision, 
may be responsible for this. Of particular concern was the patient who was 
prescribed a 2ml nasal dose whose actual delivered dose was 0.97ml, 
representing significant underdosing in comparison to intended delivery. To 
minimise any influence of unintentional dose-response differences, it is 
important to ensure that an intended volume is delivered consistently between 
patients, particularly with repeated dosing (as occurs in the multidose trial) as 
such dose discrepancies may assume a greater importance. This could easily be 
achieved by weighing nasal spray bottles (and/or nebuliser chambers) during 
dosing to guide volumes administered rather than at conclusion of dosing as has 
been carried out in the Pilot study. This will then ensure that comparison 
between different outcome measures is dependent on ‘true’ response rather 
than variability in administered dose.  
4.10.2 Safety outcomes 
4.10.2.1 Relationship to lung dose cohort 
We observed a post dose inflammatory response following administration of the 
lung dose (section 4.5). The magnitude of this response was dose dependent, 
with patients receiving the 20ml lung dose experiencing greater adverse 
response than those in the 5 or 10ml cohort. The outcomes collected for 
spirometry, LCI and gas transfer provide information on different aspects of 
airway function. They collectively capture a cross-sectional snapshot of function 
at a particular time point. The sites of importance in terms of disease pathology 
(e.g. small airways and information provided by LCI) may be useful sites to 
measure for both safety and efficacy. Conversely, others may only be important 
for safety (e.g. gas transfer) in the relatively well CF populations included in the 
UKCFGTC clinical programme. 
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4.10.2.2 Airway physiology 
The post dose response following nebulised gene therapy was associated with a 
decline in FEV1 and FVC in the 6 hours post dosing. Repeated spirometry 
measurements during this time were often met with reluctance by the patient. 
Knowledge of the time period over which this decline occurs now prevents the 
requirement for such intense monitoring during the multidose trial. A single 
measurement at e.g. 6 hours post dose is also likely to be more representative of 
‘true’ lung function at that point rather than also reflecting fatigue.  
Gas transfer is a test of alveolar function (rather than that of the conducting 
airways as assessed by spirometry and lung clearance index). It is not usually 
impaired in cystic fibrosis lung disease, as it is the small airways rather than 
alveoli which contribute to greatest morbidity. However, its inclusion in the 
Pilot protocol reflects its role as a safety outcome. Any new intervention such as 
a nebulised gene therapy product may impact on mechanisms outside the 
traditional pathways of disease pathogenesis associated with cystic fibrosis and 
therefore tests are required that can detect change reflecting this.  
We observed a decrease in gas transfer at day 2 which had normalised by day 14, 
again with a greater decline seen in the 20ml dose cohort (section 4.5.2). Gas 
transfer was not measured in the period 6 hours post dose (the time point of 
maximal change in spirometry) nor on day 1 post dose. It is therefore unknown 
whether the results at day 2 represent an improvement from an earlier time 
point, or a genuine lag behind the more immediate decline in FEV1 and FVC. 
Comparisons between pre- and post dose gas transfer measurements relied on a 
single pre-dose test. As demonstrated with other physiological outcomes in the 
Run-In study (Chapter 3, section 3.3), there is a variability over time which is 
important to consider when assessing change in response to an intervention.  
4.10.2.3 Systemic inflammatory response 
Counter to our expectations based on plasmid design and pre-clinical animal 
testing, it became clear early in the trial that a familiar flu-like response was 
being experienced during the 48 hours post dosing. Given the complete removal 
of all CpGs from the plasmid, the pathological processes driving this response 
remain uncertain; it is possible that some genomic unmethylated CpG repeats 
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exist in the preparation and work is ongoing within the UKCFGTC to identify the 
source of this. 
Whilst the severity of the inflammatory response in terms of symptoms and 
biochemical/clinical parameters appeared to be related to dose on a group level 
(section 4.5), for individual patients responses were highly variable. In addition 
to less severe adverse responses in the 10ml and 5ml lung dose patients in 
comparison to those receiving 20mls, they also requested less ‘as required’ 
medications for adverse symptoms (section 4.7, Table 4.3). Therefore the 
greater tolerability of the lower doses was likely to have been genuine. 
Detailed profiling of laboratory markers and clinical outcomes has identified the 
chronology of the response, in order that further monitoring in a multi-dose trial 
can be rationalised similar to that described for repeated spirometry results as 
described above.  
4.10.3 Efficacy  
4.10.3.1 Molecular evidence of effective gene transfer 
The rate of positive detection for vector specific CFTR mRNA in nasal and lower 
airway brushings was low (section 4.8.1). An absence of association between 
upper and lower airway results, and with functional measurements in the upper 
and lower airway (Chapter 6) suggests that this relates to low sensitivity of the 
assay, but interpretation is difficult. However, despite these results, there is 
encouraging molecular data from researchers within the Consortium at the 
Oxford site following repeated dosing with pGM169/GL67A in mice 
(unpublished). Therefore, assessment of mRNA may be more appropriate as an 
endpoint in trials following repeated rather than single occasion dosing. 
However, if this is the case, the results from the Pilot study will provide 
important comparative data at an early time point, assuming the patient 
populations are representative of each other.  
4.10.3.2 Clinical end points 
The Pilot study was not designed (or powered) to assess clinical efficacy; indeed, 
we did not expect clinical benefit after a single dose of gene therapy. 
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Therefore, it was surprising to observe the changes in LCI in the 5 and 10 ml lung 
group (Figure 4.6) as LCI was incorporated as a safety outcome, and it is difficult 
to know how best to interpret these. Unfortunately, data quality at trial onset 
for LCI meant that a proportion of early tests had to be excluded (Chapter 2, 
section 2.3.2.11). Reasons for this have been discussed in Chapter 3, section 
3.7.1. However, despite these limitations, the LCI data is nevertheless of 
interest and LCI has been included as a major secondary outcome in the 
subsequent multidose trial. LCI was not measured in the Lancet study (or any 
other previous trial of gene therapy) and therefore no comparisons can be made. 
Although as an outcome measure for CF LCI remains in its infancy, detectable 
changes in treatment groups post intervention have been reported. This includes 
improvement following hypertonic saline, RhDNase and the small molecule drug 
Ivacaftor (50;69;70). These studies all reported LCI as an outcome measure in 
terms of absolute change. In the Pilot study, it would be inappropriate to map 
any change in LCI suggestive of improvement with change in other outcomes 
such as FEV1, however following the multidose trial this will be possible. An 
increasing body of literature incorporating LCI as an outcome measure in CF will 
help determine appropriate minimal clinical differences and whether this should 
be considered as absolute change from baseline, percentage change, or change 
in relation to normal values according to age and gender. It may be that a 
combined small improvement in several outcomes (e.g. both FEV1 and LCI) is of 
equivalent clinical significance to a larger improvement in one alone (FEV1). 
Again, Pilot study data is inappropriate for such an analysis and the results from 
multidose are awaited.  
4.10.4 Adjuvant therapy 
Surprisingly, planned adjuvant therapy with ibuprofen or prednisolone did not 
alter the typical post dose profile. However, paracetamol did appear to be 
beneficial, measured both by a dampening of the systemic markers of 
inflammation and by patient report of influenza-like symptoms (less additional 
‘as required’ additional adjuvant therapy was taken by this group). There is 
evidence that paracetamol is effective at reducing influenza-induced pathology 
(including decreased infiltration of inflammatory cells into the airway spaces and 
preserving lung function) in mice (122).  
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The use of any adjuvant therapy in a clinical trial creates additional challenges 
for data analysis and appropriate placebo in subsequent multidose trial. 
However its absence would create problems with blinding both for the patient 
and researcher. Inclusion of planned adjuvant treatment with paracetamol in 
both active treatment and placebo groups in the multidose trial is hoped to 
address this. 
4.10.5 Conclusions 
This chapter has discussed the results of safety outcomes including airway 
physiology, clinical and laboratory markers of inflammation and molecular tests 
of functional efficacy. In conjunction with the results from airway PD outcomes 
which are described in Chapters 5 and 6, this has allowed an assessment of the 
suitability of pGM169/GL67A to be taken forward to multidose trial according to 
review by the CF Trust’s Scientific Advisory Committee, and to rationalise 
protocol design to reflect appropriate time points of testing. It is always going to 
be a challenge to design a clinical trial for a novel therapeutic agent which has 
not previously been administered to man. Difficulties exist with small ‘n’ 
numbers, choosing appropriate markers for comparisons (with variables 
introduced by factors to do with delivered dose and time for administration) and 
including single or multiple pre-intervention measurements balanced against an 
acceptable trial protocol from the perspective of the patients volunteering to 
take part.  
Despite these challenges, the Pilot study was able to quantify differences in the 
safety profile according to delivered dose and thus able to select the 5ml dose 
to take forward to the multi-dose trial.
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5 Results: nasal PD measurement 
5.1 Pilot study nasal PDs 
The total number of nasal PD tests completed in the Pilot study was 143 in 33 
subjects. An additional 4 tests (involving 3 subjects) were abandoned part way 
through due to patient discomfort (n=2 tests (same subject, 021)), or inability to 
maintain a stable baseline (n=2 tests)(see Table 5.1 and below). All within-
subject measurements throughout the study were performed in the same nostril 
with the exception of three tests where the other nostril was used (inability to 
achieve a basal PD measurement (n=1; subject 002), uncharacteristic response 
to Ringers with amiloride perfusion (n=1; subject 011) and pain on insertion of 
PD catheter (n=1; subject 021 as above)). In all 3 subjects, measurement in the 
other nostril occurred on a single occasion only therefore in none did a problem 
exist where all pre-dose tests were performed on a different side to post-dose 
tests. 
Eleven patients had at least one nasal PD attempted but did not go on to receive 
a nasal dose (total n=17 tests, including one of the abandoned tests). Reasons 
for this included evidence of chloride secretion on nasal PD in pre-treatment 
measurements (n=5 subjects), and withdrawal from study pre-dosing either due 
to patient request or clinical instability (n=6).  
Twenty two subjects received a nasal dose of gene therapy, with three receiving 
a 1ml nasal dose and 19 a 2ml nasal dose as described in Chapter 4. The 
schedule of nasal PD tests for the 127 tests undertaken within patients receiving 












Day 2 Day 6 Day 14 Day 28 > Day 
28 
001 1ml 2 Y     
002 1ml 2 Y     
003 2ml 3 Y     
004 1ml 2 Y     
005 2ml 3 Y     
007 2ml 2 Y  Y Y Y (1) 
010 2ml 3 Y Y Y Y  
011 2ml 3 Y Y Y Y  
012 2ml 3 Y Y Y Y  
014 2ml 3 Y Y Y   
015 2ml 3 Y Y Y   
017 2ml 3 Y Y  Y  
020 2ml 2 Y     
021 2ml 2* Y  *   
022 2ml 3 Y Y Y Y Y (3) 
023 2ml 3 Y Y Y   
028 2ml 3 Y Y Y Y  
029 2ml 3  Y Y Y  
030 2ml 3  Y Y Y Y (5)* 
031 2ml 3  Y Y Y  
034 2ml 3  Y Y Y  
041 2ml 3  Y Y Y Y (1) 
Total  60 17 14 14 12 10 
 
Table 5.1. Schedule of nasal PDs for each patient receiving a 1ml or 2ml 
dose of CF nasal gene therapy. For tests after day 28 (> Day 28), the number 
represents the number of additional tests performed.*Denotes an additional test which 
was intended but not completed. For 021, the reason included inability to tolerate the 
PD catheter, and for patient 030 an intercurrent upper respiratory tract infection meant 
that testing was not possible.  
The number of nasal PDs undertaken in an individual patient receiving the nasal 
dose of CF gene therapy ranged from 3 to 11. Four subjects returned for at least 
one visit after day 28 for a nasal PD, at intervals convenient to the patient and 
depending on the visual analysis of the PD trace. One of these patients was 
subject 030, who also had a nasal PD performed opportunistically as part of 
another study during this period of extended follow up. This test is not included 
in the above table, nor are formal results reported here (due to differences in 
the experimental set up) however evidence of chloride secretion on this test led 
to a further Pilot nasal PD for which the results are described below.   
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5.2 Pilot study nasal PD results 
5.2.1 Nasal PD circuit integrity 
The mean offset for electrodes prior to offset correction across all nasal PD tests 
was -0.55mV (SD 2.56 mV). Skin PD was greater (more negative) than -30mV for 
each patient on each test occasion.  
5.2.2 Agreement between analysers 
The outcome of the consensus review process between GD and JD for all 118 
nasal PD tests from patients with a 2ml nasal dose (472 sections for inter-
reporter agreement analysis) is summarised in the flow chart in Figure 5.1.  
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Figure 5.1. Flow chart describing outcome of nasal PD data analysis and 
consensus review process between GD and JD. RA: ringers with amiloride, ZCA: 
zero chloride with amiloride, ZCAI: zero chloride with amiloride and isoprenaline. For 
the n=13 sections surviving the consensus review process but remaining outside the 
initial ‘rules’ for maximum differences, the magnitude of the difference was as follows: 
basal PD (n=1) 2.001mV; ZCA (n=3): mean 1.7, max 2.05mV; and ZCAI (n=9): mean 1.5, 
max 2.50mV). 
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There was no directional bias to the analysis for nasal PD values pre-consensus 
between JD and GD (the Bland Altman plots can be found in Appendix 9.6). 
Following comparison of the independently analysed results, JD and GD reviewed 
tests where a discrepancy existed between analysers, or which either or both 
analysers felt required further discussion. This resulted in several sections of 
tests being excluded from data analysis. Reasons for tests not being analysable 
included electrical artefacts during testing or multiple steep ‘blips’ in the mV 
trace unlikely to reflect underlying ion transport. Several tests had an 
interpretable baseline but the zero chloride response was not interpretable.  
395/472 (84%) sections of nasal PD tests passed the GD/JD initial inter-reporter 
agreement process of being within pre-defined maximal differences for each test 
section and did not require further review. For all other sections, following 
discussion about inclusion or exclusion (including those with a mV difference 
outwith the maximum pre-defined difference for each variable), repeat analysis 
was performed by one or both persons, still blinded as to identifying details. This 
resulted in 49 additional acceptable sections (10%) to define the final PD values. 
These included 13 sections where the difference remained outside the maximal 
difference following the review process, but the consensus from both GD and JD 
was to include both values to contribute to the final mean value (as each was 
considered equally valid). The remaining 28 sections (6%) were excluded from 
contributing to final PD results following review by GD and JD. Therefore 
following the review process, 444 sections (representing 94.1% of total sections) 
of nasal PDs were included in the final dataset. The Intraclass correlation 
coefficients (ICCs) for results for these sections prior to and following the 
consensing exercise are summarised in Table 5.2.  
 Basal PD RA delta ZCA delta ZCAI delta  
Independent 
analysis (initial) 




0.999 0.998 0.997 0.986 
Table 5.2. Intra-reporter variability in nasal PD analysis. The values in the table 
are the intra class correlation coefficients (ICC) for GD/JD nasal PD analysis for all 
patients with 2ml nasal dose for initial independent analysis (top row) and following 
consensus review (bottom row). RA: ringers with amiloride, ZCA: zero chloride with 
amiloride, ZCAI: zero chloride with amiloride and isoprenaline. 
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5.2.3 Nasal PD results for initial (1ml) nasal dose cohort 
The pre-dosing results from the three patients receiving a 1ml nasal dose are 
summarised in Table 5.3. The SD for pre-dose basal PD in subject 002 was large – 
each of the two pre-dose tests were performed in a different nostril as a stable 








delta SD RA 
Mean 
ZCA 
delta SD ZCA 
Mean 
ZCAI 
delta SD ZCAI 
001 -45.0 0.2 -21.0 4.4 5.9 3.4 -2.5 2.1 
002 -36.6 23.1 -17.6 18.0 -3.2 3.4 -3.8 4.1 
004 -44.9 2.8 -32.2 0.4 -2.8 4.6 4.8* N/A 
 
Table 5.3. Pre-dosing nasal PD summary for the 1ml nasal dose patients. The 
values in the table (in millivolts) are mean and standard deviations (SD) for each section 
of nasal PD, for all pre-dosing tests. *Represents single measurement only. RA: ringers 
with amiloride, ZCA: zero chloride with amiloride, ZCAI: zero chloride with amiloride 
and isoprenaline. 
 
Post treatment nasal PDs in the first 3 patients involved in the Pilot study (1ml 
nasal dose) were limited to day 2 post treatment. This coincided with the timing 
of the post dose nasal brushing and no further nasal PDs were attempted after 
this time point, as per protocol design. Results for intrinsic zero chloride 
response (ZCA delta) and total chloride secretion (ZCA + ZCAI delta) are shown 
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Figure 5.2. Intrinsic chloride secretion at all pre- and post dosing tests for 
the n=3 patients receiving a 1ml nasal dose. Patients identified according to 
study number (001, 002 and 004). ZCA: Zero chloride with amiloride; D2: day 2 post 
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Figure 5.3. Total chloride secretion at all pre- and post dosing tests for the 
n=3 patients receiving a 1ml nasal dose. Patients identified according to study 
number (001, 002 and 004) as before. Total chloride secretion is the sum of deltas for 
zero chloride with amiloride and zero chloride with amiloride and isoprenaline 
response. D2: day 2 post nasal gene therapy dose. 
5.2.4 Final PD values for main (2ml) nasal dose cohort  
All results for the n=19 patients receiving the 2ml nasal dose are the final GD/JD 
values following the consensus review process for each section of the PD test 
(basal, delta RA, ZCA and ZCAI responses). 
5.2.4.1 Variability in pre-dosing PD measurements 
All 19 subjects had at least two pre-dose nasal PD tests available for analysis, 
and 16/19 (85%) had 3 pre-dosing PDs. However one patient (patient 003) with 
three pre-dosing tests only had two with values contributing to final results as 
their entire initial visit PD was excluded as it had been deemed unanalysable.  
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The pre-gene therapy nasal PD results for basal measurements and deltas for RA, 
ZCA and ZCAI sections are displayed in Table 5.4, with mean and standard 
deviation (SD) displayed for each patient. Overall for the entire 2ml nasal dose 
cohort, the median coefficient of variation for basal PD was 17.1%, and 32.2% for 
the RA delta. Due to the proximity to zero and the presence of negative and 
positive values for chloride transport the CV is invalid so variability is 










delta SD RA 
Mean 
ZCA 
delta SD ZCA 
Mean 
ZCAI 
delta SD ZCAI 
028 -37.2 9.6 -8.5 2.2 1.8 0.7 -1.3 1.1 
029 -52.1 10.3 -27.3 24.3 -1.3 0.1 -0.5 4.0 
030 -21.4 2.5 -8.2 2.6 0.3 0.8 -0.4 2.0 
031 -35.8 6.2 -23.2 9.9 -1.9 2.2 -0.9 0.4 
034 -31.9 2.5 -19.8 5.5 -1.9 1.2 0.2 0.6 
041 -46.4 15.8 -25.9 3.3 -0.7 3.1 0.7 N/A 
003 -40.3 5.8 -17.9 1.4 -5.0 1.4 -0.7 1.1 
005 -65.0 4.5 -42.9 8.4 -6.6 7.6 -3.0 4.4 
007 -36.2 10.0 -18.9 4.1 -1.5 3.4 -2.0 N/A 
010 -38.5 6.6 -16.8 8.0 3.2 0.5 -0.3 2.7 
011 -42.0 6.0 -12.5 7.0 -2.0 3.3 -2.3 1.8 
012 -50.1 16.7 -22.8 11.3 0.8 1.4 -4.5 3.0 
014 -49.8 4.7 -20.1 7.5 -0.8 0.2 -3.7 1.2 
015 -21.1 1.8 -6.3 3.6 0.4 1.6 -1.1 1.1 
017 -51.4 11.1 -24.1 8.1 -0.7 1.0 1.5 2.4 
020 -48.3 5.3 -21.9 2.6 5.3 0.5 -1.8 1.7 
021 -37.1 4.0 -13.3 1.7 1.4 N/A -2.7 N/A 
022 -29.9 6.5 -12.6 9.6 -2.8 2.8 0.0 1.8 
023 -41.7 20.5 -17.5 3.3 0.8 3.5 -2.7 1.2 
Mean -40.9 7.9 -19.0 6.6 -0.6 2.0 -1.3 1.9 
Median -40.3 6.2 -18.9 5.5 -0.7 1.4 -1.1 1.8 
 
Table 5.4. Pre-dosing nasal PD summary for the 2ml nasal dose patients. The 
values in the table (in millivolts) are mean and standard deviation (SD) results for each 
section of nasal PD, for all pre-dosing tests. Missing values are present when only one 
pre-dose result was available. RA: ringers with amiloride, ZCA: zero chloride with 
amiloride, ZCAI: zero chloride with amiloride and isoprenaline. 
 
 
5.2.4.2 Evidence of CFTR correction and timing of nasal PD 
Comparisons between pre- and post-dosing measurements were based on the 
mean pre-dose values as described above in Table 5.4.  
The number of nasal PDs performed at post dosing study visits was n=14 at day 2, 
6, and 14 and n=12 at day 28. The stage of the Pilot study (A or B) at dosing for 
each patient determined the dates of PD tests.  For example, for some patients 
  202 
the latest post dose test was at day 2 (e.g. initial non-bronchoscopic arm in Pilot 
A), whereas for others later in the trial nasal PDs were performed until day 28 
visit.  
5.2.4.3 Basal PD and response to perfusion with Ringers with amiloride 
solution 
Basal and Ringers amiloride responses were analysed to investigate the influence 
of the single dose of gene therapy on sodium hyperabsorption. No differences 
were seen between basal PD pre- and post-dosing measurements. The paired 
results for mean pre- basal PD and post dosing measurements at day 2,6,14 and 
28 are shown in Figure 5.4A-D. Similarly, no differences were seen in a direction 
consistent with non-CF values between mean pre- and post-dosing measurements 
in the change in PD as a result of perfusion with Ringers containing amiloride 
(Figure 5.4E-H).  
    
Figure 5.4A. Basal to day 2   Figure 5.4B. Basal to day 6 
 
    Figure 5.4C. Basal to day 14   Figure 5.4D. Basal to day 28 
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Figure 5.4E. Delta RA to day 2      Figure 5.4F. Delta RA to day 6 
     
Figure 5.4G.Delta RA to day 14   Figure 5.4H. Delta RA to day 28  
Figure 5.4. Paired results for Basal PD and response to Ringers amiloride 
perfusion. Results are for comparison of mean pre- with day 2,6,14 and 28 values. 
Figure 5.4A-D are for basal PD; and 5.4E-H for response to Ringers amiloride (‘Delta 
RA’). No differences at any time point between pre- and post dosing were significant for 
basal results. There was a significantly greater depolarisation to RA (in an opposite 
direction to that of efficacy) between pre- and day 6 (Wilcoxon matched pairs test 
p=0.02), no differences at any other time point.  
 
5.2.4.4 Chloride response 
The change in PD (‘delta’) with zero chloride solution containing amiloride (ZCA) 
perfusion (to assess intrinsic chloride secretion) and for the sum of the ZCA and 
ZCAI sections (to assess total chloride transport) are presented according to 
timing of post dose measurement. An overall summary of results (according to 
the three definitions of ‘response’ in Chapter 2, section 2.5.3.6) can be found at 
the end of this section. 
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5.2.4.5 Intrinsic chloride secretion (ZCA delta) 
The individual results for each patient (including each pre-dose and all post dose 
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Figure 5.5. Intrinsic chloride secretion at all pre- and post dosing tests for 
the n=19 patients receiving a 2ml nasal dose. Patients identified according to 
study number as before. ZCA: Zero chloride with amiloride; Dx: day ‘x’ post nasal gene 
therapy dose.  
 
The change in PD following ZCA solution perfusion is summarised in Figure 5.6 
for the overall cohort. This is presented for all valid measurements taken at day 
2, 6, 14 and 28 post dose in comparison to mean pre-dosing values.  
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Figure 5.6A Delta ZCA to D2  Figure 5.6B Delta ZCA to D6 
 
Figure 5.6C Delta ZCA to D14  Figure 5.6D Delta ZCA to D28 
Figure 5.6. Intrinsic chloride secretion at post dose for patients with tests 
performed at day 2,6,14 or 28 (Not all patients had tests performed at each time 
point). Figures represent the different post dose time points as shown. 
 
5.2.4.6 Total chloride transport (ZCA + ZCAI deltas) 
The individual patient results for total chloride transport are shown in Figure 5.7 
according to date of nasal PD. As per format for ZCA response, all pre- dosing 
results are plotted to demonstrate variability in measurement pre- intervention. 
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Figure 5.7. Total chloride secretion at all pre- and post dosing tests for the 
n=19 patients receiving a 2ml nasal dose. Patients identified according to study 
number as before. Total chloride secretion is the sum of deltas for zero chloride with 
amiloride and zero chloride with amiloride and isoprenaline response. Dx: day ‘x’ post 
nasal gene therapy dose. 
 
To allow comparisons in overall group responses according to post dose time 
points, the results for total chloride transport are displayed in Figure 5.8, with 
the same format as applied to the presentation of intrinsic chloride secretion 
results above.  
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Figure 5.8A Total Cl- transport to D2. Figure 5.8B Total Cl- transport to D6. 
 
Figure 5.8C. Total Cl- transport to D14. Figure 5.8D. Total Cl- transport to D28. 
Figure 5.8. Total chloride secretion at post dose for patients with tests 
performed at day 2,6,14 or 28 (Not all patients had tests performed at each time 
point). Figures represent the different post dose time points as shown. 
 
5.2.4.7 Chloride secretion ‘responses’ according to definition 
A summary of the proportion of patients meeting the criteria for a chloride 
secretion ‘response’ on a post dose nasal PD according to the definitions 
described in Chapter 2, section 2.5.3.6 is shown in Tables 5.5-5.8 according to 
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Day 2 
 Method 1: 
Greater than any 
pre-dose test 
Method 2:  
Change between 
mean pre- and 





secretion > -5mV 
Intrinsic chloride 
secretion       
(ZCA delta) 
2/13 (15.4%) 3/13 (23.1%) 1/13 (7.7%) 
Stimulated 
chloride 
secretion       
(ZCAI delta) 




4/13 (30.8%) 2/13 (15.4%) 1/13 (7.7%) 
Table 5.5. Proportion of patients with a chloride ‘response’ according to 
each definition and section(s) of nasal PD test at day 2 post dose. Results are 
displayed for number of patients with ‘response’ according to definition of interest, and 
total number of patients with valid PD result for the section of PD of interest.  
Day 6 
 Method 1: 
Greater than any 
pre-dose test 
Method 2:  
Change between 
mean pre- and 





secretion > -5mV 
Intrinsic chloride 
secretion       
(ZCA delta) 
4/13 (30.8%) 4/13 (30.8%) 3/13 (23.1%) 
Stimulated 
chloride 
secretion      
(ZCAI delta) 




5/13 (38.5%) 4/13 (30.8%) 2/13 (15.4%) 
Table 5.6. Proportion of patients with a chloride ‘response’ according to 
each definition and section of nasal PD test at day 6 post dose. Results are 
presented as described for day 2 tests. 
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Day 14 
 Method 1: 
Greater than any 
pre-dose test 
Method 2:  
Change between 
mean pre- and 




secretion > -5mV 
Intrinsic chloride 
secretion       
(ZCA delta) 
4/13 (30.8%) 4/13 (30.8%) 3/13 (23.1%) 
Stimulated 
chloride 
secretion      
(ZCAI delta) 




3/12 (25.0%) 4/12 (33.3%) 3/12 (25.0%) 
Table 5.7. Proportion of patients with a chloride ‘response’ according to 
each definition and section of nasal PD test at day 14 post dose. Results are 
presented as described for day 2 tests. 
 
Day 28 
 Method 1: 
Greater than any 
pre-dose test 
Method 2:  
Change between 
mean pre- and 




secretion > -5mV 
Intrinsic chloride 
secretion         
(ZCA delta) 
4/12 (25.0%) 2/12 (16.7%) 0/12 (0.0%) 
Stimulated 
chloride 
secretion        
(ZCAI delta) 




2/10 (20.0%) 2/10 (20.0%) 2/10 (20.0%) 
Table 5.8. Proportion of patients with a chloride ‘response’ according to 
each definition and section of nasal PD test at day 28 post dose. Results are 
presented as described for day 2 tests.  




5.2.4.7.1 Mean pre-dose values vs. post-dose results in patients with 
tests on Days 6, 14 and 28 
Ten patients had nasal PDs performed pre-dose, and on D6, D14 and D28 post 
dose. Figure 5.9 shows the mean (SD) results for intrinsic and total chloride 
secretion at mean pre-, day 6, 14 and 28 tests.  
 
  Figure 5.9A 
     
Figure 5.9B 
Figure 5.9. Chloride transport at post dosing time points for all patients with 
tests at day 2, 6, 14 and 28 post dose. Figure 5.9A summarises intrinsic chloride 
secretion (ZCA delta) at mean pre-dose and day 2,6,14 and 28 post dose. Figure 
5.9B summarises total chloride transport at mean pre-dose and day 2,6,14 and 
28 post dose.  
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Because the pre-dose values for paired comparisons were means and because 
the time point of any changes seen post dose were not universal, the mean post 
dose values were also calculated to reduce some of the variability seen between 
tests within-subject. The mean pre- intrinsic (ZCA delta) and also total chloride 
secretion were compared to the mean of these responses for all patients with 
nasal PDs performed at day 6,14 and 28 post dose (data not shown). There was 
no significant difference between mean pre- results and mean [day 6,14 and 28] 
results for either intrinsic or total chloride secretion (paired t-test p=0.11 for 
both analyses).   
5.2.4.7.2 Mean pre- to post-treatment values for individual patients 
The definition used determined the number of patients with a chloride 
‘response’. At early time points (day 2 post dosing), the proportion of subjects 
with a ‘response’ was low according to the definition of response greater than 
any pre-dose test. Only 1SD003 and 1SD022 had a chloride secretion convincingly 
>1mV outside pre-dosing values. Patient 1SD003 was in an early cohort of the 
2ml nasal/20ml lung dose and therefore did not have PD measurements made at 
time points beyond day 2. In contrast, later patients did not have measurements 
performed at day 2 with the earliest post dose measurement at day 6. 
A pattern was observed in individual patients (e.g. 1SD007) where a trace 
considered a ‘response’ (D14) was followed by staged return to ‘non-response’ 
(and therefore pre-dose) levels. In other patients, a different pattern was 
observed. Where a ‘response’ had been observed and a ‘non-response’ followed, 
further ‘response’ results were obtained at subsequent testing dates (see patient 
1SD030 for example).   
The greatest post-dose intrinsic chloride hyperpolarisations were 13.4mV 
(patient 1SD011, D6), 11.5mV and 13.7mV (from patient 1SD022, tests performed 
on day 28 and 41 respectively). The greatest post-dose total chloride 
hyperpolarisations were 10.5mV (patient 1SD029, day 14), 11.9 mV (patient 
1SD030 day 83) and 10.0mV and 14.8mV (from patient 1SD022, again tests 
performed on day 28 and 41 respectively).  
For intrinsic chloride secretion (ZCA delta), 5/19 (26.3%) patients had at least 
one post dose nasal PD categorised as ‘response’ according to all three 
definitions and a further 4 patients met ‘response’ criteria according to two 
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definitions (and therefore overall 9/19 (47.4%) met ‘response’ according to ≥2/3 
definitions)(Table 5.9).  
 Intrinsic chloride secretion at any post dose test 
Patient 
Method 1: 
Greater than any 
pre-dose test 
 
Method 2: Change 
between mean 
pre- and post- 




secretion > -5mV 
028 N N N 
029 Y Y N 
030 Y Y Y 
031 N* N N 
034 N* N N 
041 Y Y N 
003 Y Y N 
005 N* Y N 
007 Y Y Y 
010 Y N Y 
011 Y Y Y 
012 N N N 
014 N* N N 
015 N N N 
017 Y Y Y 
020 N N N 
021 N* N N 
022 Y Y Y 
023 N N N 
Total  
Y: 9/19 (47.4%) 
N: 10/19 (52.6%) 
Y: 9/19 (47.4%) 
N: 10/19 (52.6%) 
Y: 6/19 (31.6%) 
N: 13/19 (68.4%) 
 
Table 5.9. Intrinsic chloride secretion ‘response’ post dose at any time point 
according to definition used. Y=meets criteria for response, N=does not meet 
criteria. *Although greater than pre-dose test, minimal difference and therefore 
considered non-response.  
 
 
Similarly for total chloride transport (ZCA + ZCAI delta), 5/19 (26.3%) patients 
had at least one post dose nasal PD categorised as ‘response’ according to all 
three definitions. Four of these were the same patients meeting all 3 definitions 
for intrinsic chloride response (007, 011, 017, 022 and 030). A further 3 patients 
met ‘response’ criteria for total chloride transport according to two definitions 
(and therefore overall 8/19 (42.1%) met ‘response’ according to ≥2/3 
definitions)(Table 5.10).  
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 Total chloride secretion at any post dose test 
Patient 
Method 1: 
Greater than any 
pre-dose test 
Method 2: Change 
between mean 
pre- and post- 




secretion > -5mV 
028 N N N 
029 Y Y Y 
030 Y Y Y 
031 Y Y N 
034 N N N 
041 N* N N 
003 Y N N 
005 N* Y N 
007 Y Y Y 
010 N N N 
011 Y Y Y 
012 N N N 
014 Y N N 
015 N N N 
017 N N N 
020 Y N Y 
021 Y N N 
022 Y Y Y 
023 Y Y N 
Total  
Y: 11/19 (57.9%) 
N: 8/19 (42.1%) 
Y: 8/19 (42.1%) 
N: 11/19 (57.9%) 
Y: 6/19 (31.6%) 
N: 13/19 (68.4%) 
 
Table 5.10. Total chloride secretion ‘response’ post dose at any time point 
according to definition used. Y=meets criteria for response, N=does not meet 
criteria. *Although greater than pre-dose test, minimal difference and therefore 
considered non-response.  
 
PD responses at extended time points were investigated in some subjects with a 
trace seen at the day 28 visit which, on visual inspection, was consistent with a 
‘response’, and who were willing to attend further visits for testing. This applied 
to four patients. Two of these patients had evidence of sustained changes in 
chloride secretion beyond the original series of nasal PD time points to day 28, 
as shown previously in the individual graphs for intrinsic and total chloride 
secretion (patients 1SD022 and 030).  
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5.2.5 Actual nasal dose (absolute volume) delivered and evidence 
of CFTR function 
The actual volume of nasal gene therapy delivered following the administration 
of the specified number of nasal spray actuations is described in Chapter 4, 
section 4.3. There was no correlation between the actual volume of gene 
therapy delivered and the likelihood of a ‘response’ (Table 5.11).   
  
Volume administered (ml) mean (SD) Comparison 
 Post dose nasal PD 
response* 




2.0 (0.4) 1.8 (0.2) p=0.45 
Total chloride 
secretion 
2.0 (0.2) 1.8 (0.4) p=0.12 
 
Table 5.11. Actual volume of nasal gene therapy delivered (2ml dose cohort) 
and nasal PD outcome for intrinsic and total chloride secretion. *criteria met 
according to 2 or more definitions at any post dose test. Unpaired t-tests were used to 
compare differences in response according to actual volume administered.  
 
 
5.2.6 Comparison with other CFTR outcomes 
5.2.6.1 Nasal PD and molecular results  
As described in Chapter 2, section 2.7, patients in the nasal dosing cohort had a 
nasal brushing at a single time point post dose for vector specific CFTR mRNA. 
No patients receiving a 1ml nasal dose had a positive mRNA result. Three 
patients in the main 2ml cohort had detectable mRNA in their post dose test 
(although positive, the values were not quantifiable)(Table 5.12). There was no 
















028 N N Positive (D28) 
029 Y Y Not detected 
030 Y Y Not detected** 
031 N Y Not detected 
034 N N Not detected 
041 Y N Not detected 
003 Y N Not detected 
005 N N Not detected 
007 Y Y Not detected 
010 Y N Not done 
011 Y Y Positive (D14) 
012 N N Not detected 
014 N N Not detected 
015 N N Not detected 
017 Y N Not detected 
020 N Y Not detected 
021 N N Positive (D14) 
022 Y Y Not detected 
023 N Y Not detected 
 
Table 5.12. Summary of nasal PD chloride secretion outcome and molecular 
evidence of vector specific CFTR on post 2ml dose nasal brushing.  *criteria 
met according to 2 or more definitions at any post dose test. Not detected: Sample 
taken but no vector specific mRNA detected. **Two post dose brushing samples taken, 
one at day 28 and one at an extended time point > day 28, both were negative for 
mRNA. Not done: no post dose sample (patient refused nasal brushing). 
  
5.2.6.2 Nasal PD and lower airway PD 
Ten patients had pre- and post-dose bronchoscopies during which measurements 
of lower airway PD were made. Nasal PD tests were carried out on the same day. 
Associations between upper and lower airway PD results are described in 
Chapter 6.  
5.2.7 Characteristics of patients with chloride response on post 
dose nasal PD 
The genotypes of all 22 patients receiving a nasal dose of gene therapy are 
described in Chapter 4, section 4.2.2; all patients receiving the 2ml nasal dose 
had at least one p.Phe508del mutation. A summary of patient characteristics 
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including genotype, gender, age and lung function at recruitment is shown in 
Table 5.13. There was no difference in genotype distribution, gender, age or 
FEV1 % predicted at recruitment between patients with or without evidence of an 
intrinsic nasal PD ‘response’ on one or more post dose tests. There was a 
significant difference in gender distribution according to the presence of a total 
chloride ‘response’ but the small number of females in the cohort (n=5; 26%) this 
result should be interpreted with caution.  
 Intrinsic chloride 
‘response’ on nasal 
PD?* 
 Total chloride 
secretion ‘response’ 
on nasal PD?* 
 Yes No  Yes No 
Genotype    
p.Phe508del/p.Phe508del 5 6  3 8 
p.Phe508del/other 2 2  3 1 
p.Phe508del/unknown 2 2  2 2 
Gender    
Male 7 7  8 6 
Female 2 3  0 5 








FEV1 % predicted at Initial 










Table 5.13. Patient characteristics according to evidence of chloride 
‘response’ on nasal PD (2ml dose cohort). *criteria met according to 2 or more 
definitions at any post dose test. Comparisons made between ‘response’ and ‘no 
response’ with Mann Whitney and Fishers exact tests; all were non-significant (p>0.05) 
for the presence of an intrinsic chloride response. For total chloride secretion, there 
was a significant difference between evidence of chloride response vs. non-response for 
gender (Fisher’s exact test p=0.04) but not for age or FEV1% predicted (Mann Whitney 
p=0.3 and p=0.6 respectively).   
 
5.3 Novel approach to nasal PD 
5.3.1 Measurements in the non-CF and CF nose  
The results described in section 5.2 were all performed with the LR4 voltmeter 
and nasal PD set up (Chapter 2, section 2.5.1-2.5.2). A novel approach to nasal 
PD testing was investigated using the LR5 device (Chapter 2, section 2.5.3). The 
PD measurements obtained using the LR4 were identical to readings obtained 
from the LR5 prior to clamp application. Application of a clamp was able to 
influence the measured PD, with an effect size dependent on the magnitude of 
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clamp applied. There was no relationship between clamp duration and the rate 
of return (number of data values collected at 33 Hz before return to pre-clamp 
values) to basal PD. The change in PD (post standard nasal PD testing protocol 
including solution perfusion) in response to different clamp settings is shown in 
Figure 5.10.  
 
Figure 5.10. Recovery to baseline PD following application of maximal clamp 
setting. Triplicate measurements in n=2 subjects (one subject with 2 tests). 
Data was captured every 0.03 seconds, and it can be seen that return to baseline 
(pre-clamp) PD was achieved within 0.12 seconds.  
 
The recovery time post clamp removal was almost instantaneous (within the 
33Hz detection capabilities) irrespective of filter setting used for CF and non-CF 
subjects. There was no difference in rate of return to pre-clamp PD post clamp 
removal between non-CF and CF. In non-CF subjects, there was no difference 
between traces obtained either in isolation or immediately following a standard 
LR4 nasal PD (i.e. post perfusion steps). 
One of the CF patients included in the CF group had a significant chloride 
response on ‘standard’ nasal PD testing. Therefore only one nasal PD (LR4 and 
LR5) was carried out on this subject as he was subsequently excluded from the 
nasal dosing cohort. There was substantial overlap between CF and non-CF 
subjects in recovery of PD post clamp removal, irrespective of whether the 
traces were obtained immediately following or in isolation of a standard PD. 
Regardless of filter setting, return to baseline PD was almost instantaneous 
within the detection capabilities of the hardware. All results for patients with CF 
completely overlapped those from non-CF subjects. 
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The change in mV expressed as a % of baseline PD during clamp application was 
no different pre- and post- administration of a single dose of CF gene therapy (a 
representative result from patient 1SD028 is shown in Figure 5.11). Following 
release of the clamp return to baseline was within the first 2-3 data capture 
points (within 0.1 seconds) in all tests performed.  
 
Figure 5.11. Change in baseline PD in response to clamp setting. Clamp 9 is 
the maximal load. Increasing load changed the measured PD consistently 
between tests irrespective of relationship to gene therapy dose. Pre = pre dose; 
D2 and D6 refer to day 2 and day 6 post dose respectively. 
 
5.3.2 Further experimental work 
The results confirmed that the application of an electrical ‘load’ could influence 
the PD measured across the respiratory epithelium, but the characteristics were 
not different between CF and non-CF individuals. It was hypothesised by the 
author that changes in PD post clamp application could reflect high impedance 
of the entire epithelial cell and test equipment ‘circuit’ under test, in 
particular, that the Foley catheter containing the nasal electrode was a 
potential source of high impedance.  
5.3.2.1 Electrode type 
In order to exclude the high impedance components of the electrode / electrode 
cream / Foley catheter combination at the exploring electrode, an alternative 
electrode was sourced. A nasopharyngeal electrode (DW020, Digitimer, UK) CE 
marked for use in vivo during electrode encephalogram (EEG) testing met the 
criteria required: the electrode was comprised of a silver/silver chloride 
electrode small ball (not disk), on the end of the semi-rigid coated wire which 
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could be inserted directly into the nose and negate the requirement for a Foley 
catheter. The electrode comprises the recording ball ‘tip’ (3mm diameter) and 
1.5m silicone wire (Figure 5.12). A disk electrode alone was unsuitable due to 
the diameter and discomfort on insertion. As no perfusion steps are carried out 
during tests with the LR5, it was not necessary to have a channel for perfusion 
which is the purpose of the Foley catheter during standard nasal PD testing. 
 
Figure 5.12. Silver/silver chloride ball electrode. This photograph shows the 
ball electrode (top) with the disk electrode used in our existing nasal PD testing 
set up (bottom) for comparison. 
This electrode was compared with the standard nasal electrode set up (disk 
electrode in Foley catheter as described in Chapter 2, section 2.5) in a non-CF 
subject. The nasopharyngeal electrode was inserted along the floor of the nasal 
cavity to the site of most negative PD (3cm into nose). The ball tip of the 
electrode had been dipped in electrode cream prior to insertion to improve 
connectivity with the nasal epithelium. F1 and WB filtering of the measured PD 
were used, with maximal clamp (setting 9) and clamp time (10 seconds).  
5.3.2.2 Results 
No differences were observed between n=3 tests at each clamp setting (load) or 
signal filter setting performed with the disk electrode in Foley catheter vs. 
Ag/AgCl ball electrode for the single subject (author). The electrode caused 
discomfort whilst in situ and therefore further testing in other subjects was not 
carried out. Comparison with the original nasal electrode / catheter 
arrangement is shown in Figure 5.13. Overall, no difference was observed with 
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the use of the direct nasopharyngeal electrode in comparison to the standard 
electrode set up.  
 
Figure 5.13. Comparison of electrode set up with LR5. Each data point 
represents the mean of 3 values, perfomed with the original electrode and Foley 
catheter and disk electrode set-up, and with the nasopharyngeal ball electrode. 
Each test was performed in triplicate as shown.  
 
From the initial test results, none were obtained to support the hypothesis that 
patients with CF would have a slower return to baseline PD than non-CF 
subjects, and no change was seen in the limited testing points post nasal gene 
therapy. However of note, no post dosing tests were performed in patients with 
the LR5 at time points when a change in chloride transport was observed with 
standard PD testing, and results obtained were limited to a small number of 
subjects. Despite these limitations, the absence of any CF/ non-CF difference 
and an additional time factor added to the Pilot nasal PD for patients as a result 
of testing with the LR5 meant that a decision was taken by the author not to 
pursue further investigation in the Pilot study.  
5.4 Discussion 
This chapter has described the nasal PD results performed in the CF gene 
therapy Pilot study. Results demonstrated that on an individual patient level, a 
single nasal dose of CF gene therapy (pGM169/GL67A) can result in detectable 
changes in chloride secretion on nasal PD testing with a perfusion protocol 
including Ringers, RA, ZCA and ZCAI solutions. Although some non-significant 
trends towards a ‘response’ on a group level were seen, the PD changes are not 
universal. In some patients, prolonged changes in PD in response to zero chloride 
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solutions were seen beyond initial expectations at trial onset. Yet in others, who 
were not obviously different in terms of genotype, disease severity (as assessed 
by FEV1), gender and age, it did not change. This chapter has also described 
results from a preliminary investigation of a novel approach to PD testing with 
which the author had hoped to improve the quantitative ability of PD to detect 
change post gene therapy (section 5.3). It was felt by the author that on the 
basis of the initial results that further testing in the Pilot study was not justified, 
despite only performing post dose measurements in n=2 subjects. This is 
discussed in more detail below.  
5.4.1 Feasibility of airway PD testing 
When considering appropriate outcome measures for early phase clinical trials, 
it is important that patient, personnel and economic factors are taken into 
consideration.  Although it is not painful, nasal PD measurement is not 
considered by most patients a particularly pleasant test. It involves sitting still 
without talking for 20-30 minutes and a slow constant dripping of perfusate from 
the nose during this time. Patients tolerated repeated measurements in the Pilot 
study very well. However, more frequent testing may not be as well tolerated. 
With the (necessary and important) GCP modifications to the PD set up as 
described in Chapter 2, section 2.5.1-2.5.2, nasal PD changed from being a test 
with relatively low running costs to becoming extremely expensive. This was 
further complicated with repeated testing necessitated by uncertainty over the 
kinetics of gene expression in a ‘first in man’ study, the inherent within subject 
variability and absence of a uniform response (or pattern of response). 
Studies such as the Pilot study may help better guide appropriate time lines for 
testing, but for ‘first in man’ studies protocol design can only be guided by the 
results of pre-clinical studies. Flexibility within the trial protocol is important, 
but nasal PD will always be a cross-sectional test of a dynamic process over a 
small area of tissue and at intermittent points in time.  
For nasal PD to be adopted more widely as an outcome measure in the UK, 
appropriate training for investigators is important. The LR4 voltmeter set up 
used in the Pilot study was not CE marked and therefore to meet regulatory 
requirements, responsibility was transferred from the inventor to the RBH 
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clinical engineering department. For studies involving centres outside RBH this 
might not be acceptable to relevant regulatory authorities, and in the absence 
of CE approval, alternative hardware for PD testing might need to be sought 
(such as the PowerLab (AD Instruments, Colorado, US)), as recommended by the 
US Therapeutic Development Network Standard Operating Procedure (TDN SOP) 
(110)). Furthermore, there is an issue of technical experience and expertise. All 
nasal PDs in this study were performed either by the author or JD. Each test 
takes around 30 minutes to perform but the times involved in test preparation 
are significantly greater. Similarly, data analysis takes around 25 minutes per 
nasal PD test for a single analyser. Although likely to have a greater role to play 
in the clinic in the future, at present only a limited number of tests are 
performed outwith the trial setting. Opportunity for learning, and adoption of a 
standardised technique would be required in Europe, similar to that achieved in 
the US with their TDN approach and indeed standardisation process is taking 
place currently within the European CF Society Clinical Trials Network (94). 
However, it is important to bear in mind that increasing the number of sites and 
operators is likely to increase variability in results.  
In the UK CFGT Consortium’s current multidose trial, PD is being undertaken 
using the methodology described in Chapter 2, section 2.5.1-2.5.2 at a single 
(London) site (RBH) despite patients being recruited from both the London and 
Edinburgh sites, in an effort to avoid the variability which would be introduced 
by multi-site testing.   
5.4.2 Strengths of design 
In line with the published literature (94), we observed variation in pre-dosing 
tests at all stages of the test (section 5.2.4.1). However, by increasing the 
number of pre-dose tests from the original study reported by Alton et al (35)(the 
‘Lancet study’) where only one pre-dose test was performed, there is better 
opportunity to be able to detect real change and understand the internal 
variability of PD within a subject over time. Use of the mean pre-treatment 
values was not always optimal in determining ‘response’. This was because a 
post dose result could be ‘greater’ than mean pre-dose levels yet still be within 
the overall range of pre-dose values. 
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We undertook up to three pre-dosing nasal PD measurements in study 
participants and in the latter phase of the trial excluded patients with evidence 
of chloride secretion considered within the normal range from the nasal arm of 
the study. There are examples in the literature where nasal PD outcome post 
intervention is compared with only one pre-dosing measurement both for studies 
of CF gene therapy and small molecule treatments (35;36;96;97). Variability in 
nasal PD between pre- and post-dosing results may reflect de novo CFTR 
expression and resultant changes in chloride secretion, or just expected 
variability within that patient (irrespective of any intervention) hence the 
importance of being able to have as much information as reasonably possible on 
pre-dosing measurements. Variation in results due to experimental set up and 
personnel undertaking the test are of considerable importance. In the US, the 
development of the TDN SOP (110) for nasal PD measurement was in response to 
considerable variability seen between 4 different centres involved in a Phase I 
trial evaluating a potential CFTR corrector (8-cyclopentyl-1,3-dipropylzanthine 
[CPX]) (85) as reported by Ahrens et al (84). This trial failed to detect change in 
treated patients on the basis of nasal PD results. Rowe et al (109) have collated 
the results from the CPX trial reported by Ahrens et al and compared it to a 
different multicentre trial performed post development of the US TDN SOP 
(topical aminoglycosides, analysis performed involving n=5 sites using the TDN 
SOP)(123). Total chloride secretion was similar, yet the variance was greatly 
reduced post SOP (CPX mean total chloride secretion 1.9mV, SD 6.6; nasal 
aminoglycosides mean total chloride secretion 2.6mV, SD 2.97) (109).  
The basal PD values observed in the Pilot study are similar to those reported by 
Middleton et al (75) and by other groups reporting measurements in CF subjects, 
recently collated by the European Cystic Fibrosis Society Clinical Trial 
Standardisation Committee (94).  
The nasal PD data collection in the Pilot study was also strengthened by the 
nasal PDs being performed by only 2 operators and being a single site study. 
Therefore there were no additional variables such as equipment set up or PD 
solution composition. In addition, all data analysis was performed blinded to 
subject and chronology. A robust process of data analysis and high levels of 
inter-reporter agreement between tests (further improved post consensus 
review) as described in section 5.2.2 added to the quality of data. I considered 
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performing an inter-reporter agreement for whether GD or JD had performed the 
nasal PD within individual patients. However, there were several important 
confounding factors (such as the proportion of tests performed within subjects 
by each operator) which meant that I considered such an analysis was not valid.  
In Pilot part B, we excluded patients from nasal dosing if they had evidence of a 
significant (>5mV) hyperpolarisation response to zero chloride solution 
perfusion. Inclusion of patients with evidence of significant hyperpolarisation 
can make interpretation of post intervention results challenging. Leonard et al 
have recently reported the results of a randomised placebo controlled crossover 
trial of miglustat (N-butyldeoxynojyrimicin, Zavesca®) which used change in 
total chloride secretion on nasal PD as the primary outcome measure (124). 
There was no evidence of a treatment effect, however at baseline measurement 
half of the patients had evidence of significant chloride secretion, potentially 
influencing trial outcome. They recommended excluding patients with evidence 
of chloride secretion for future trials in combination with improving 
standardisation of data collection and analysis (124). Our practice to exclude 
such patients in the latter phase of the Pilot study is continuing for participation 
in the nasal cohort of the UKCFGTC multidose trial.     
5.4.3 Limitations of nasal PD procedure and trial design 
Although it must be emphasised that the trial was not intended to be powered 
for change in any PD parameter on a group level, the evaluation of PD response 
within a pre-determined protocol limited the duration of post-dose testing for 
patients in part A of the study. However, the results provide a useful framework 
for an evaluation of a single nasal dose of CF gene therapy product 
pGM169/GL67A.  
With the benefit of hindsight, the Pilot trial protocol could have been designed 
to better allow the opportunity to capture any potential long duration changes. 
Time points for testing were not uniform between subjects in view of the 
iterative trial design. Trial design was driven mainly by time points for safety 
outcome measures, with time points for efficacy end points were based 
(appropriately) on best available evidence at the time of trial design (35). For 
the patients receiving a 1ml nasal dose and the first 3 patients receiving a 2ml 
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nasal dose, the last nasal PD was on day 2 post treatment. Therefore, for a 
substantial proportion of patients receiving a nasal dose in the early phases of 
the Pilot study (Pilot part A), the final nasal PD measurement was often within 
the first week post treatment. However all but 2 patients in Part A having a 
nasal PD at day 14 also had a PD on day 28, and therefore for the purposes of 
comparisons all patients with tests at pre, day 6, day 14 and day 28 were 
included (n=10)(section 5.2.4.7.1). Following up patients post day 28 on the 
basis of a suggestion of chloride secretion identified in real time during testing 
may be acceptable in this open label study, but would be problematic for 
blinding in placebo controlled trials.  
5.4.4 Absence of association between nasal PD and molecular 
results  
We did not see an association between nasal PD responses and the detection of 
CFTR on mRNA from post-dosing nasal brushings (section 5.2.6.1). Several 
possible explanations have been considered: a) this may be a genuine reflection 
of different levels of sensitivity of the two assays. Very few mRNA positives were 
detected over the course of the trial and data from other trials suggest the 
sensitivity of this assay is poor; b) the two sites of sampling in the nose are 
different, brushing being performed more proximally than nasal PD; perhaps 
delivery of the nasal dose was more successful further into the nose; c) since 
only a single post dosing nasal brushing was performed, the optimal time for 
detection may have been missed. The latter seems unlikely as in several cases, a 
negative mRNA sample was obtained on the same visit as a nasal PD with 
evidence of a chloride response (section 5.2.6.1). 
5.4.5 Influence on chloride response 
Consistent with the Lancet study, the most pronounced changes post gene 
therapy were observed during the ZCA phase rather than the isoprenaline phase 
of the nasal PD tests (35). Alton et al stated that there was a significant 
difference in PD response to a low chloride solution between the active and 
placebo groups when assessed over the duration of the measurements. No 
changes were detected in basal PD, response to amiloride or response to 
isoprenaline perfusion between active and placebo treated patients. The 
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absence of a placebo group in the Pilot study makes similar comparisons 
impossible, but we observed changes in chloride secretion in individual patients 
but only trends towards improved chloride secretion when results were collated 
(section 5.2.4.4-5.2.4.7).   
5.4.6 Influence on basal PD  
In the Pilot study, we did not detect any change in basal PD measurement 
between pre- and post treatment tests (section 5.2.4.3). No clinical trial of CF 
gene therapy has changed the basal PD, which is thought largely to reflect 
sodium transport. Importantly though, there is evidence from the literature that 
this may not be fundamental for clinical efficacy. Phase II studies using nasal PD 
as an outcome measure for the small molecule drug Ivacaftor (Vertex, US) found 
it had only a small, non-consistent effect on basal PD despite a significant 
impact on chloride secretion within subjects (97). This drug has been shown to 
result in clinical improvement, providing evidence for the theory that correction 
of the sodium transport defect in CF (responsible for the higher baseline in 
comparison to healthy controls) may not be necessary for clinical improvement. 
It will be of great interest in the future multidose trial to see if the basal PD 
changes following repeated dosing, and to map this on to clinical change in the 
cohort of patients who will have nasal PD testing during the trial. 
5.4.7 Evidence of prolonged gene expression 
It became apparent during the Pilot study that for some individuals, the PD 
changes persisted far longer than had been anticipated on the basis of pre-
clinical investigation (e.g. patient 022, section 5.2.4.5). Therefore the timing of 
post treatment PD was amended to reflect the pre-clinical data and based on 
previous clinical trial (35). In Part B, PDs were performed on day 6, 12 and 28 
post gene therapy. Nasal brushing was carried out at day 28. This later time 
point for molecular testing was chosen because of the theoretical risk of an 
unobtainable nasal PD post brushing because of a disrupted nasal epithelium. 
Absence of an intact epithelium would be expected to, in much the same way as 
an upper respiratory tract infection, cause an unobtainable or low basal PD. 
However, where a day 28 PD appeared to show a ‘response’, further PD 
measurements were undertaken (if the patient agreed) despite the fact that 
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brushing had already been undertaken. We learnt over the course of the trial 
that it was in fact possible to obtain nasal PD measurements post nasal brushing, 
likely reflecting the different sampling distance into the nose attained by the 
nasal PD catheter. That nasal brushing did not appear to contraindicate 
subsequent nasal PD testing is useful information to any future early phase gene 
therapy trial incorporating molecular and functional evidence of CFTR 
correction.  
Interestingly in the Pilot study there was no single time point at which a chloride 
‘response’ consistent with efficacy was most likely to be seen (section 5.2.4.4-
5.2.4.7). Therefore in terms of trial planning, these data do not help to 
rationalise the protocol for appropriate time points for measurement. The data 
would lend some support for the focus to be on later time points (after 1 week). 
There is a balance between identifying group changes which may be small if a 
minority of the group ‘respond’ vs. individual changes where the majority of 
patients may have readings unchanged from pre-treatment values but some have 
impressive changes out to prolonged time points; the latter is, I believe, the 
situation in this trial. 
Whereas for some patients maximal zero chloride secretion appeared to occur 
relatively early (patients 1SD011 and 017), for others it was later (patients 
1SD041, 022), and for some the signal actually appeared intermittently (e.g. 
1SD030), discussed below. There are additional challenges in our dataset 
introduced by time points of testing: patient 1SD003 only had one post dose 
measurement performed on day 2, which was >5mV greater in terms of ZCA 
delta than either pre-dosing measurement (Figure 5.5, section 5.2.4.5), and 
therefore no comment can be made about duration of the persistence of 
response.  
5.4.8 Intermittent PD responses 
Whereas for certain patients there was a clear evolution in nasal PD response 
over time between pre- and post dosing measurements, in others the response 
had a less obvious chronological pattern. Zero chloride responses in patient 011 
and 022 provide examples where there is a clear, biologically plausible 
relationship between pre- and post-dosing measurements which seems unlikely 
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to have arisen by chance (Figure 5.5 and 5.7). In contrast, it is a challenge to 
explain the nasal PD results in patients with intermittent responses (e.g. patient 
030). A single application of CFTR gene therapy to the nasal airway with plasmid 
DNA would not be expected to produce fluctuations in CFTR expression. If gene 
transfer has been successful and functional CFTR protein produced, it would be 
hypothesised that nasal PD should be able to detect a consistent change 
reflecting chloride secretion until a non-reversible end to CFTR gene expression. 
The most likely explanation for this in my view is that despite the nasal PD 
catheters being marked to ensure that the distance into the nose was consistent 
between tests, a degree of rotation may have altered the exact site of PD 
readings. Alternatively, reversible changes in airway integrity, for example in 
the presence of a subclinical viral infection, could lead to a measurement with 
apparently absent chloride secretion being flanked by measurements apparently 
demonstrating correction. If these intermittent responses are real and do reflect 
functional CFTR, it may mean that some patients in whom we saw an absence of 
response at day 28 following a response at day 14 may have had detectable 
changes towards normality at later time points. Therefore it is possible that 
more patients may have had prolonged evidence of chloride secretion indicating 
sustained presence of functional CFTR protein.  
Intermittent nasal PD responses are not unique to the Pilot study. In the Lancet 
study active treatment group, electrical evidence of chloride secretion 
significantly greater than pre-treatment values were shown at day 1, 5 and 15 
after treatment, but not at other post dosing time points (day 3,7,11 and 23) 
(35). Given that these time points at which a statistical difference was present 
were interspersed by intervals with no difference, this provides some support for 
the intermittent nature of the ‘signal’ seen in some Pilot study patients. 
5.4.9 Electrical changes and clinical correlates 
Airway PD was included as an outcome measure in the Pilot study to act as a 
‘readout’ of function of de novo CFTR, and provide information on duration of 
expression. The clinical relevance of any change after our gene therapy product 
is unknown in several regards, for example: a) the degree of electrical 
correction required to influence the clinical picture and conversely b) whether 
the absence of change in electrical measurements correlates with a likely lack of 
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clinical response. Comparison of lower airway, upper airway and clinical end 
points from the Pilot study suggest that this relationship is likely to be 
complicated. However, there is some evidence that the degree of chloride 
secretion or basal PD measurement in the upper airway is related to clinical 
status. In the literature, there is evidence that the spectrum of disease caused 
by mutations in CFTR is broadly associated with the degree of abnormality 
detected in airway PD measurement (82).  
Encouragingly, data from the UK CF Gene Therapy Consortium investigating 
molecular (mRNA) expression in mice suggests that gene expression increases 
with repeated doses of the CF gene therapy product (unpublished). Therefore 
absence of a change in airway PD following a single nasal dose may be 
inappropriate to use as a screening tool for detecting patients as ‘responders’ or 
‘non-responders’ in CF gene therapy trials. 
It must also be remembered that nasal PD in its current form lacks the ability to 
be able to quantify change in terms of proportion of cells in which electrical 
correction may have occurred due to CFTR expression. It was disappointing that 
the novel approach to PD testing described in section 5.3 and discussed below 
was unsuccessful in this regard. 
5.4.10 Novel approach to nasal PD 
Although changes in the chloride secretion response demonstrated some 
evidence of functional correction post gene therapy, the degree to which this 
correction has occurred (in terms of the proportion of cells successfully 
transfected) remained largely unknown using our standard experimental set up.  
Using the novel set up with the LR5 unit, the author has shown that it is possible 
to manipulate the PD reading by applying an electrical load in the form of an 
additional ‘path’ for the circuit with the influence on PD dependent on the 
resistance load associated with this clamp (Figure 5.10 and 5.11). Tests have 
also demonstrated that this change in voltage is not purely due to alteration in 
mV caused by high impedance of the electrode / Foley catheter set up used for 
standard nasal PD testing (Figure 5.13).  
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However, unfortunately the results obtained from testing with the LR5 were not 
as originally hypothesised. The change in PD as a result of applying different 
loads was remarkably consistent over time, both when repeated in immediate 
sequence of testing and when performed on differing days (as observed in the CF 
patients’ repeated measurements pre- and post CF gene therapy). Although it 
was consistently achievable to apply an electrical load that was able to alter the 
measured transepithelial PD, the change in PD both and the start and end of 
clamp (i.e. return to baseline PD) occurred with greater speed than anticipated.  
As shown with multiple testing, in nasal measurement, return to pre-clamp PD 
was almost instantaneous as viewed within the proprietary LR5 software (Figure 
5.10). Significant overlap was observed both within an individual and between 
individuals. In terms of original hypothesis that there may be a difference in rate 
of ‘recovery’ to baseline PD post clamp between CF and non-CF patients, this 
was not observed. This may represent a true non-difference between the two 
groups, or suggest that any differences are not able to be observed with the 
existing LR5 experimental set up. There are several reasons why no difference 
between CF and non-CF subjects was seen with the LR5 approach. Potentially, a) 
the speed at which the millivolt data is captured may not be fast enough to 
‘detect’ any such differences; b) the maximal electrical load permissible with 
the LR5 set up is too ‘weak’; or c) the maximal time for which the clamp could 
be applied (10 seconds) is not long enough to induce any measurable electrical 
change. In terms of the latter two points, it may be that although these 
parameters are sufficient to alter the transepithelial PD, they are not sufficient 
to produce a sustained impact on the epithelial cells in a similar manner to 
which is achieved by e.g. amiloride with the standard PD set up. Discussion with 
the inventor of the LR5 suggested that neither enhanced frequency of data 
capture nor altering maximal loads applied would be feasible. Therefore, 
although very small in terms of patient numbers and testing carried out, in the 
author’s opinion, the lack of further investigation with the existing LR5 set up 
was justified. Interestingly, although further investigation of electrical 
manipulation may not be warranted given the disappointing results reported, an 
alternative approach for future investigation could include analysis of return to 
baseline PD following e.g. amiloride perfusion. At present, it is the amount 
(delta) by which the PD changes from basal level following perfusion with 
Ringers amiloride solution that is measured. No attempt is made to measure how 
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long it takes for this ‘chemical’ manipulation of PD to return to baseline values. 
The action of amiloride on airway epithelial PD is rapid (<2 minutes) (74). In 
conventional PD analysis, the outcome of interest post amiloride perfusion is 
maximal change in PD from baseline. Within CF subjects, rate of return to basal 
PD following exposure of the nasal epithelium to agents capable of altering the 
measured PD has been studied in the context of CF therapeutics development. 
For example, a study of the effects of a nasal spray to deliver benzamil (a benzyl 
substituted analogue of amiloride) and amiloride on nasal PD in CF involved 10 
subjects and tracked nasal PD at sequential intervals until 8 hours post 
administration. It found that 2 hours post administration there was little 
difference from pre-treatment values for amiloride (in contrast to benzamil in 
which return to basal PD had still not occurred by 8 hours post testing) (125). 
Further investigation of chemical ‘loads’ could, as a result of the airway 
epithelial cells being arranged as a parallel electrical ‘circuit’, attempt to 
‘drain’ the cells electrically during load application and then measure electrical 
‘recovery’ as ion transport normalises. 
5.4.11 Chapter summary and conclusions 
The nasal PD results from the Pilot study provide evidence of the potential to 
partially restore CFTR function following a single nasal dose of gene therapy. 
However, the results were not universal, and no associations were seen with the 
molecular CFTR results. The multidose trial is designed to investigate the effect 
of repeated doses of gene therapy on clinical efficacy and it will be interesting 
to correlate these with nasal PD outcomes, and investigate how responses may 
be sustained or even accumulate with repeated dosing.  
We must find out what the clinical consequences of certain degrees of electrical 
correction mean, and develop improved methods in quantifying ‘response’ in 
addition to being able to select the most appropriate timings for post-dosing 
measurements. In particular, it will be of great interest to find out whether 
repeated dosing (as opposed to the single nebulised dose administered in the 
Pilot study) results in a cumulative and more impressive change in the electrical 
characteristics of airway cells in CF patients receiving CF gene therapy. 
Ultimately, it is not measurements of the electrical components of the airway 
surface which are important for therapeutic development, clinical improvement 
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is required. Yet for subgroups of patients in these larger later phase trials, an 
opportunity exists to increase much needed understanding of measurement 
variation and functional efficacy which can then be appropriately mapped with 
clinical course. 
Trials such as the UK CF Gene Therapy Consortium multidose trial, along with 
phase III trials of small molecule drugs aimed at correcting the underlying defect 
in CFTR (which also have existing data on nasal PD outcomes from earlier phase 
trials) will provide an unrivalled source of data to be able to map clinical change 




6 Results: Lower airway PD measurement  
6.1 Pilot study bronchoscopies 
Twenty four bronchoscopies were carried out as part of the Pilot study, between 
March and October 2009. This included 14 pre-dose and 10 post- dose 
bronchoscopies. The mean age of patients that underwent bronchoscopy was 
26.1 (range 17.1-44.0) years. Of the four patients with only a pre-dose 
bronchoscopy, two entered a post-dose ‘non bronchoscopic’ arm of the trial (this 
was for reasons unrelated to the bronchial PD however fortuitously, these 
happened to be the two patients whose pre-dose bronchoscopies where 
characterised by prohibitively high offsets and unstable traces). Two others 
withdrew from the study prior to receiving the dose of gene therapy for personal 
reasons. 
Ten patients had paired pre- and post- gene therapy bronchoscopies (for the 
latter, n=4 at day 6, n=6 at day 14).  
6.2 Lower airway PD 
All distal lower airway PD measurements were made on a single side. With the 
exception of two pre- and three post- dose bronchoscopies, all distal 
measurements were made within airways of the right lung.   
Technically acceptable readings were achieved in all patients with paired 
bronchoscopies. However, there was evidence of significant hyperpolarisation in 
response to zero chloride isoprenaline solution on the pre-dosing bronchoscopies 
from n=2 patients; the degree of change placed them outside 2 standard 
deviations of the mean for a) the rest of this cohort and b) the CF subjects 
included in any of our previous studies (35;113). We therefore considered it 
reasonable to perform data analysis both with and without these outliers.  Basal 
measurements from both carinal and distal sites were analysed with the entire 
data set.  
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6.2.1 Agreement between JD and GD 
In total, the pre- and post- dosing PDs from the ten patients with paired tests 
resulted in sixty sections of analysis (e.g. 20 carinal basal sections; 20 distal 
basal sections etc).  
A flow chart summarising the outcome of the review of GD and JD values is 
shown in Figure 6.1. 10% of sections were discrepant following initial analysis, all 
were from pre-dose bronchoscopies. Following review, a consensus opinion was 
reached for all tests.  
 
Figure 6.1. Data analysis algorithm for Pilot study lower airway PD results 
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To compare intra-reporter agreement for data analysis, intraclass correlation 
coefficients (ICC) were calculated. ICCs following initial data analysis and 
following consensus opinion between GD and JD are shown in Table 6.1. The 
agreement between analysers was superior to that observed with nasal PD 









chloride delta  
Independent analysis 
(initial) 
0.971 0.992 0.992 
Final values (following 
consensus review) 
0.998 0.998 0.997 
 
Table 6.1. Intra class correlation coefficients (ICC). For GD/JD bronchial PD 
analysis for initial independent analysis (top row) and following consensus review 
(bottom row).  
6.2.2 Final lower airway PD results 
The variability in basal carinal and distal results at the single pre- and post gene 
therapy time point is summarised graphically in Figure 6.2. The mean 
coefficients of variation for pre- and post-dose carinal basal measurements were 
29.4% and 31.8% respectively. Similarly for distal basal measurements, they were 
37.8% and 24.8%. Due to the presence of both negative and positive values for 
magnitude of chloride response, coefficient of variation was invalid. However, 
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Figure 6.2A. Pre-dose basal carina     Figure 6.2B.     Post-dose carina 
 
Figure 6.2C. Pre-dose distal basal    Figure 6.2D.     Post-dose distal basal 
Figure 6.2. Intra-patient variability in basal PD in the lower airway. The intra-
patient variability in carinal basal measurements (millivolts, mV) at pre- and post- dose 
bronchoscopy is shown in graph 6.2A and 6.2B respectively. Similarly, variability in pre- 
and post- distal basal measurements is shown in graphs 6.2C and 6.2D. Each patient is 
represented according to study number on the X-axis, with data points for the 4 carinal 
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Figure 6.3A. Pre-dose chloride transport      Figure 6.3B Post-dose chloride 
             transport 
  
Figure 6.3. Intra-patient variability in distal zero chloride isoprenaline (ZCI) 
response. The intra-patient variability in distal chloride transport (with deltas in 
millivolts, mV), at pre- (6.3A) and post- (6.3B) dose bronchoscopy is displayed. As 
previously, each patient is represented according to study number on the X-axis, with 
data points for each of the 3 distal perfusion deltas plotted.  
 
The pre- and post dose carinal measurements at each site of measurement are 
summarised in Figure 6.4. The mean basal proximal measurements were on 
average 9.1mV higher (more negative) than those measured distally (-18.6 vs. -
9.5mV, p = 0.006). This difference was only seen pre-dosing. A trend was seen 
towards lower mean carinal basal measurements post dose (Figure 6.5), making 
basal measurements more uniform across proximal and distal sites. No 
differences were observed between pre- and post-dose mean distal basal 
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Figure 6.4A Anterior wall of carina Figure 6.4B. Posterior wall of 
carina 
     
Figure 6.4C. Left lateral wall carina Figure 6.4D. Right lateral wall 
carina 
Figure 6.4. Site-specific basal carinal measurements. Box and Whisker summary 
plots for basal carinal measurements at each site for all patients (6.4A-D) with pre- and 
post dose bronchoscopy (n=10), plots represent range, median and quartiles at pre- and 
post dose bronchoscopy visits. There were no significant differences between pre- and 
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Figure 6.5A. Mean basal carinal  Figure 6.5B. Mean distal basal 
Figure 6.5. Mean basal carinal and distal measurements. Mean basal PD 
measurements for all patients with pre- and post dose bronchoscopy (n=10) at carinal 
(6.5A) and distal (6.5B) locations in the lower airway. As above, Box and Whisker plots 
represent range, median and quartiles at pre- and post gene therapy bronchoscopy 
visits. Wilcoxon signed rank test for carinal basal measurements pre- and post dose 
p=0.08, and for basal PD at distal locations p=0.49.  
 
The mean change in PD following zero chloride perfusion for the three distal 
perfusion sections for n=8 subjects excluding the outliers is shown in Figure 6.6. 
Using the same format to graphically display results as basal measurements, they 
are displayed as individual paired values for pre / post tests and overall group 
results in Box and Whisker plots. Chloride secretion was greater in 7 out of 8 
patients in post- as compared to pre-dose bronchoscopies, being on average 2.44 
mV greater than on pre-dosing bronchoscopies (paired t-test p=0.03).  
 
Figure 6.6A     Figure 6.6B 
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Figure 6.6. Zero chloride responses for n=8 patients excluding the 2 outliers. 
Results are represented as individual patient data (Figure 6.6A) and collectively 
summarised (Figure 6.6B) in the Box and Whisker plots. Paired t-test for pre- vs. post 
measurements p=0.03. 
The results for all 10 patients including outliers are shown in Figure 6.7. There 
was no statistically significant difference between pre- and post dose measures 
(paired t-test p=0.93).  
   
Figure 6.7A     Figure 6.7B 
Figure 6.7. Zero chloride responses for all n=10 patients. Results are 
represented as individual patient data (Figure 6.7A) and collectively summarised (Figure 
6.7B) in the Box and Whisker plot. Paired t-test for pre- vs. post measurements p=0.93. 
 
The trend to a reduction in basal PD at the carinal site was unexpected as no 
previous trial of gene therapy has succeeded in reducing sodium 
hyperabsorption. An alternative explanation could be that this resulted from 
inflammation. An intra-individual correlation of the change in this measure and 
that in distal chloride secretion after dosing (which is highly likely the result of 
gene transfer) seemed an appropriate way to explore this. For the reasons 
above, I limited this analysis to the 8 patients excluding the outliers; there was 
no significant correlation (Figure 6.8). 
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Figure 6.8. Correlation between pre- and post dose bronchoscopy 
measurement of chloride secretion with mean carinal basal PD. N=8 subjects, 
each represented by an individual data point, r=0.49, p=0.22.   
 
There was no obvious difference between the magnitude of change in chloride 
secretion between pre and post-dosing tests carried out at either day 6 or day 14 
post dosing. No statistical tests have been carried out as the n numbers are 
small, however substantial overlap was seen between results for the two time 
points. In the two patients with the greatest change in chloride secretion 
between pre and post measurements, one had their bronchoscopy carried out at 
day 6 (5.82 mV, patient 1SD015) and the other at day 14 (5.81 mV, patient 
1SD011) post dose. 
6.3 Comparison with nasal PD results 
The magnitude of any changes seen in lower airway PDs was smaller than those 
observed for nasal measurements (Chapter 5) on an individual patient basis. 
There was no clear association between ‘response’ on nasal PD and change 
toward normal values in lower airway PD.  The two patients with the highest mV 
achieved in response to zero chloride amiloride perfusion on nasal PD testing 
were 1SD011 and 1SD022 (see Chapter 5, section 5.2.4.5 and 5.2.4.7.2). 
Interestingly, 1SD011 had the second highest increase in chloride secretion in the 
lower airway post dose (day 14). In contrast, 1SD022 had no evidence of 
increased chloride secretion in the lower airway post dose (day 14). 1SD022 was 
the only subject in the cohort of 8 patients to have less chloride secretion on 
post dosing measurements. However, this patient also had a significantly lower 
basal nasal PD at day 14 than at any of their other nine nasal PD measurements 
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(basal PD = -11.6mV at day 14 visit, median basal PD from all 10 tests throughout 
Pilot study = -29.0mV), perhaps indicating a contributory effect from 
inflammation.  
6.4 Comparison with molecular CFTR results 
As described in Chapter 2, section 2.7, following the pre- and post-dose 
bronchoscopy lower airway PD measurements, bronchial brushings were taken to 
determine molecular evidence of effective gene transfer including vector-
specific CFTR mRNA. All of the pre-dosing samples were (as expected) negative, 
as were the majority of the post-dosing samples; only two patients (1SD007 and 
1SD023) had vector-specific CFTR mRNA detected in post dosing bronchial 
brushings (one at day 6 and the other at day 14) as described in Chapter 4, 
section 4.8.1. Furthermore, although above limits of detection, the proportion 
of CFTR mRNA was not quantifiable for one of these patients. Both these 
patients had improved chloride secretion post dose (2.15 and 1.51 mV 
respectively). However the n=5 other patients with lower airway PD results 
consistent with improved chloride secretion had negative lower airway mRNA 
results. 
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6.5 Discussion  
In Chapter 2, section 2.6, a method for measuring lower airway PD using 
pharmaceutical grade reagents and incorporating steps to evaluate both basal 
and chloride secretory responses to perfusion has been reported, and 
successfully used to collect all lower airway PD measurements throughout the 
Pilot study. The results obtained from pre- and post dosing measurements have 
been reported in this chapter, alongside associations between these and 
molecular evidence of de novo CFTR expression and to upper airway PD results. 
Several themes merit further discussion. 
6.5.1 Experimental set up and design 
6.5.1.1 Development 
The methodology described in Chapter 2, section 2.6 has allowed data collection 
pre- and post a single dose of CF gene therapy in the Pilot study and is currently 
being utilised in the ongoing multidose trial. A newly designed circuit and 
careful circuit preparation, in conjunction with warmed solutions and other 
modifications enabled technically acceptable recordings. 
However, lower airway PD has its limitations. These include technical difficulty, 
time for testing and requirement for general anaesthetic. The test itself adds 
time (approximately 30 minutes) to the bronchoscopy procedure whilst the 
patient is under general anaesthetic – we observed one SAE following 
bronchoscopy as described in Chapter 4, section 4.9. Time for data analysis at 
conclusion of trial was also not insignificant. Similar to nasal PD data analysis, 
each test took the author around 30 minutes to analyse, not including time 
taken to collate results and reach a consensus opinion with JD on any discrepant 
results as defined above. 
6.5.1.2 Comparison with literature 
Development of a method to measure lower airway PD suitable for use in a 
clinical trial in the current regulatory environment was a primary aim of this 
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work. A single lumen catheter technique for measuring lower airway PD, similar 
to that developed for the Pilot study, has previously been described by our group 
for testing suitable for use with the paediatric bronchoscope (113). This was no 
longer suitable as GCP requirements have evolved. Davies et al measured basal 
PD in CF and non-CF subjects, with tracheal values being significantly more 
negative in CF than non-CF (113). Lower basal PDs were observed at more distal 
sites, where there was no longer any difference between CF and non-CF 
children. In the paediatric study, responses to ZCI perfusion in a segmental (3rd 
generation) bronchus in the non-CF group showed a mean hyperpolarisation of 
10.1mV after 3 minutes perfusion, but in contrast a small depolarisation was 
observed in the CF group (mean change -1.3mV) with no overlap between 
groups. Comparison data for adults measured using a double lumen catheter 
technique were reported in the same paper, with mean CF adult tracheal and 
segmental bronchus PD measurements around -17mV (vs. -9mV for control 
subjects), and mean sub segmental and wedge PDs in CF adults around -15mV 
and -6mV respectively. All measurements by Davies et al (113) were obtained 
using the glass Calomel electrodes and intravenous electrical bridge, rather than 
the solid Ag/AgCl electrodes utilised in the Pilot study.   
A solid Ag/AgCl electrode technique has been described by Fajac et al (114), 
with a thin wire extending down the bronchoscope with a small ball at its distal 
end providing electrical contact. Using their electrode set up (which permits 
basal readings but no perfusion protocol), Fajac et al, first validated the 
technique against nasal PD readings with a perfused electrode and Ag/AgCl 
electrode in the nose, before using the solid electrode for measurements in the 
lower airways. This was used to propose a normal range for lower airway basal 
PDs, although of note their subject group involved adult patients with lung 
cancer and interstitial lung disease (mean (SD) age 60 (19) years) rather than 
healthy controls. Despite potential limitations caused by patient group, their 
results are consistent with other studies reported in the literature, with a small 
but progressive decline in basal PD traversing distally through the lower airway 
from trachea to segmental and sub segmental bronchi (mean PD distal trachea -
13.4mV; mean PD segmental and sub segmental bronchi -10.6mV) (113;114). 
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6.5.1.3 Suggestions for improvement 
Although we were satisfied with the technical quality of the lower airway PD 
measurements in the Pilot study, several suggestions can be made for further 
refinement of the experimental set up. The method developed for Pilot used the 
sheath of a cytology brush to contain the fluid acting as an electrical conductor 
for measurements through the bronchoscope (Chapter 2, section 2.6.2.5). This 
tube is ideal in that it is sterile, fits easily through the lumen of the 
bronchoscope channel and is designed and marketed for use during 
bronchoscopy. The process of simply discarding the cytology brush was wasteful, 
but we were unable to source an alternative type of tubing with the relevant 
clinical and regulatory approval.  
6.5.2 Data analysis 
Data analysis of all lower airway PDs was performed blinded to patient and test 
order, according to the criteria described in Chapter 2, section 2.6.1 and a strict 
quality control process was employed to ensure that results from the two 
analysers (author and JD) were appropriate. The degree of intra-reporter 
agreement was excellent pre- consensing with a limited number of tests with 
discrepant results. The author considers it vital that traces can be reviewed and 
discussed to reach a consensus agreement as small discrepancies in a mV result 
could have implications for final group comparisons and differences between 
pre- and post dosing tests when any potential treatment effects may be small. 
Due to the scarcity of research groups undertaking lower airway PD 
measurements on a worldwide scale, there is no accepted ‘gold standard’ 
approach to data analysis. However, components of scoring employed here 
including blinding, more than one analyser, and taking the mean of multiple 
data points over a short period of stability to identify the appropriate mV result 
should be considered standard.  
The importance of multiple basal (carinal and distal) and zero chloride 
isoprenaline perfusion steps was demonstrated by the high coefficient of 
variation between measurements performed at the same bronchoscopy. This 
variability in PD according to site (e.g. between different 5th generation airways) 
means it is crucial to perform multiple measurements to obtain a more 
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representative ‘mean’ PD at that site. Each perfusion step takes five minutes 
and therefore there is an importance balance between extent of data collection 
and potential for additional patient morbidity due to general anaesthesia and 
additional fluid instilled into the airway.  
6.5.3 Results from Pilot study 
6.5.3.1 Basal measurements 
In the CF gene therapy study described by Alton et al (the ‘Lancet study’) (35), 
basal lower airway PD measurements at the four carinal sites were not different 
from each other and therefore the mean value was used to define basal carinal 
PD. We utilised this approach for Pilot study results analysis. The basal 
measurements at the carina in the Pilot study were comparable to those 
reported in the Lancet study (35). Caution must be exercised in comparing 
absolute values due to differences in the methodology used for measurement, 
nevertheless the absolute values for measured PD were similar. No changes in 
basal PD post dose were observed in the Lancet study, however the date of 
testing was different (all post dosing measurements made on day 2).  
In the Pilot study, despite the absence of a statistically significant difference, 
the post dose carinal basal PD measurements appeared to be lower (less 
negative) than pre-dosing measurements (Figure 6.5, section 6.2.2). As 
mentioned, this could be related to inflammation or evidence of functional 
efficacy. Unfortunately the data do not provide definitive proof of mechanism. 
There are factors suggesting that these measurements could be related to 
inflammation (e.g. a known impact on distal airways post dosing as detected by 
gas transfer, see Chapter 4 section 4.5.2).  Although by day 6 post dose (the 
earliest time point for post dose bronchoscopy in the Pilot study), blood and 
clinical evidence of a post dose inflammatory reaction had subsided (Chapter 4 
sections 4.4-4.5), it is possible that there were on-going inflammatory responses 
at the level of the airway epithelium at the time of post dose bronchoscopy at 
either day 6 or day 14. Inflammation causes the airway epithelium to become 
‘leaky’ electrically and, as occurs during acute upper respiratory tract infection, 
PD measurement is not possible. However a greater ability of the epithelium to 
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secrete chloride on post -dosing tests (discussed below) may instead point more 
towards efficacy.  
6.5.3.2 Chloride secretion 
Two patients had significant evidence of chloride secretion in the lower airway 
at the pre-dosing bronchoscopy visit (in ≥2 distal carinal zero chloride 
isoprenaline perfusion measurements), as shown in Figure 6.3, section 6.2.2. For 
both patients, hyperpolarisation of PD in response to ZCI exceeded the expected 
range in CF (35;113). The presence of chloride secretion on pre- dosing tests 
(which interestingly was absent on their post dosing measurements) makes 
interpretation of any cohort change in overall chloride secretion challenging. 
Later in the Pilot study, patients were excluded from the nasal cohort if they 
had evidence of chloride secretion on pre-dosing nasal PDs and received a lung 
dose (in the non-invasive cohort, and therefore no lower airway PD 
measurements) alone. This approach is also being employed in the multidose 
trial. For completeness, the author chose to present findings both including and 
excluding these two subjects (1SD017 and 1SD021).  
Interestingly, neither patient had significant evidence of chloride secretion on 
pre-dose nasal PD. Again, the relationship between upper and lower airway 
results is uncertain. The Pilot study was primarily a safety study and outcome 
measures reflecting this were obtained at bronchoscopy (including any 
histological evidence of change in endobronchial biopsies post dose), however if 
bronchoscopy is performed for the sole purpose of efficacy measurements, then 
patients with pre-dose evidence of chloride secretion should not undergo post-
dose bronchoscopy. 
For those patients without significant evidence of chloride secretion on pre-
dosing tests, the improvement in chloride secretion post dosing provides some 
evidence to support successful CFTR gene transfer (Figure 6.6, section 2.2.2). 
The clinical consequences of this small but statistically significant improvement 
are unknown but will be investigated in the multidose trial which is taking place 
currently. Any therapeutic consequences of potentially being able to alter 
proximal basal measurements are also unknown, particularly as pathologically, 
CF is a disease of the distal airways. Statistically significant changes in mV in the 
lower airway suggestive of improved chloride secretion were reported by Alton 
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et al in the Lancet study for change from pre-dose measurements at day 2 post 
dose in their gene therapy clinical trial (35). Again caution must be used to 
compare absolute values, the magnitude of change in mV seen in the Pilot study 
was smaller than that observed in the Lancet study, where an improvement of 
around 5mV in the active treatment group was reported (which the authors 
describe as representing 25% restoration of chloride channel function in 
comparison to healthy controls) (35). Due to considerable differences in 
measurement circuit and PD solutions it is difficult to say with certainty whether 
the results are truly different or whether for the same patient the same results 
would be obtained using different testing set-up. In addition, as stated 
previously the time points for post-dosing measurements were not the same. 
In the Pilot study, no post dosing bronchoscopies were carried out after day 14. 
However, changes in nasal PD measurements were sometimes seen at later time 
points. In addition, patients with a small increment in chloride secretion may 
have had a greater degree of chloride secretion at day 14 (or later) but the 
single post –dosing measurement time point makes any comment on change 
within individuals over time (i.e. potential duration of gene expression and de 
novo functional CFTR) not possible. The clinical trial plasmid used in the Pilot 
study was known from in vitro work to have a slower onset but longer duration 
of action than the plasmid investigated previously (100). Therefore it is possible 
that our opportunity to detect efficacy was impinged by the cross-sectional time 
points chosen. However subjecting a patient to repeated general anaesthetics 
for serial lower airway PDs would be unethical and likely contribute to additional 
morbidity. This remains a challenge for planning clinical trials incorporating 
lower airway PD measurements.    
6.5.3.3 Comparison with upper airway PD and molecular evidence of CFTR 
As described in section 6.3, there was no relationship between evidence of 
chloride secretion on post dose bronchoscopy and similar evidence on nasal PD. 
The reasons behind this are likely to include differences in method of delivery of 
the nasal and lower airway dose, the site of deposition and the sites of 
measurement. There was also no association between lower airway PD and 
mRNA positive results for vector specific CFTR in post dosing tests (section 6.4). 
Although seven patients (70%) had greater chloride secretion on post dosing 
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tests, the magnitude of this increase as measured in millivolts was small. This, in 
combination with the low number of patients positive on mRNA testing makes 
any formal attempt at sensitivity analysis futile, however the results from the 
Pilot study suggest that lower airway PD is more sensitive than mRNA. There 
were no PD ‘negative’ and mRNA ‘positive’ results.  
The nasal PD findings from the Pilot study (Chapter 4) could have provided a 
useful benchmark for the most appropriate time points for lower airway PD, 
however the absence of a clear association between upper and lower airway 
results, and maximal chloride secretion at different time points post dosing 
between different patients again creates additional challenge. Furthermore the 
absence of a relationship between molecular evidence of CFTR function (mRNA) 
and lower airway PD results is also not helpful to guide appropriate time points 
for optimal changes of detecting maximal change in future clinical trial.  
With the uncertainties in interpretation of results and, in particular, the 
relationship with other outcome measures explored in the Pilot study, does the 
author feel that lower airway PDs are an ethically justified outcome measure in 
early phase clinical trials? On balance, the author suggests that the information 
obtained from lower airway measurement can, in combination with other 
outcome measures, provide additional information at the site of interest. The 
difficulty is that it may not be possible to determine the significance (or 
otherwise) of the measurements until they are mapped to change in clinically 
meaningful end points as explored in a multidose trial. This would be useful 
because once we understand how certain PD changes correlate clinically, we can 
utilise this information to rationalise clinical trial design.  
6.5.4 Chapter summary and conclusions 
The lower airway measurements performed in the Pilot study lend support to 
evidence of CFTR expression in the lower airway, although the magnitude of 
electrical change was small and less than previously reported in the Lancet study 
(35). We will need to await the results of the current multidose trial in order to 
be able to make real sense of the results described here. The same 
measurement set up described here is being taken forward for use in the 
multidose trial. Until further information becomes available, the lower airway 
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PD results should not be reviewed in isolation but taken in combination with 
upper airway results, and molecular evidence of successful CFTR gene transfer 
and functional CFTR protein.  
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7 Overall summary and conclusions 
This thesis has described the investigation of outcome measures for CF gene 
therapy clinical trials. It has concentrated on two categories: those that focus on 
the ion transport underlying defect in CFTR and physiological tests which 
measure downstream consequences of disease. These outcome measures have 
been evaluated within the context of the UKCFGTC clinical programme. 
The opportunity for timely evaluation of results from the observational Run-In 
study alongside the interventional Pilot study provided an excellent platform for 
data analysis. Each results chapter in this thesis has concluded with a discussion 
section relevant to the issues raised therein. This final chapter brings together 
the themes which traverse the thesis.  
7.1 Measuring outcome 
7.1.1 Why? 
Accurate measurement and appropriate interpretation of outcome is 
fundamental for the evaluation of novel treatments. This thesis has described 
well-established, evolving, and novel outcome measures. However, even for 
longstanding outcome measures such as FEV1 issues relating to appropriate 
handling of raw data have been shown critically to affect interpretation of the 
tests performed (from meeting inclusion criteria for a trial to influencing 
assessment of rate of decline over time). Others such as lung clearance index 
are more recent and still in a relative infancy in terms of recognition in a clinical 
trial and regulatory setting. The relationship between commercial companies 
and academia in terms of opportunities for analysis of the true raw data and 
appropriate interpretation has again been a learning point. Informed scientific 
interpretation relies fundamentally on acquiring accurate raw data and being 
able to convert these to meaningful values to permit appropriate data analysis. 
The advent of increasingly sophisticated measurement devices is a tempting 
setting for extensive data collection. An ability to translate this into something 
relevant for a clinical trial (or the wider clinical picture) remains a further, 
equally important and certainly not insignificant, challenge. The author now has 
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a greater awareness of the potential problems resulting from ‘black box’ tests 
which will be relevant to future research and clinical practice.  
7.1.2 When? 
The most appropriate time points for data collection will differ according to 
both the intervention and the outcome of interest. This was illustrated in the 
Pilot study with the safety outcomes (including airway physiology and systemic 
inflammatory markers) having differential post-dose time points for maximal 
change. This has implications for protocol design including efforts to minimise 
the number of study visits/ assays performed at each visit without compromising 
the evaluation of appropriate outcomes. It is not always possible to be aware of 
optimal time points at the stage of protocol design, particularly for first in man 
studies such as the Pilot study. However, recognisable patterns in post-
intervention responses can enable a more pragmatic approach to subsequent 
data collection in future trials as is being applied in our multidose trial. Even 
more challenging was the finding that there was no uniform time point of 
maximal change for evidence of functional efficacy in the nasal PD tests from 
the Pilot study – cross-sectional testing at intermittent study intervals may still 
‘miss’ a response in some cases. The importance of this will be clearer following 
the multidose trial, when downstream endpoints can more appropriately be 
correlated with functional evidence of CFTR on nasal (and/or) lower airway PD.   
The Run In study and Pilot study have demonstrated the potential utility of 
increasing the number of tests undertaken prior to any intervention rather than 
relying on a single pre-dose measurement for comparisons. For tests with high 
intra-subject variability during periods of clinical stability, repeated 
measurements improve the reliability of a pre-dose result on which to base post 
dose comparisons. However, the influence of inherent variability for post dosing 
tests should also not be forgotten, particularly when comparisons with a single 
post dose value are made.   
7.1.3 How? 
The Run-In and Pilot study data support the hypothesis that the lower airway 
requires more than one measure of function or status to reflect pathologies at 
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different sites. Outcomes for efficacy or toxicity may also require the researcher 
to ‘look’ at a different site of the airway to those conventionally measured in 
CF. The analysis of airway physiology outcomes in the Run-In study demonstrated 
that conventionally held impressions of particular indices reflecting a certain 
airway site may not hold true. The finding that airway physiological outcomes 
correlated with measures of systemic inflammation in the Run-In study (but 
interestingly not in the Pilot study post dosing) may reflect a single or parallel 
underlying disease process yet at present we do not have appropriate tests to 
help disentangle this further. The complex relationship between disease severity 
and variability between results at different testing dates (as seen with the Run-
In study dataset) is also a challenge for effective clinical trial design and 
evaluation.  
The Pilot study was primarily a safety study but also included CFTR molecular 
and functional end points. The author supports this combined approach due to 
the relatively small patient population and logistical, time and financial 
implications of multiple separate clinical trials. Although no relationships were 
observed in Pilot between molecular or functional CFTR outcomes with 
downstream end points, the multidose trial is powered to detect clinical benefit 
and therefore will provide an opportunity to analyse in detail the consequences 
of ‘positive’ or ‘response’ results at endpoints detecting correction of the 
underlying molecular defect. This will also permit greater understanding of the 
results obtained during the single dose study. There are likely to be issues with 
sensitivity of PD and molecular testing (mRNA); the absence of change in airway 
PD does not necessarily translate into the absence of clinical benefit (conversely 
change in airway PD does not necessarily correlate with clinical improvements). 
It remains a challenge how best to use functional and molecular evidence of 
CFTR correction in terms of interpretation and application to later phase gene 
therapy clinical trials. However there is evidence in the wider literature 
involving small molecule drugs that changes in nasal PD can relate to clinical 
endpoints (99). Such comparisons will also help determine the most appropriate 
method of defining and quantifying any response seen. 
The author has described modification of the conventional set up for lower 
airway PD measurement and successfully used this to measure bronchial PD pre 
and post a single nebulised dose of CF gene therapy in the Pilot study. Serial 
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nasal PD measurements have also been made, with subsequent detailed and 
intensive data analysis. Due to a limitation of existing airway PD measurements 
to quantify the proportion of cells corrected by gene therapy, a novel set up was 
proposed with the theoretical capability to achieve this. It was disappointing 
that the new approach to PD measurement, using the LR5, did not move the 
field forward in terms of being able to quantify change.   
7.2 The multidose trial 
The Run-In study was designed to ‘run in’ to the multidose trial. However, it 
became apparent from data analysis that during periods of clinical stability, 
there is often no discernible slope representing decline in respiratory status 
across relatively short longitudinal follow up. Despite this, the primary and 
secondary outcomes of interest were identified following analysis of results in 
the Run-In study. Optimal dosing strategy was guided by the Pilot study results. 
The placebo controlled multidose trial of nebulised pGM169/GL67A began after 
the author left the department and is ongoing at the time of writing. It has been 
referred to on multiple occasions throughout this thesis, in part reflecting the 
close association between all three clinical studies (Run In, Pilot and multidose) 
as described in Chapter 1, section 1.5.  Patient recruitment commenced in June 
2012, following completion of the Pilot study and a successful extensive pre-
clinical toxicology package. Patients from London and Edinburgh sites are 
randomised to active treatment or placebo administered on a monthly basis for 
one year. The CF gene therapy complex used in the multidose trial is identical to 
that used in the Pilot study (pGM169/GL67A), with a 5ml nebulised dose. The 
placebo is 5ml 0.9% sodium chloride. All patients receive planned adjuvant 
treatment with paracetamol for a 24 hour period on dosing days. A sub-cohort of 
patients are also randomised to additional repeated (monthly) nasal dosing with 
associated nasal PD measurement, and to an invasive cohort where 
bronchoscopies are performed to assess molecular and functional evidence of 
successful CFTR gene transfer after repeated dose (or placebo) administration 
using the methodology developed by the author described in Chapter 2, section 
2.6.  
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The multidose trial will allow an appropriately powered evaluation of clinical 
efficacy. The author also hopes it will enable us to investigate further the 
relationship between functional measurements and evidence of clinical efficacy. 
It will also be particularly interesting to discover whether the apparent 
improvement in LCI between pre- and post dosing measurements in the Pilot 
study is confirmed with greater patient numbers and whether any such effect is 
sustained or improved further with repeated dosing.  
7.3 The future 
There is no ideal single outcome measure for CF because it is a heterogeneous 
disease with a non-uniform path of disease progression. Processes occurring as 
an adverse response post therapeutic intervention may be separate from usual 
disease processes (and affect different parts of the airway) and therefore 
require assessment of outcomes not typically associated with monitoring of CF 
lung disease.  
We are entering a new era in the management of cystic fibrosis, with a genuine 
prospect of managing our patients with treatments aimed at correcting the 
underlying defect rather than fire fighting downstream consequences of disease. 
It is of fundamental importance that we continue to investigate better ways of 
measuring disease, both for efficacy and toxicity, and ensure that such measures 
are able to be mapped on to meaningful outcomes for patients. With new 
technologies, this field will continue to evolve. Just as commitment to novel 
therapies and their translation from the laboratory to the clinic is a research 
priority, so must there be ongoing commitment to measuring outcome. A ‘fine-
tooth comb’ approach to development and appropriate evaluation of emerging 
candidates, whilst not forgetting simultaneously to put existing outcome 
measures through forensic examination, is mandatory for success. 
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9.1 Run-In study: schedule of visits and investigations 




Symptom diary card      
Clinical examination      
Pulse oximetry      
Sputum (spontaneous/induction if 
required) 
Clinical microbiology 
    
 Total and diff cell count     
 24 hour collection weight    (24hr pre)  
 Wet and dry weight     
 Inflammatory markers     
Bloods Full blood count and differential     
 C-Reactive protein     
 Urea, creatinine and electrolytes,      
 Liver function tests     
 Inflammatory proteins     
 CFTR mutation analysis (if not known)     
 T-Lymphocytes (anti CFTR immune responses)     
Spirometry EasyOne      
 Piko-6      
Exhaled breath condensate pH     
 Inflammatory markers     
 Glucose     
Urine Cotinine     
 Pregnancy test (if female and CT visit)     
 Inflammatory markers     
Quality of life questionnaire      
Lung clearance index      
Shuttle exercise test      
Pedometer     (7 days pre-visit)  
CT chest      
Lung mucocilliary clearance (MCC) scan      
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Day 2 Day 6  Day 14 
Post dose 
bronchoscopy 
(invasive cohort part 
A), day 6 or 14 only  
Day 28 
Physical exam/ History   * * * *  $ * * * * * 
Diary cards   Daily from enrolment to end of trial (day 28) 
Routine bloods CRP   * *  * * * * * * 
 FBC & differential   * *  * * * * * * 
 ESR      * * * * * * 
 Liver function tests   * *  * * * * * * 
 Renal   * *  * * * * * * 
 Coagulation   *         
Specialised bloods cytokines   *   * * * * * * 
 T-cells/ ANA      *     * 
Urine routine urinalysis   *   * *   * * 
 Cotinine   *         
 Exploratory   *   * *   * * 
 Pregnancy test   *   *      
Sputum (induced if 
required) 
Count/ differential 






* * * only if spontaneous * 
 Culture 






* * * only if spontaneous * 
 Cytokines 






* * * only if spontaneous * 
Radiology Limited CT     *  *   * * 
Physiology EasyOne Spirometry   * * * *  $ * * * * * 
 Piko spirometry   Daily from enrolment to end of trial (day 28) 
 TLCO     *  *  * * (if at day 14) * 
 Pulse oximetry    * * *  $ * *  * * 
 LCI   *  *  * (*) (*) Not performed * 
nasal PD    * * *  * (*) (*) * (*) 
nasal brushing mRNA/ IHC    *      *  
bronchial PD     *      *  
bronchial Brushing (x10) mRNA    *      *  
bronchial biopsy (x2) Histology    *      *  
 
Chest CT scan and sputum induction were only performed in Pilot part A.  
 
NB. For patients receiving a Lung dose only (i.e. no nasal dose of gene therapy) in Pilot part B there was no day 6 visit. The testing dates for nasal PD depended on the patient’s dose cohort. Nasal brushings for 
the first 3 patients receiving a 1ml nasal dose/10ml lung dose and 2ml nasal dose/20ml lung dose were performed on day 2. 
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9.3 Run-In study symptom score 
Run-In study visits were undertaken during periods of clinical stability. This was 
assessed by using a symptom score. The symptom score sheet was developed by 
the UKCFGTC prior to the start of the Run-In study, and had been used 
previously in clinical studies performed by the Consortium. This allowed an 
assessment of symptoms as reported by the patient to determine whether they 
were clinically ‘stable’ and could participate in their Run-In study visit. The 
score included seven questions relating to different aspects of respiratory 
function:  
1. How severe is your cough? 
2. How severe is your breathlessness? 
3. How tired or lethargic are you? 
4. How far can you walk easily? 
5. How much sputum are you producing? 
6. Has the shade of sputum changed? 
7. How thick is your sputum? 
 
Potential responses were on a 5 point Likert scale from -2 (much 
worse/dark/thicker than usual) to +2 (much better than usual). No overall 
change from usual is represented by a score of 0. The score from each question 
was summed to produce a final symptom score (potential range -14 to +14). 
Patients were required to have a score of greater than -4 to continue with their 
Run-In study visit. 
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9.4 Composition of nasal PD solutions 
Stock PD solutions are prepared at a pharmacy manufacturing unit and supplied 
sterile in EVA bags (100ml volume). Solutions are supplied in sealed EVA bags 
have a 3 month expiry when kept refrigerated. Solution composition is according 
to the US Cystic Fibrosis Foundation Therapeutics Development Network 
Standard Operating Procedure.   
9.4.1 Ringers (R) solution 
Raw Material Concentration 






9.4.2 Ringers amiloride (RA) solution 
Raw Material Concentration 





Amiloride  0.03g/L  
 
9.4.3 Zero chloride amiloride (ZCA) solution 
Raw Material Concentration 
Sodium Gluconate 29.43g/L 
Calcium Gluconate 0.95g/L 
K2HPO4 USP 0.42g/L 
KH2PO4 0.05g/L 
MgSO4.7H2O 0.3g/L 
Amiloride  0.03g/L 
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9.4.4 Zero chloride isoprenaline and Zero chloride amiloride 
isoprenaline solution 
Isoprenaline sulphate is added to either ZC (bronchial PD) or ZCA (nasal PD) 
solution immediately prior to PD measurement (in view of an expiry time of 2 
hours). 0.125mg is added to each 50ml ZC or ZCA volume. 
 
9.5 Composition of bronchial PD solutions 
Stock PD solutions are prepared at a pharmacy manufacturing unit and supplied 
sterile in EVA bags (100ml volume). Solutions are supplied in sealed EVA bags 
have a 3 month expiry when kept refrigerated. Solution composition is according 
to the US Cystic Fibrosis Foundation Therapeutics Development Network 
Standard Operating Procedure.   
9.5.1 Ringers (R) solution 
Raw Material Concentration 






9.5.2 Zero chloride (ZC) solution 
Raw Material Concentration 
Sodium Gluconate 29.43g/L 
Calcium Gluconate 0.95g/L 




9.5.3 Zero chloride isoprenaline solution 
Isoprenaline sulphate is added to ZC (bronchial PD) solution immediately prior to 
PD measurement (in view of an expiry time of 2 hours). 0.125mg is added to 
each 50ml ZC volume. 
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9.6 Nasal PD analysis agreement for chloride secretion 
Nasal PD tests in the Pilot study were analysed by the author (GD) and JD. The 
figures below show the agreement between analysers following their own 
individual independent analysis, and prior to consensing to agree final results for 
all nasal PDs in the 2ml nasal dose cohort.  
 
 
The top figure is a summary of results for chloride secretion in response to 
perfusion with ZCA solution (mean bias 0.06mV, 95% limits of agreement -2.41 to 
2.79mV) for the analysers JD and GD. The bottom figure is a summary of chloride 
secretion in response to ZCAI solution (mean bias -0.01mV, 95% limits of 
agreement -2.45 to 2.44mV). There was no bias between analysers when 
assessing the magnitude of chloride secretion in Pilot nasal PD tests.  
